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Abstract 
 
Background: Current smoking-cessation medicines can assist smokers to quit, but have 
limited efficacy. Supplementing them with a replacement for the sensory and behavioural 
aspects of smoking, which are hypothesised to act as secondary reinforcers, could in theory 
help to alleviate urges to smoke and withdrawal, and may assist smoking cessation.  
Methods: Three studies were conducted to examine sensorimotor replacement (SMR) 
effects. The first two employed a cross-over design to assess the effects of two SMR 
products, nicotine-free electronic cigarettes (ECs) and de-nicotinised cigarettes (DNCs), on 
short-term withdrawal, urges to smoke, and user acceptability. Study 1 (N= 35), compared 
EC to a stress ball (SB) to control for behavioural distraction and Study 2 (N=41) tested 
whether SMR effects were ‘dose dependent’ by comparing DNCs with ECs. The final study 
was part of a randomised controlled trial (N= 200) of DNCs in combination with standard 
treatment. It examined whether SMR effects on abstinence are moderated by scores on a 
‘behavioural’ dependence measure (GN-SBQ).  
Results: The EC was preferred over the SB, and alleviated urge to smoke more than SB, but 
the effect was modest and short-lived. The DNC and EC had similar effects acutely, but DNC 
suppressed urges to smoke and withdrawal to a somewhat greater extent over a day of 
abstinence. DNCs combined with standard smoking-cessation treatment improved short-
term abstinence regardless of GN-SBQ scores. 
Conclusion: SMR effects on urge and withdrawal alleviation were modest and a ‘dose 
response’ effect was not clearly established. An attempt to identify smokers for whom SMR 
may be of particular benefit was not successful. SMR however, was perceived as helpful 
and appealing, and results from the trial suggest that adding SMR may enhance existing 
treatments. It was proposed that rather than directly alleviating urges/withdrawal, SMR 
may operate as a coping tool in ‘high-risk’ situations, by providing an alternative to 
smoking. 
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1 Introduction 
 
Smoking still remains one of the leading causes of mortality in England, with an estimated 
one in five deaths in those aged over 35 attributed to it (The Health and Social Care 
Information Centre, 2013). Prevalence has steadily reduced over the last 30 years with 39% 
of adults reporting smoking in 1980 to 20% in 2010. This is mostly due to a rise in never or 
occasional smokers (from 43% to 55%), whilst the proportion of ex-smokers increased by 
only 2% (The Health and Social Care Information Centre, 2013). Helping smokers to quit and 
achieve abstinence long-term still remains a significant challenge. 
Nicotine has long been identified as the fundamental component in tobacco addiction. 
Recognising the addictive nature of nicotine and the nicotine withdrawal syndrome which 
accompanies smoking cessation, led to the development of effective treatments for 
smokers. Nicotine Replacement Therapy (NRT) was introduced over 20 years ago on the 
assumption that if smokers were smoking primarily to obtain nicotine, replacing the source 
of nicotine via a clean and safe method would help lower the prevalence of smoking (Rose, 
2006). It is well documented that NRT and other medications such as varenicline and 
bupropion can enhance people’s chances of successfully quitting long-term (Stead et al., 
2008), but their efficacy is limited. The quantity of nicotine delivered via NRT for example, is 
considerably less than from cigarettes and the speed of delivery is slower, meaning that 
NRT helps at best to moderate the intensity of urges to smoke and other withdrawal 
symptoms.  
The NHS Stop Smoking Service (NHS-SSS) provides a combination of medication and weekly 
behavioural support that incorporates cognitive and behavioural techniques to help 
facilitate cessation, as well as encouraging correct and adequate medication use. Although 
the NHS-SSS is currently the most effective approach, with over 50% of service users setting 
a quit date abstinent at four weeks (The Health and Social Care Information Centre, 2012), 
there is still considerable room for improvement.   
There is no denying the primacy of nicotine in the development and maintenance of 
tobacco addiction, but there is evidence to suggest that non-nicotine factors may also 
contribute, and that addressing these could help improve smoking cessation treatment 
(Rose, 2006). Many smokers attempting to quit miss the behaviour of smoking (e.g. holding 
the cigarette, puffing, inhaling/exhaling) and sensations that accompany it (e.g. smell/taste 
of smoke, throat ‘scratch’, and other airway sensations), yet there is little focus of these 
 15 
 
sensorimotor factors in treatment. The nicotine inhalator is currently the only licensed 
smoking cessation medication which attempts to address these factors, but it provides only 
limited sensorimotor input. Providing an adequate replacement for the sensory and 
behavioural aspects of smoking may theoretically help aid cessation by alleviating urges to 
smoke and withdrawal acutely; extinguishing smokers’ reactions to the cues/triggers 
associated with smoking; or by providing a concrete behavioural coping strategy during 
high-risk relapse situations.  
This thesis will aim to answer a number of theoretical questions still outstanding in the 
sensorimotor literature, and provide further data on whether or not sensorimotor 
replacement (SMR) may have clinical utility. SMR will be investigated through the use of 
two products which provide at least some of the sensations of smoking, but contain no or 
negligible amounts nicotine: de-nicotinised cigarettes (DNCs) and nicotine-free electronic 
cigarettes (ECs). Briefly, DNCs are tobacco cigarettes which are smoked as per conventional 
cigarettes, but have an extremely low nicotine content (machine yield <0.1 mg nicotine), 
believed to have no central effects (Rose, 2006). ECs on the other hand, are tobacco-free 
battery powered devices, where with each puff, a visible vapour or mist is created which 
resembles smoke. They are comprised of a battery, atomizer and cartridge containing 
propylene glycol/glycerine and other flavourings, and can be purchased with or without 
nicotine. 
The thesis will begin with the theoretical background of how sensorimotor factors may 
contribute to tobacco dependence and what the implications of this are for treatment. 
Next, the literature in support of SMR will be reviewed. This includes a summary of early 
research which highlights the importance of sensorimotor factors, and the effects of SMR 
products (non-nicotine inhalators/aerosols, DNCs and ECs) on key outcomes of 
craving/urges to smoke1, withdrawal alleviation and smoking cessation. Where applicable, 
the effect of SMR on other measures of reinforcement and user acceptability will be 
summarised. The current research undertaken will then be presented. Each study is 
reported separately (i.e. methods, results and discussion), followed by an overall discussion 
and considerations for future research. 
    
                                                          
1
 The terms ‘urges to smoke’ and ‘craving’ are used interchangeably throughout; there is little 
evidence that these terms differ semantically (see Tiffany & Wray, 2012). 
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2 Theoretical Background  
   
The contribution of sensorimotor factors to the development and maintenance of tobacco 
addiction may be explained by an instrumental learning approach (Rose and Levin, 1991). 
At its most basic, this view identifies nicotine as a primary reinforcer, and sensorimotor 
stimuli as secondary or conditioned reinforcers. Nicotine acts as both a positive and 
negative reinforcer by stimulating the reward areas of the brain, and by providing escape 
from or avoidance of nicotine withdrawal symptoms, respectively. Sensorimotor stimuli 
reinforce smoking behaviour through their association with the pharmacological effects of 
nicotine. This happens through classical or ‘Pavlovian’ conditioning, whereby a previously 
neutral stimulus becomes rewarding if it is closely followed by a real reward. For example, 
the throat ‘scratch’ that smokers experience when smoke is inhaled after each puff is 
quickly followed by the rewarding effects of nicotine. Given many pairings of this over time, 
smokers come to like and expect this sensation (West and Hardy, 2006). 
The mechanisms behind instrumental learning are widely believed to stem from the 
increase in the neurotransmitter dopamine (DA) in the reward circuitry of the brain, 
specifically the nucleus accumbens (West and Hardy, 2006). The increase in DA in this area 
has been noted as a key characteristic of drugs of dependence in animal models and 
accordingly, research suggests that the ability of nicotine to stimulate the DA projections to 
the nucleus accumbens is what gives nicotine its reinforcing properties (Balfour, 2004). 
Although nicotine, like other drugs of dependence, stimulates DA overflow in the nucleus 
accumbens, this alone may be over simplistic to explain the highly addictive nature of 
smoking. Firstly, unlike other psychostimulant drugs such as cocaine and amphetamine, 
nicotine does not have strong euphoriant effects, and the amount of DA overflow in the 
nucleus accumbens is relatively small compared to other drugs of dependence (Balfour, 
2004). Indeed, smokers sometimes report not enjoying smoking, but still continue to do so. 
Secondly and on a related note, Balfour (2004), highlights that habitual smoking throughout 
the day can lead to concentrations of nicotine which desensitize neuronal nicotinic 
receptors and prevent further stimulation of DA overflow, yet smokers continue to smoke 
despite receiving no hedonic reward from nicotine. Of course, instrumental learning also 
postulates that nicotine is a negative reinforcer, thus one probable explanation for this is 
that smokers are avoiding the unpleasant effects of nicotine withdrawal. Balfour’s variation 
on the DA theory of reward attempts to provide an explanation as to why nicotine is highly 
addictive despite its weak euphoriant effects, and in doing so, suggests that conditioned 
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stimuli, namely sensorimotor factors, are important contributors to tobacco dependence 
(Balfour, 2004, Balfour, 2008). 
This hypothesis is underpinned by a wealth of research utilising animal models. These 
studies typically use a self-administration paradigm, whereby animals learn to administer 
nicotine via an intravenous infusion, by performing a response such as lever pressing 
(Chaudhri et al., 2006). Early studies reported inconsistent results with regards to voluntary 
nicotine self-administration; it became apparent that in order to generate high and stable 
rates of responding for nicotine, a strict set of experimental parameters was required, 
suggesting that nicotine alone is a relatively weak reinforcer (Henningfield and Goldberg, 
1983).  
One such parameter is the pairing of nicotine with a non-pharmacological stimulus, which is 
now a common feature of animal nicotine self-administration models. In one of the 
pioneering investigations, Goldberg (1981), reported high rates of operant responding 
when a light was paired with nicotine delivery. The removal of the light cue subsequently 
reduced responding, despite the continued availability of nicotine. This provided some 
preliminary evidence that such stimuli could contribute to nicotine reinforcement.  
Further research has supported the contribution of conditioned stimuli to various stages of 
nicotine reinforcement in animal models (Chaudhri et al., 2006). The acquisition of lever 
pressing for nicotine in rats is facilitated by the paring of nicotine delivery with a visual 
stimulus (a light cue), compared to when either are presented alone (Caggiula et al., 2002). 
In addition, given this pairing, lever pressing can be maintained with a wide range of 
nicotine doses; on the other hand, when there is no stimulus pairing, sustained and stable 
responding is only maintained with higher doses of nicotine (Chaudhri et al., 2006). Finally, 
during extinction procedures where nicotine delivery is replaced with saline, if these paired 
stimuli are present, lever pressing is reduced but continues at a stable rate. When the 
stimulus is then removed, lever pressing reduces further, until it is finally extinguished. 
Lever pressing can then be reinstated by priming with nicotine, or notably, by the 
presentation of the previously paired stimulus (Caggiula et al., 2001). It should be noted, 
however, that additional parameters are required to facilitate these responses, such as diet 
restriction and experimental testing during the dark phase of a rat’s light/dark cycle. 
Together, this body of research demonstrates that (i) nicotine is a relatively weak primary 
reinforcer on its own (unless administered at high doses); (ii) the pairing of a non-
pharmacological stimulus with nicotine can enhance responding; and (iii) resistance to 
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extinction results mostly from the presence of these paired stimuli, suggesting a role for 
non-nicotine factors in tobacco dependence.  
 
2.1 Differential drug effects within the nucleus accumbens  
 
Balfour’s theory makes a distinction between DA overflow in two subdivisions of the 
nucleus accumbens: the medial shell and the core. Importantly, both are hypothesised to 
have complementary roles in tobacco addiction. The increase in DA in the medial shell is 
proposed to give behaviours associated with this DA overflow hedonic properties. It is 
important to note that it is the behaviour (smoking) not the outcome (pharmacological 
effect of nicotine) that then becomes enjoyable. This enables the behaviour of smoking, as 
well as other stimuli associated with the delivery of nicotine, to acquire reinforcing 
properties and smoking is then more likely to be repeated. On the other hand, the increase 
in DA in the core of the accumbens is presumed to give cues which are associated with the 
delivery of nicotine ‘incentive salience’, which then facilitates stimulus-response behaviour. 
Thus DA in the core is hypothesised to play a significant role in promoting the effects of 
conditioned reinforcers and stimuli on smoking behaviour. Furthermore, there is 
sensitisation of this effect of nicotine on DA levels in the core, and it is thought that this is 
what leads to the transition from normal use to addiction. The theory therefore explicitly 
suggests a role for sensory and behavioural factors and other smoking-related cues, in the 
development and maintenance of tobacco addiction.  
As noted previously, the accumulation of nicotine throughout the day can desensitise 
nicotinic receptors, preventing the release of subsequent DA. Balfour’s theory suggests that 
smoking behaviour still continues under these circumstances because of conditioned 
stimuli, as well as the motivation to avoid unpleasant withdrawal symptoms. Importantly, 
when smokers do experience periods of abstinence, such as at work or when they sleep, 
these receptors are no longer desensitised so that when a cigarette is smoked, DA overflow 
is stimulated and the associations between sensorimotor factors or other stimuli and DA 
overflow are once again strengthened (Balfour, 2004). 
One of the main concerns of this theory relates to the fact that much of the research in this 
area utilises animal models with intravenous (IV) nicotine, making the findings less 
generalisable to the effects of inhaled tobacco smoke in humans (Balfour, 2004). 
Additionally, the quantities of nicotine injected in animal studies often leads to significantly 
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higher venous levels compared to when a cigarette is smoked, again limiting 
generalisations. There is however some support for the use of animal models; research 
suggests that there are similarities between IV nicotine and the nicotine inhaled in each 
bolus of tobacco smoke; that increases in DA in the nucleus accumbens do occur following 
inhalation of tobacco smoke in human brains; and that this mediates the reinforcing 
properties of nicotine administered via tobacco smoke (Balfour, 2004). Thus concerns 
regarding the generalisation from animal models to humans may be mitigated. A more 
pressing concern with the hypothesis is that strong evidence in support of the role of excess 
DA in the core specifically, is currently lacking (Balfour, 2008). 
The theoretical account outlined above proposes that sensorimotor factors contribute to 
tobacco dependence via their associations with nicotine-related DA overflow, whereby 
these sensorimotor factors themselves are able to acquire reinforcing properties. Balfour 
suggests this to be of importance during times when blood nicotine is raised and DA is no 
longer released. In addition, other cues related to nicotine delivery may trigger smoking 
behaviour. Although acknowledged in the model, the relative contribution of negative 
reinforcement (i.e. the avoidance of nicotine withdrawal symptoms) in the maintenance of 
smoking is not entirely clear, and the hypothesis places more emphasis on the role of 
positive reinforcement of conditioned stimuli.  
In a distinct but related vein, Baker et al (2006), have stressed the importance of negative 
reinforcement in tobacco dependence, in that avoidance of withdrawal symptoms is the 
main motivator behind continued drug use. This view still conforms to an instrumental 
learning account, and suggests a role for sensorimotor factors by proposing that cessation 
of smoking results in a second form of withdrawal, termed ‘behavioural’ withdrawal.  
 
2.2 Behavioural Withdrawal  
 
The model of behavioural withdrawal asserts that many dependent drug users continue to 
use drugs in order to regulate affect. Thus when blood nicotine levels fall and smokers 
experience withdrawal symptoms, and in particular negative affect and urges, smoking a 
cigarette helps them to cope with or regulate these symptoms (termed ‘symptom-
regulation’). This, as with the conventional instrumental learning account, occurs because 
of a learned association between drug use and symptom relief (Baker et al., 2006). It is 
important to note that it is the self-administration ritual or behaviour (i.e. smoking) which 
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allows smokers to cope with or regulate their negative affect and/or urges. It is therefore 
proposed that when smokers quit they will experience both pharmacological withdrawal as 
well as behavioural withdrawal (i.e. the absence of the self-administration ritual). As a 
result, there will be a disruption in symptom-regulation, and withdrawal symptoms will be 
exacerbated because individuals cannot revert to their usual means of coping, (i.e. smoking 
a cigarette). Moreover, symptoms such as negative affect and craving, may be triggered 
months later by stress or negative life events and smoking-related cues (e.g. sight or smell 
of cigarettes, environments previously associated with smoking), respectively. Each time 
this occurs, it is proposed that individuals will experience behavioural withdrawal as they 
cannot perform the self-administration ritual to regulate these symptoms. Baker et al argue 
that withdrawal should be seen as ‘symptom-dysregulation’, and it is proposed that 
symptom-dysregulation will continue until the value of smoking-related cues extinguish, or 
the individual finds an effective coping strategy which replaces smoking (Baker et al., 2006). 
In this way, the model can help to explain why ex-smokers may still report strong craving or 
negative affect months after cessation, after pharmacological withdrawal (which typically 
lasts 2-4 weeks post-cessation) has dissipated. 
Symptom-dysregulation is suggested to be a cause of both pharmacological and 
behavioural withdrawal. However, behavioural withdrawal is hypothesised to account for 
prolonged symptom-dysregulation, volatility and variability of symptoms as well as 
exacerbated reactions to environmental events or smoking-related cues (Baker et al., 
2006). It is also hypothesised that pharmacological nicotine withdrawal symptoms should 
be eased even if the self-administration ritual is performed without delivery of nicotine 
(e.g. with DNCs). Equally, if nicotine is administered without the usual ritual, such as in the 
case of NRT, withdrawal symptoms will not be fully alleviated and this may help to explain 
why the success of NRT is limited.  
This view is consistent with Balfour’s notion that it is the behaviour which is reinforced 
rather than the effect of the drug, and proposes that both nicotine and non-nicotine factors 
are important in tobacco dependence. It also recognises the role of smoking-related cues, 
which may trigger smoking behaviour. Underlying both of these accounts is of course the 
assumption that an association has been formed, via classical conditioning, between the 
behaviour/sensations of smoking and other stimuli, and the pharmacological effects of 
nicotine in the first place. 
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2.3 Other non-nicotine factors 
2.3.1 Tobacco smoke constituents  
 
Sensorimotor factors are not the sole non-nicotine factors which could be contributing to 
tobacco dependence. Rose (2006), summarised the evidence with respect to tobacco 
smoke constituents which could have direct pharmacological effects on the brain or could 
be potentiating the reinforcing effects of nicotine. Acetaldehyde for example, may increase 
the reinforcing effects of nicotine, and ammonia may increase the absorption of nicotine. 
Menthol is thought to interact with nicotine to control its perception (i.e. reduces irritation 
of nicotine), delivery and uptake, as it is believed to increase permeability of membranes. 
Tobacco smoke is also believed to contain monoamine oxidase (MAO) inhibitors which may 
have direct anti-depressant effects, and/or may increase the lifetime of DA 
neurotransmitters released by nicotine; whatever the mechanism may be, research points 
to some role for MAO inhibitors in smoking cessation treatment, withdrawal symptoms, 
and nicotine self-administration in animal models (Rose, 2006).  
 
2.3.2 Expectancy theory 
 
So far it has been argued that sensorimotor stimuli become reinforcing due to a classical 
conditioning process. However, some of these reinforcing effects may be in part explained 
by expectancy theory, a theory often applied to a wide range of placebo effects. This is of 
particular relevance for DNCs as they are still smoked as per conventional cigarettes, but 
the nicotine has been removed, though the same principles could be applied to ECs.  
Expectancy theory asserts that DNCs may alleviate urges to smoke and withdrawal, because 
the smoker has the belief or expectation that they are smoking a nicotine cigarette (known 
as the stimulus or dose expectancy) together with the expectation that nicotine alleviates 
urges to smoke (known as the response expectancy; Perkins et al., 2003). Both classical 
conditioning and expectancy theory have been put forward as mechanisms for placebo 
effects in general, but it is likely that both mechanisms play a role (Perkins et al., 2003, 
Stewart-Williams and Podd, 2004). In an attempt to clarify the mechanisms involved, 
Stewart-Williams and Podd (2004), concluded that both classical conditioning and verbal 
information can be sources of learning for placebo effects. Furthermore, when the source is 
verbal information, placebo effects are mediated only through conscious expectations. For 
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classical conditioning however, placebo effects may be mediated by both conscious 
expectation or automatic, non-cognitive processes. They further hypothesise that in the 
case of pharmacological placebo effects, automatic processes and conscious expectations 
may have an additive effect, but that non-pharmacological placebo effects are mediated 
solely through expectation.    
Even if the sensorimotor stimulation provided by DNCs acted as conditioned reinforcers, it 
still remains that the expectation of receiving nicotine could contribute to their potential 
reinforcing efficacy. In support of expectancy theory, a number of studies have directly 
explored the relationship between nicotine dose and nicotine dose expectancies on 
smoking related outcomes. To do this, studies have employed the balanced placebo design 
(BPD; Rohsenow and Marlatt, 1981), in which participants are randomised to receive 
nicotine or placebo cigarettes (DNCs), with half of the participants in each group told they 
have received nicotine, and the other half told they have received a placebo.  
Research in this area has found that when participants believe they are smoking nicotine, 
regardless of nicotine content, they show reduced urges to smoke (Perkins et al., 2008, 
Kelemen and Kaighobadi, 2007), increased satisfaction/liking and other subjective effects 
such as improved concentration, reduced irritability, feeling more calm etc. (Kelemen and 
Kaighobadi, 2007, Perkins et al., 2004, Perkins et al., 2008, Juliano et al., 2011), and less 
mood disturbance (Juliano et al., 2011). No effects of dose expectancies have been 
reported on measures of withdrawal symptoms however (Perkins et al., 2004, Perkins et al., 
2008, Juliano and Brandon, 2002). Latency to first puff has also been found to be shorter in 
those told they are smoking nicotine vs. placebo, though the total number of puffs taken 
did not differ (Perkins et al., 2008). In one study (Darredeau et al., 2013), nicotine 
expectancy showed less consistent effects, whereby those participants told they were 
smoking nicotine vs. placebo reported greater intention to smoke (Factor 1 of the 
Questionnaire of Smoking Urges [QSU]; Tiffany and Drobes, 1991), but there was no effect 
evident on withdrawal relief (Factor 2, QSU). Participants did however work harder on the 
progressive ratio task to earn more puffs when told nicotine vs. placebo, regardless of 
actual nicotine content.  
Significant interactions between nicotine expectancy and actual nicotine intake were also 
reported. Here, the expectation of nicotine reduced craving in those smoking DNCs but no 
effects of dose expectancies were found in those smoking nicotine cigarettes (Juliano et al., 
2011, Juliano and Brandon, 2002). The number of puffs earned on a progressive ratio task 
was greater in those told they were smoking nicotine in the DNC group, but no differences 
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were found in the nicotine cigarette group (Perkins et al., 2004). In contrast however, 
Juliano et al (2011), found that the total number of puffs taken in the nicotine group was 
greater for those told they were smoking nicotine; amongst those smoking DNCs, those 
who were told nicotine took less puffs than those told they were smoking placebos.  
One limitation of the BPD is that results can only be interpreted meaningfully if participants 
have successfully been deceived. There is mixed evidence as to which condition (given 
nicotine/told placebo or given placebo/told nicotine) is more problematic in this respect 
and differences may lie in the procedural aspects of the studies and measures used to 
assess disbelief (Juliano et al., 2011). Previous research has attempted to counteract this 
problem by assessing participants’ level of belief/disbelief, and excluding the data from 
those participants whose beliefs were not consistent with the condition they were assigned 
to. 
Aside from some inconsistencies, there is some evidence to suggest that any reinforcing 
effects of DNCs may be boosted by the expectation of nicotine delivery.  
 
2.4 Treatment implications 
 
Given the probable role of sensorimotor factors as secondary reinforcers in tobacco 
dependence, it stands to reason that treatments for smoking cessation may be improved if 
these reinforcers are also addressed, alongside the primary reinforcer, nicotine. This could 
be implemented by providing a substitute which mimics the sensory and behavioural 
aspects of smoking, i.e. a sensorimotor replacement (SMR) product, to help moderate urges 
to smoke and withdrawal symptoms during abstinence.  
In theory, SMR could also aid cessation via extinction of the previously learnt associations 
between nicotine and the behaviours and sensations of smoking; and/or by extinguishing 
other cues associated with smoking, which also result from classical conditioning processes. 
Extinguishing smoking-related cues has been tried and tested with cue-exposure therapy 
but with limited success (Ferguson and Shiffman, 2009). The efficacy of cue-exposure 
therapy may in part be limited by ‘renewal’ effects, where a conditioned response returns 
after extinction, because of a change in context to the one where extinction originally took 
place. Moreover, there is evidence to suggest that removing the reward (i.e. nicotine), 
whilst still engaging in the behaviour (smoking), is a more effective approach to extinguish 
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learnt behaviours (Conklin and Tiffany, 2002). SMR could therefore enhance extinction by 
(i) allowing unreinforced smoking behaviour (e.g. with DNCs) and (ii) enabling this to occur 
in a variety of contexts, therefore mitigating renewal effects.  
SMR could potentially also provide a concrete behavioural tool or coping strategy during 
high-risk situations in which a lapse back to smoking may be likely. This may not necessarily 
directly alleviate any urge to smoke, but may help the individual to cope with and manage 
the situation.  
There is of course a risk that SMR could itself be a trigger for smoking; indeed Balfour 
highlights the fact that sensorimotor cues could be just that- cues or conditioned stimuli 
which enhance responding for the primary reinforcer (Balfour, 2004). However, these 
stimuli are also hypothesised to be conditioned reinforcers, which by definition, become 
rewarding in themselves. In the context of treatment mechanisms then, the central 
hypothesis is that SMR may acutely alleviate urges to smoke and potentially also other 
nicotine withdrawal symptoms.   
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3 Literature review 
 
The literature review is presented in two main sections. The first will examine the evidence 
that the sensorimotor aspects of smoking have some significance in tobacco dependence, 
and builds a foundation for the SMR hypothesis. The second will review the evidence in 
support of the SMR hypothesis, i.e. the impact of SMR on key outcomes of craving/urges to 
smoke, withdrawal and smoking cessation. 
 
3.1 How important are the sensory effects of smoking? 
 
The majority of research on sensorimotor factors originates from Dr. Jed Rose and 
colleagues, though the contribution of sensory reward to tobacco addiction was recognised 
prior to this (Russell, 1971, Russell et al., 1974). In an early study, 60% of smokers reported 
at least a little enjoyment from the sensory effects of cigarettes (i.e. feeling of smoke in the 
throat and chest) and 10% of smokers liked this ‘very much’ (Rose, 1988). This observation 
led to further investigations regarding the independent effects of nicotine and tobacco 
smoke, and specifically the sensorimotor effects, via a number of different research 
paradigms. The findings of these studies are discussed further below. 
 
3.1.1 Depth of smoke inhalation 
 
Firstly, in a study where the depth of inhalation of smoke was controlled, shallow 
inhalations were found to be just as satisfying as deeper inhalations (Rose, 1988). Since 
deeper inhalations of smoke were assumed to provide more of a pharmacological effect of 
nicotine, these findings loosely suggested that the sensations elicited by cigarette smoke 
could be as satisfying as the central effects of nicotine.  
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3.1.2 Refined smoke 
 
Rose and colleagues carried out a series of experiments with a refined smoke aerosol. This 
device was created by firstly collecting smoke condensate from conventional cigarettes, 
and then heating in a cigarette-sized tube to generate an aerosol similar to conventional 
cigarette smoke. Using smoke condensate and heating only moderately, greatly reduced or 
eliminated many toxic constituents found in tobacco smoke (e.g. carbon monoxide [CO], 
formaldehyde, ammonia) as well as nicotine (Rose and Behm, 1987). The aim of the refined 
smoke aerosol was to reduce the harm and nicotine associated with cigarette smoke, much 
like low nicotine and tar cigarettes, but importantly, without compromising the desired 
sensory effects of cigarette smoke. Although low nicotine and tar cigarettes were marketed 
as safer or healthier cigarettes, these cigarettes are often associated with compensatory 
smoking (i.e. increase in number of puffs, inhaling more deeply, taking larger puffs), thus 
enabling smokers to maintain high levels of nicotine, tar and CO. They have also been rated 
low on satisfaction and flavour (Rose and Behm, 1987). Rose and colleagues hypothesised 
that low nicotine cigarettes could be satisfying if the sensations they elicit were perceived 
as strong, and aimed to test this with the refined smoke aerosol.   
In the first experiment, the refined smoke aerosol was rated higher on liking, similarity to 
own brand, harshness and strength compared to a conventional low nicotine and tar 
cigarette, even though nicotine content was lower in the refined smoke aerosol (Rose and 
Behm, 1987). In the second experiment, these findings were extended by showing that the 
relatively low level of nicotine afforded by the refined smoke aerosol could be satisfying 
over repeated use and following overnight abstinence. The aerosol was compared to a 
conventional low nicotine cigarette with a similar nicotine level. The refined smoke was 
rated higher on satisfaction, sensory effects and was able to reduce craving to a greater 
extent than the conventional cigarette (Rose and Behm, 1987). Since both the conventional 
cigarette and the refined smoke aerosol delivered comparable nicotine levels, it was 
proposed that the aerosol was more satisfactory because of the stronger sensations it 
provided.  
In further research, the strength of the aerosol in terms of sensory effects was found to be 
comparable to conventional high nicotine cigarettes, as was the reduction in desire/craving 
for a cigarette, despite the conventional cigarette containing 20 times more nicotine (Behm 
et al., 1990). Since the aerosol was rated significantly higher on ‘liking’ compared to an unlit 
control cigarette, it was argued that this reduction in desire for a cigarette was not simply 
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due to the aerosol being perceived as aversive. In another experiment, Rose et al (1993), 
investigated ad-libitum smoking behaviour over 3 hours, of refined smoke compared to a 
conventional high nicotine cigarette and a low nicotine cigarette. As expected, the low 
nicotine smoke led to compensatory smoking, whereas refined and high nicotine smoke did 
not, and were puffed and inhaled in a similar way. These findings seemed to suggest that 
smokers were regulating their smoke intake to achieve satisfying sensory effects rather 
than regulating nicotine levels. Craving reduction with refined smoke was comparable to 
the high nicotine cigarette, but greater versus the low nicotine condition. Despite this, 
results should be taken with caution as differences between refined smoke and low 
nicotine were marginal at the end of the 3 hour session. In addition, the low nicotine 
cigarette was in fact rated as more satisfying than refined smoke. 
Taken together, these studies suggest that refined smoke, despite containing minimal 
amounts of nicotine, could be satisfying and reduce craving acutely and importantly, 
without the need for compensatory smoking. Although hypothesised to be because of the 
strong sensory effects provided by the refined smoke, the sensory ratings reported in the 
last experiment (Rose et al., 1993) may somewhat negate this hypothesis. With the 
exception of strength ratings in the windpipe, all other sensory ratings (perceived strength 
on tongue, throat, nose and chest) were comparable across conditions; thus despite 
somewhat better craving alleviation with refined smoke vs. the low nicotine cigarette, the 
sensory effects were rated similarly between the two. Moreover, the low nicotine cigarette 
was rated as more satisfying. This may of course be a result of the compensatory smoking 
that occurred in the low nicotine cigarette condition, but this is not entirely clear. 
 
3.1.3 Sensory blockade 
 
Further support for sensorimotor factors in smoking has emerged from experiments where 
the sensory effects of cigarette smoke have been blocked by anaesthetising the upper and 
lower respiratory tract. This line of research aimed to show that if nicotine intake was the 
sole motivation for smoking, removing the sensations from cigarette smoke should not 
greatly impact upon a smoker’s desire for a cigarette or the enjoyment/satisfaction gained 
from smoking.  
In the first experiment, craving (measured before smoking, but after anaesthetisation) 
reduced linearly as the area of partial anaesthesia increased (Rose et al., 1984). For 
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example, craving was significantly higher when only the mouth was anaesthetised 
compared to when the mouth and the upper and lower airways were anaesthetised. 
Craving reduction (taking into account pre-smoking craving), was not significantly affected 
by anaesthetisation. Given the reduction in craving via the anaesthetisation procedure 
itself, the insignificant findings may be a result of floor effects. Desire for a cigarette was 
reduced by anaesthetisation only for the first few puffs; the effect diminished by the end of 
the smoking periods. This seems to provide little support for the role of sensory factors, but 
the ratings of cigarette puffs suggest the extent of sensory blockade may have been 
insufficient. Ratings of harshness and strength of puffs were not affected by anaesthesia 
and participants reported feeling the smoke in their chest. It is possible that this un-
anaesthetised area may have been enough to allow them to discriminate how strong and 
harsh the puffs were, or alternatively as puff volume was not controlled, participants may 
have taken larger puffs and/or inhaled more to gain the same sensory effect (Rose et al., 
1984); the findings of the next experiment support the former explanation. 
The second experiment (Rose et al., 1985) reported significantly less reduction in craving 
following smoking after anaesthetisation compared to saline (control condition). This effect 
remained even when pre-smoking craving ratings were taken into account. Sensory 
blockade also reduced the desirability of puffs, but had no effect on subsequent ad-libitum 
smoking behaviour (though the anaesthetic had mostly dissipated by this stage). As before, 
craving measured before smoking but after anaesthetisation, was reduced by 
anaesthetisation and there were no differences in ratings of strength and harshness 
between the two conditions. Since smoking topography was controlled in this study unlike 
in the previous one, it is likely that this was due to incomplete sensory blockade of the 
lower respiratory tract.  
In addition to the experiments above, Perkins et al (2001) and Baldinger et al (1995c) 
examined the effect of blocking visual and olfactory cues on ratings of cigarettes, and 
subsequent smoking behaviour. Baldinger et al (1995c), reported that blocking olfactory 
cues reduced enjoyment and taste of cigarettes and average puff volume, but did not 
impact upon craving or ratings of strength. In the first experiment by Perkins et al (2001), 
blockade of both visual and olfactory cues reduced hedonic ratings of puffs (ratings of ‘like 
puff’ and ‘satisfaction’), similarity to own brand, and the amount that people were willing 
to pay for another cigarette, but overall ratings of strength of cigarettes did not differ 
between the sensory blockade and no blockade conditions. The number of puffs and CO 
boost in the subsequent ad-libitum smoking session was also reduced by sensory blockade. 
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The second experiment confirmed that these effects were due to the blockade of olfactory 
rather than visual cues.  
It could of course be argued that the procedures used to block sensations (nose clips, 
goggles, anaesthetic solutions etc.) contribute to reduced satisfaction, in that participants 
may have felt uncomfortable in these conditions. It was clear that anaesthetisation 
procedures for example had an impact on subjective craving ratings before smoking even 
took place (Rose et al., 1984, Rose et al., 1985). To control for this, during the no blockade 
condition in the Perkins et al (2001) study, participants still wore goggles that did not 
obscure vision (i.e. they were clear) and nose clips positioned in a way which did not block 
the nostrils and as such would not obscure olfactory cues. Additionally, to examine whether 
sensory blockade procedures had any non-specific effects, participants also rated classical 
music, with and without visual and olfactory blockade. No main effects of condition were 
reported on ratings of music, suggesting any potential discomfort from these procedures 
did not contribute to the findings (Perkins et al., 2001). 
The findings of these experiments suggest that sensory blockade may impact upon the 
hedonic properties of smoking, but perhaps not on the actual sensations of smoking. As 
noted previously, this is likely due to inadequate sensory blockade procedures. There were 
mixed results on the effect of sensory blockade on craving; it is not unrealistic to expect 
little difference in craving however, especially where participants were smoking nicotine 
cigarettes in both sensory blockade or no blockade conditions. Instead, this research 
paradigm lends some support for the positive reinforcing effects of sensory factors, 
whereby even partial sensory blockade may attenuate smoking satisfaction/enjoyment. 
  
3.1.4 Intravenous (IV) nicotine administration    
 
The distinction between nicotine and sensory effects has also been highlighted with 
procedures where nicotine has been delivered independently from tobacco smoke. Since 
conventional NRT delivers smaller amounts of nicotine at a much slower rate than 
cigarettes, Rose and colleagues used a procedure whereby nicotine was administered 
intravenously and importantly, in a similar way to the puff-by-puff bolus delivery of 
cigarette smoke (Westman et al., 1996b).  
Research using such procedures showed that DNCs, in combination with saline or IV 
nicotine, provided greater immediate relief from craving compared to conditions where IV 
 30 
 
nicotine/saline was presented without smoking (Rose et al., 2000, Westman et al., 1996b). 
Both of these studies however reported no differences between conditions on the 
Shiffman-Jarvik craving measure (Shiffman and Jarvik, 1976). One study did report 
significantly less craving on this measure following administration of DNCs with saline vs. 
saline alone, but equivalent craving relief between DNCs and saline vs. IV nicotine alone 
(Rose et al., 2003). Another study found greater immediate craving relief and craving 
reduction measured by the Shiffman-Jarvik questionnaire, in conditions where IV 
nicotine/saline were presented alongside de-nicotinised smoke vs. puffs of air, or so called 
‘sham’ smoking (Rose et al., 2010).  
Other subjective effects such as satisfaction and reward were also noted to be greater with 
de-nicotinised smoke vs. IV nicotine/saline conditions (Rose et al., 2000), and DNCs were 
able to satiate smokers to a greater extent than IV nicotine, indicating that satiation was 
more dependent on the delivery of smoke and sensory effects than nicotine itself (Rose et 
al., 2003, Rose et al., 2010). De-nicotinised smoke was also preferred over IV nicotine in a 
concurrent choice paradigm by most participants (Rose et al., 2010). 
This line of research also demonstrates that when IV nicotine is combined with DNCs, many 
of the effects of conventional cigarettes can be replicated, such as craving and withdrawal 
reduction, satisfaction, enjoyment, reward and satiation (Rose et al., 2000, Rose et al., 
2003, Westman et al., 1996b). In one study, the combination of IV nicotine with DNCs 
reduced craving to a greater extent than either alone (Rose et al., 2010). These studies have 
however typically assessed the effects of IV nicotine and DNCs over relatively short periods 
of time, and given longer periods of abstinence from smoking, DNCs may become less 
rewarding and satiating, and nicotine delivery more so.  
Although there is some support here for the role of sensorimotor factors, the assumption 
that inhaled nicotine smoke should be more rewarding than nicotine administered without 
the sensorimotor aspects (i.e. intravenously), has not always been supported. Some studies 
discussed here (Rose et al., 2003), and previous work (Henningfield et al., 1985) have 
reported comparable effects of IV nicotine to inhaled (nicotine) smoke. For example, 
Henningfield et al reported that nicotine delivery via either of these routes resulted in 
similar increases in “drug liking” and decreases in craving. These comparable effects of IV 
nicotine to inhaled smoke could be explained by the IV nicotine administration procedure 
used, whereby extremely fast and large doses were delivered; in contrast, Rose and 
colleagues matched the dose of IV nicotine to that inhaled from conventional cigarettes by 
participants (Rose, 2006).  
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3.1.5 Summary 
 
Through a variety of research paradigms, Rose and colleagues and other research groups 
have demonstrated that sensorimotor factors likely play some role in the maintenance of 
smoking and are considered important to smokers. The more recent research with IV 
nicotine and DNCs has been a particularly useful research paradigm, enabling the 
independent and combined effects of nicotine and sensory cues to be examined, and 
provides additional evidence in support of SMR. 
 
3.2 Sensorimotor Replacement Products  
 
As described previously, replacing the sensorimotor aspects of smoking may have potential 
in smoking cessation, especially if combined with current treatments so that both the 
primary and secondary reinforcers of smoking are addressed. This however is not a novel 
idea; the nicotine inhalator was designed for this purpose - to provide both nicotine and 
SMR. The inhalator however, needs to be puffed intensely over 20 minutes to provide an 
adequate level of nicotine (Russell et al., 1987), but compliance with its recommended use 
has been reported to be low (Hajek et al., 1999). Thus the limited nicotine delivery may 
cancel out any gains it provides in terms of behavioural replacement. Furthermore, it 
remains a poor sensory replacement as the airway sensations do not resemble cigarette 
effects closely enough. 
Several other products which provide sensorimotor stimuli have been developed and 
evaluated. These are non-nicotine inhalators and aerosols, DNCs, and more recently ECs.  
The evidence in support of SMR with these products will be reviewed in turn. Given the 
theory that sensorimotor factors have become conditioned reinforcers in smoking, central 
to the SMR hypothesis is the alleviation of urges to smoke and withdrawal symptoms, 
which may translate to smoking cessation success. The review will therefore include data 
on craving/urges to smoke, withdrawal, and where available, smoking cessation outcomes. 
SMR could theoretically also aid cessation via extinction; evidence pertaining to this will 
also be considered. To further ascertain the clinical utility of these products, results from 
other subjective and objective measures will also be summarised.   
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3.2.1 Non-nicotine inhalators and aerosols 
 
Rose and colleagues developed and evaluated several non-nicotine inhalators/aerosols 
using various substances designed to replace some of the airway sensory effects of 
smoking. Citric acid, ascorbic acid (Vitamin C), and black pepper extract were chosen 
because of their ability to mimic the throat ‘scratch’ of smoke inhalation (Westman et al., 
1996a). 
 
3.2.1.1 Citric Acid 
 
Studies with citric acid have reported significantly reduced craving compared to controlled 
puffs of air (Rose and Hickman, 1987), to an unflavoured placebo aerosol (Levin et al., 1990, 
Behm et al., 1993), and effects comparable to a low nicotine and tar cigarette (Rose and 
Hickman, 1987). Any craving relief from citric acid may however be short-lived; Levin et al 
(1990) found significant craving reduction in the morning compared to the placebo group, 
but no differences between groups at later time points during 8 hours of abstinence. 
Additionally, Behm et al (1993) found a significant difference between the citric acid group 
and placebo controls on the first day of abstinence, but equivalent craving ratings from day 
5 of abstinence. A similar pattern of results was also noted for negative affect ratings. In a 
smoking cessation trial comparing a combination of the citric acid inhaler with the nicotine 
patch (Westman et al., 1995), relief from craving on the quit day was significantly higher in 
the citric acid group vs. placebo inhaler; however, no differences were found on the 
Shiffman-Jarvik withdrawal questionnaire. Other effects noted with citric acid were that it 
was significantly more likable and similar to usual brand cigarettes compared to both the 
low nicotine and tar cigarette and air; strength and harshness ratings were comparable to 
the usual brand cigarette; and it was significantly more satisfying than air, and as satisfying 
as the low nicotine and tar cigarette (Rose and Hickman, 1987). 
 
Two randomised, placebo-controlled studies investigated the efficacy of the citric acid 
inhaler on smoking cessation outcomes. In the first (Behm et al., 1993), there was a 
significantly higher point prevalence abstinence rate in the citric acid group (20% abstinent 
vs. 0% of controls; N= 74) at day 19 post-quit, as verified with CO readings, but only in a sub 
group of participants with high baseline CO readings. Overall abstinence rates were not 
reported. In the second trial (Westman et al., 1995) participants (N=100), were randomised 
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to use the citric acid inhaler or a lactose placebo inhaler for 10 weeks after quitting, in 
combination with a nicotine patch for the first 6 weeks. Ten-week CO-validated continuous 
abstinence rates were significantly higher in the citric acid group than placebo (19.5% vs. 
6.8%, respectively). However, when adjusted for baseline differences in participant 
characteristics (number of cigarettes smoked per day, number of years smoked, baseline 
CO) this effect was marginal (p= 0.06). At the 24 week follow-up, virtually all participants 
had relapsed and abstinence rates were 0% and 5.1% in the citric acid and placebo groups, 
respectively. 
 
In summary, the citric acid aerosol/inhaler may have some benefit in alleviating withdrawal, 
but effects are likely to be short lived. There is some suggestion that the respiratory 
sensations provided by citric acid may not have been strong enough. For example, 72% of 
participants stated they would have liked stronger throat sensations from the inhaler 
(Behm et al., 1993). This may be of particular importance as perception of strength from 
the inhaler was significantly correlated to satisfaction and liking (Levin et al., 1990), and to 
craving relief, help in refraining from smoking, and abstinence rates (Westman et al., 1995). 
Although the last trial was placebo controlled, use of the placebo inhaler may still have 
afforded some SMR, and at the very least a distraction from smoking. In fact, the positive 
association between perception of sensations and craving relief, help in refraining from 
smoking and even abstinence rates, were evident for both the citric acid inhaler and the 
placebo inhaler.  
 
3.2.1.2 Ascorbic Acid 
 
Two trials examined an ascorbic acid aerosol on craving relief and smoking cessation (Levin 
et al., 1993). In study 1, participants (N= 63), were randomised to use either the aerosol in 
combination with behavioural support, or behavioural support alone. In addition to this, all 
participants were asked to switch to low-nicotine cigarettes prior to quitting. CO-validated 
point prevalence abstinence rates were significantly higher in the ascorbic acid group at 
days 3 (~84% vs. ~60%, p= 0.05) and 22 post-cessation (~58% vs. ~22%, p< 0.01), with a 
trend evident at one week post-cessation (~73% vs. ~52%, p= 0.09). Abstinence rates by the 
6 and 12 week follow ups fell below 20%, with no differences between groups.  
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With respects to craving, greater levels were reported one week post-cessation in those 
using the aerosol compared to controls using nothing. Three weeks post-cessation, this 
effect was marginal. Since only abstainers were included in the analysis of craving, it could 
be the case that participants with high craving in the control group relapsed, whereas the 
aerosol helped those participants remain abstinent despite high levels of craving (Levin et 
al., 1993). Alternatively, the sensations provided by the aerosol may have had the 
unwanted effect of triggering or cueing craving much like other conditioned stimuli. This 
may be unlikely though, as the aerosol was rated as moderately helpful in both alleviating 
craving immediately, and craving reduction over all, and in helping participants to remain 
abstinent. Furthermore, the difference in craving between groups, although significant, was 
small with a mean difference of 0.82 on a 7-point scale. There were no differences between 
groups on other withdrawal symptoms, apart from ‘habit’ withdrawal which was 
significantly higher in the experimental group, but only at 6-weeks post-quit. 
 
In study 2, two different types of ascorbic acid aerosols were compared (fine vs. coarse 
particles). Since fine particles would provide more of a throat ‘scratch’, it was hypothesised 
that this aerosol would be more effective. There were, however, no significant differences 
in overall abstinence rates between the two groups or with craving ratings during aerosol 
use. Participants who had used the coarse aerosol did report a significant increase in 
craving one week after stopping use, whereas craving continued to reduce in the fine 
aerosol condition. The authors propose that this may have been a result of more effective 
extinction with the fine particle aerosol (Levin et al., 1993). Despite this, the initial 
hypothesis that the fine particle aerosol would be more effective due to stronger airway 
sensations specifically in the throat is difficult to accept or reject with these findings, as the 
throat sensations delivered from the coarse aerosol were also reported to be somewhat 
strong. The coarse aerosol therefore may not have been an adequate control device.  
 
3.2.1.3 Black Pepper Extract 
 
One study investigated the use of a black pepper inhalator on withdrawal symptoms and 
other subjective effects (Rose and Behm, 1994). Participants were randomly assigned to 
one of 3 inhalator conditions: black pepper, mint/menthol or no flavour (empty cartridge). 
Following 8 hours of abstinence, participants used their allocated inhalators ad-libitum for 3 
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hours at the study centre and completed subjective measures every hour. The black pepper 
inhalator decreased craving to a greater extent compared to both control conditions.  
 
Additionally, compared to the placebo inhalator, negative affect and anxiety were also 
significantly reduced in the black pepper condition, but satisfaction ratings were 
comparable across all conditions. It could be argued that these results may be due to the 
aversive or irritating effects of black pepper, although this seems unlikely as participants 
reported liking the black pepper and menthol inhalators more than the placebo, and airway 
sensory effects were only rated stronger for the black pepper inhalator in the chest, with no 
differences between inhalators in other areas. Furthermore, as with previous studies with 
citric acid (Levin et al., 1990, Westman et al., 1995) craving reduction was found to be 
significantly correlated with sensations in the chest. 
 
3.2.1.4 Substitute/’dummy cigarettes’ 
 
No further work has been conducted with the citric acid, ascorbic acid and black pepper 
inhalators/aerosols due to extensive regulatory requirements. With few consistent results 
available it is difficult to draw any conclusions as to whether these products could have any 
value in smoking cessation treatment. Various substitute or ‘dummy cigarettes’ are 
available to buy which claim to provide smokers with some SMR and are often marketed to 
smokers as a stop smoking aid. They typically resemble cigarettes (though some are more 
akin to the inhalator) and are often tobacco flavoured but cannot be smoked (e.g. the Crafe 
Away Smokeless Cigarette). Until recently, no trials have been conducted to substantiate 
these claims.  
 
In the first study of its kind, the use of a tobacco flavoured nicotine-free inhalator in 
combination with pharmacological (nicotine patch plus bupropion) and behavioural 
treatment was conducted (Caponnetto et al., 2011a). One hundred and twenty smokers 
seeking treatment were randomised to use either the inhalator with standard treatment or 
standard treatment alone. The inhalator had no effect on abstinence rates at 4 or 24 weeks 
overall, though there was a significant effect of the inhalator in smokers who reported high 
levels of ‘behavioural dependence’ at baseline, a construct purported to be measured by 
the Glover-Nilsson Smoking Behavioural Questionnaire (GN-SBQ; Glover et al., 2005). For 
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example, at 4 weeks post-quit, 67% of participants were abstinent in the inhalator group 
compared to 35% of controls (p= 0.024). These findings were however post-hoc. 
 
3.2.1.5 Summary 
 
Taken together, these studies suggest that flavoured non-nicotine inhalators/aerosols used 
alone or in combination with standard treatment may be of some help in craving 
alleviation, but only in the short term. The utility of these products as a smoking cessation 
tool is difficult to ascertain as data are limited, and what is available is somewhat mixed. 
One study indicated that SMR may be of benefit for those who are ‘behaviourally’ 
dependent to smoking (Caponnetto et al., 2011a), but this finding requires replication.  
 
3.2.2 De-nicotinised cigarettes  
 
The development of a cigarette which contains negligible amounts of nicotine has allowed 
researchers to examine more clearly the role that nicotine and non-nicotine factors play in 
tobacco dependence. DNCs contain tobacco and other harmful constituents and are 
smoked as per conventional cigarettes. However, the nicotine content is extremely low 
(machine yield <0.1 mg nicotine), and is believed to have no central effects (Rose, 2006). 
DNCs differ from low-nicotine yield cigarettes (referred to as ‘light’ or ‘ultra-light’ 
cigarettes), which typically yield low levels of nicotine and tar. These cigarettes deliver 
diluted smoke, which when tested by machine, register low levels of nicotine. However, 
smokers can overcome this by intentionally blocking the ventilation holes in the filter, or by 
adjusting their smoking behaviour; thus these ‘light’ cigarettes can still deliver considerable 
amounts of nicotine (Robinson et al., 2000). This is possible because the nicotine content in 
these cigarettes is similar to high nicotine yield cigarettes (Kozlowski et al., 1998). 
 
DNCs on the other hand contain tobacco where almost all the nicotine has been removed 
from the tobacco leaf. Thus the nicotine content is lowered as opposed to the yield, and 
cannot be altered by the design of the cigarette or through smoking behaviour. Even after 
rapid smoking of DNCs, no significant increase in nicotine plasma levels is evident (Dallery 
et al., 2003). Various methods exist for manufacturing DNCs, such as washing tobacco with 
an alkaline solution, or more recently with genetic modification/selective breeding. These 
cigarettes also still contain high levels of tar, and at similar levels to conventional cigarettes. 
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It has been suggested that this characteristic of DNCs may reduce the need for 
compensatory smoking commonly seen with ‘light’ cigarettes (Walker et al., 2009), possibly 
because reductions in tar are thought to compromise the sensory qualities of smoke 
(Hasenfratz et al., 1993). This resonates with the early work of Rose and colleagues who 
hypothesised that low nicotine cigarettes would be appealing providing adequate sensory 
effects (Rose and Behm, 1987) . 
 
DNCs provide an almost complete behavioural and sensory replacement for cigarettes and 
deliver most of the chemicals found in conventional cigarettes, including those which may 
enhance the effects of nicotine. A considerable amount of literature exists regarding the 
effects of DNCs, particularly on craving/urges to smoke and withdrawal, but also on other 
subjective effects, smoking behaviour and other objective indicators of reinforcement. 
Recently, research has also focused on the efficacy of DNCs in smoking cessation. 
 
3.2.2.1 Acute effects on urges to smoke and withdrawal  
 
The majority of studies involving DNCs have examined their acute effects on urges to 
smoke/craving, following overnight abstinence, with measures varying from single item 
questions to more comprehensive questionnaires. Craving reduction in comparison to 
conventional nicotine cigarettes has, in a fair number of studies, been reported to be 
equivalent (Hasenfratz et al., 1993, Butschky et al., 1995, Rose et al., 1994, Baldinger et al., 
1995c, Baldinger et al., 1995b, Westman et al., 1996b, Gross et al., 1997, Pickworth et al., 
1999, Breland et al., 2002, Buchhalter et al., 2001, Dallery et al., 2003, Rose and Behm, 
2004, Eid et al., 2005, Buchhalter et al., 2005, Juliano et al., 2006, Donny et al., 2007, Brody 
et al., 2009, Cobb et al., 2010, Perkins et al., 2010, Barrett, 2010, Attwood et al., 2009, 
Domino et al., 2013). In one report, which pooled data from 9 studies, DNC effects (craving 
reduction together with satisfaction ratings) were found to be weaker than conventional 
cigarettes (Brauer et al., 2001), though males and more dependent smokers reported more 
similar ratings between the two, suggesting gender and dependency as potential 
moderators of the rewards gained from DNCs. Type of study was also a significant predictor 
of reward variability, perhaps reflecting differences between studies in terms of 
participants’ intentions to quit, ad-libitum vs. controlled smoking procedures, or the 
primary focus of the study.  
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In addition, other studies have also reported, as expected, greater urge relief with 
conventional cigarettes (Baldinger et al., 1995a, Rose et al., 2003, Pritchard et al., 1996, 
Hasenfratz et al., 1993, Hutchison et al., 2004, Juliano et al., 2011, Tidey et al., 2012). One 
recent study found greater craving relief scores with conventional cigarettes vs. DNCs on 
the first smoking bout only, and equivalent relief between the two cigarettes during the 3 
subsequent bouts (MacQueen et al., 2012). In another recent study, craving during smoking 
reduced to a similar extent with DNCs in comparison to conventional cigarettes, with 
effects most pronounced during the first smoking bout compared to the second. When 
craving was examined over the course of 25 minutes however, craving reduction was 
greater with the nicotine cigarette (Lindsey et al., 2013). Hatsukami et al (2013a) reported a 
dose-response whereby there was no difference in craving reduction between DNCs and 
medium-nicotine cigarettes, but high-nicotine cigarettes generated better craving reduction 
than DNCs.   
 
There is good evidence that DNCs can alleviate craving acutely compared to no intervention 
(Lane et al., 1995, Juliano et al., 2006, Perkins et al., 2010, Tidey et al., 2012) and control 
procedures such as puffing on an unlit cigarette or taking in puffs of air (Cobb et al., 2010, 
Rose et al., 2010). 
 
A limited number of studies have compared the acute effects of DNCs to alternative 
methods of nicotine delivery. Buchhalter et al (2001) and Breland et al (2002) examined 
potentially reduced exposure products (PREPs), Accord and Eclipse - which heat tobacco 
and deliver less nicotine than conventional cigarettes - in comparison to DNCs. DNCs were 
able to decrease craving to a greater extent than the Accord, on at least one measure of 
craving, the QSU. Craving reduction between DNCs and the Eclipse was however equivalent 
(Breland et al., 2002). Cobb et al (2010) examined DNCs and non-combustible products 
such as snus, lozenge, and Ariva (a compressed tobacco tablet). DNCs were able to reduce 
craving (relative to baseline) at almost all time points over a 2 hour period, where as non-
combustible products did not, with the exception of one brand of snus. Direct comparisons 
between the DNCs and non-combustible products were not reported.  
One study has also compared DNCs to a nicotine and placebo inhalator over 2 hours, 
following overnight abstinence (Barrett, 2010). DNCs significantly reduced craving relative 
to the placebo inhalator, and also relative to the nicotine inhalator but only on Factor 1 of 
the QSU (intention to smoke). Withdrawal/negative affect relief (Factor 2, QSU) was 
equivalent between the nicotine inhalator and DNCs. In a different design to previous 
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studies, one study reported the effects of DNCs smoked 30 minutes after administration of 
nicotine or placebo lozenges (Barrett and Darredeau, 2012). Here, both placebo and 
nicotine lozenges reduced Factor 1 scores of the QSU (from baseline to 30 minutes, 
measured prior to smoking a DNC) as did DNCs; Factor 2 scores on the other hand were 
only reduced following administration of DNCs. DNCs have also shown either similar craving 
relief  in comparison to IV nicotine delivery (Rose et al., 2003, Rose et al., 2000, Westman et 
al., 1996b), or superior craving alleviation (Rose et al., 2010, Westman et al., 1996b, Rose et 
al., 2000), depending on the craving measure used. 
With respect to short-term alleviation of other withdrawal symptoms, findings have been 
more inconsistent, with research typically showing that DNCs can alleviate at least some 
withdrawal symptoms (Rose et al., 2000, Rose et al., 2003, Hutchison et al., 2004, Rose and 
Behm, 2004, Brody et al., 2009, Rose et al., 2010, Attwood et al., 2009, Kassel et al., 2007, 
Tidey et al., 2012), and in some cases to the same extent as nicotine-containing cigarettes 
(Butschky et al., 1995, Pickworth et al., 1999, Lane et al., 1995, Rose et al., 1994, Westman 
et al., 1996b, Breland et al., 2002, Buchhalter et al., 2001, Juliano et al., 2006, Gross et al., 
1997, Perkins et al., 2010, Dallery et al., 2003, Lindsey et al., 2013). 
 
3.2.2.2 Prolonged effects on urges to smoke and withdrawal  
 
A limited number of studies have investigated the effects of DNCs over longer periods of 
time. Over 24 hours of abstinence, craving and withdrawal were significantly lower with 
DNCs than with no intervention, and craving, impatience and irritability were comparable 
between DNCs and conventional cigarettes (Baldinger et al., 1995b). In the second study 
(Buchhalter et al., 2005), craving reduction over 4 days of DNC use was observed on some, 
though not all measures,  in comparison to no intervention (i.e. complete abstinence), and 
was comparable to nicotine cigarettes. DNCs did not alleviate all withdrawal symptoms. In 
another study, participants in the DNC and no-smoking conditions did not differ in daily 
ratings of craving over 11 days of abstinence, whereas craving was significantly lower in the 
nicotine-cigarette group vs. the no-smoking group (Donny et al., 2007). No differences 
between any of the conditions were found with respect to withdrawal symptoms. Finally, 
Donny and Jones (2009), reported similar withdrawal symptom ratings over 6 days, 
between participants smoking DNCs and those smoking conventional cigarettes, whilst 
wearing a placebo patch. Although participants in the DNC group were more irritable, this 
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dissipated over time. Due to methodological problems, craving ratings could not be reliably 
interpreted in this study and were not reported. 
 
In a study which randomised participants to use one of three types of cigarettes (DNCs, 
medium-nicotine, and high nicotine; double-blinded), for one week, there were no 
differences in ratings of craving reduction between the three cigarettes (Hatsukami et al., 
2013a). However, not all participants remained abstinent from their conventional cigarettes 
during the study.  
 
3.2.2.3 Subjective measures and user acceptability 
 
Along with measurements of craving and withdrawal, studies with DNCs have also included 
assessments of subjective reinforcing effects such as satisfaction, enjoyment, and airway 
sensory effects. These are important to consider if DNCs are to be utilised in smoking 
cessation treatment as they need to be acceptable to users to ensure adherence. Research 
has also found ratings of sensory effects, as opposed to nicotine content, to be related to 
reductions in desire to smoke (Pritchard et al., 1996); additionally, there was an indication 
of a relationship between sensory effects and craving relief from studies with the citric acid 
and black pepper inhalators (Rose and Behm, 1994, Levin et al., 1990, Westman et al., 
1995). 
 
Unsurprisingly, nicotine cigarettes have typically been rated more positive than DNCs used 
in both the short and long term (Butschky et al., 1995, Cobb et al., 2010, Hasenfratz et al., 
1993, Baldinger et al., 1995a, Baldinger et al., 1995b, Baldinger et al., 1995c, Brauer et al., 
2001, Rose and Behm, 2004, Hutchison et al., 2004, Donny et al., 2007, Naqvi and Bechara, 
2005, Naqvi and Bechara, 2006, Perkins et al., 2010, Donny and Jones, 2009, Shahan et al., 
1999, Pritchard et al., 1996, MacQueen et al., 2012, Brauer et al., 1999, Juliano et al., 2011, 
King et al., 2009, Kassel et al., 2007, Tidey et al., 2012, Lindsey et al., 2013, Buchhalter et al., 
2005, Tidey et al., 2013, Hatsukami et al., 2013a). However, some exceptions have been 
noted (Dallery et al., 2003, Lane et al., 1995, Juliano et al., 2006, Pritchard et al., 1996, 
Gross et al., 1997, Pickworth et al., 1999, Westman et al., 1996b, Barrett, 2010, Kassel et al., 
2007, Strasser et al., 2007). For example, Westman et al  (1996b), found no main effects of 
cigarette type on satisfaction, liking and airway sensory effects, and no significant 
differences in satisfaction, strength, harshness, or ‘smoke vs. air’ were reported in another 
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study (Dallery et al., 2003). Barrett (2010), found no difference between the two cigarette 
types on any subjective measures, except ‘stimulation’, where nicotine cigarettes were 
rated higher. A nicotine dose-response was reported by Hatsukami et al (2013a), whereby 
high-nicotine cigarettes were rated more positively than DNCs and medium-nicotine 
cigarettes when used over 1 week, with no differences evident between these latter two 
cigarettes. 
 
DNCs were also rated as more pleasant and satisfying than a nicotine inhalator (Barrett, 
2010); more psychologically rewarding, more satisfying and gave more enjoyable airway 
sensations than sham smoking (Rose et al., 2010); plus as more pleasant, desirable and 
stronger than puffs from an unlit cigarette (Naqvi and Bechara, 2005). DNCs were reported 
to acutely increase ratings of pleasantness, stimulation, relaxation and satisfaction, and 
decreased anxiety, whereas administration of a nicotine or placebo lozenge did not (Barrett 
and Darredeau, 2012).The duration of abstinence prior to smoking DNCs (short term vs. 
overnight abstinence) has not been found to affect subjective ratings despite predictions 
that longer periods of abstinence may warrant more positive ratings (Pritchard et al., 1996, 
Pickworth et al., 1999).  
 
3.2.2.4 Objective measures of reinforcing efficacy 
 
The reinforcing effects of DNCs have mostly been inferred from self-report measures such 
as craving and withdrawal questionnaires, satisfaction ratings, and so on. It has been  
argued that the relationship between self-report data and actual smoking behaviour is 
unclear, and often seemingly related measures can provide inconsistent results (Shahan et 
al., 1999). Indeed recently, a review found that the predictive relationship between craving 
and smoking cessation was inconsistent (Wray et al., 2013). Even with the data reviewed so 
far, different measures of urges/craving have shown inconsistent results within studies 
(e.g.Westman et al., 1995, Breland et al., 2002). A number of studies have utilised objective 
measures of reinforcement such as progressive ratio tasks, preferences between cigarettes 
in a concurrent choice paradigm, and ad-libitum smoking behaviour. Although these studies 
do not directly contribute to the main evidence base on craving and withdrawal alleviation, 
they provide a more comprehensive indication of the reinforcing efficacy of sensorimotor 
input. 
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DNCs have been shown to be as acutely reinforcing as conventional cigarettes when each 
was presented alone, on a variety of indicators during a progressive ratio task; once the two 
cigarettes were provided concurrently however, nicotine cigarettes were preferred (Shahan 
et al., 1999). Shahan et al (2001), also found that consumption rates of nicotine cigarettes 
and DNCs reduced to a similar extent on a progressive ratio task as unit price increased, and 
reduced to the same extent when an alternative reinforcer (money) was available, 
suggesting similar levels of reinforcement. Tidey et al (2013) however reported slightly 
greater preferences for nicotine cigarettes vs. DNCs during a blinded choice task. 
 
Studies assessing short term ad-libitum smoking behaviour have found no differences in the 
amount of DNCs and nicotine cigarettes smoked (Baldinger et al., 1995b) and puff volume 
(Perkins et al., 2010, Tidey et al., 2012), though Rose and Behm (2004) did report 
significantly more nicotine cigarettes smoked vs. DNCs. Additionally, MacQueen et al (2012) 
reported some compensatory smoking for DNCs (e.g. increased total puff volume and puff 
length) compared to conventional cigarettes, but this effect of nicotine content reduced 
over the four smoking bouts. Finally, participants have also demonstrated a preference for 
DNC puffs compared to IV nicotine administration and sham puffs (Rose et al., 2010). 
 
Four studies have objectively explored the reinforcing efficacy of DNCs over longer periods 
of time. The number of puffs earned on a progressive ratio task was reported to have 
significantly reduced over 13 days with DNCS, but did not in the no-smoking and nicotine-
cigarette condition (Donny et al., 2007). The number of cigarettes smoked daily also 
significantly reduced over time with DNCs, but increased with nicotine cigarettes. The 
authors concluded that although the reinforcing effects of DNCs did reduce over time, DNCs 
remained somewhat reinforcing as participants still continued to smoke them. In a shorter 
study (Buchhalter et al., 2005), there was no change over time in the daily number of DNCs 
or nicotine cigarettes smoked over 4 days, but significantly more nicotine cigarettes were 
smoked vs. DNCs. This was also reported in another study where significantly less DNCs 
were smoked over one week vs. high-nicotine cigarettes (Hatsukami et al., 2013a). There 
were no differences in comparison to baseline measures of usual-brand cigarette smoking 
for the DNC group. Donny and Jones (2009) found that DNCs were as reinforcing as nicotine 
cigarettes over 9 days, as indexed by no difference in number of cigarettes smoked per day 
and no difference in average puff volume, total puff volume and total puff count, during a 1 
hour self-administration session on days 3 and 9.  
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The degree to which DNCs can satiate smokers has also been investigated by assessing 
smoking behaviour (of conventional cigarettes) following administration of DNCs. No 
differences between DNCs and conventional cigarettes in latency to first puff were found, 
but latency was significantly greater compared to when placebo and nicotine inhalators 
were used (Barrett, 2010). However, there was significantly less administration of puffs in 
the conventional cigarette condition compared to DNCs and inhalator conditions, 
suggesting as expected, that DNCs were less satiating than conventional cigarettes. DNCs 
were able to satiate smokers compared to a no smoking condition (Rose et al., 2003, Tidey 
et al., 2012), and in comparison to IV nicotine delivery (Rose et al., 2010).  Following 
smoking of DNCs or conventional cigarettes, latency to smoke preferred cigarettes, number 
of puffs, number of cigarettes over 3 hours, and number of cigarettes each hour, did not 
differ between cigarette type in another study (Dallery et al., 2003).  
 
In summary, as with subjective measures, the available literature is somewhat mixed. 
Nevertheless there is some evidence to suggest that with the removal of nicotine, 
conditioned sensorimotor stimuli may remain reinforcing even over longer periods of 
abstinence. Research investigating the satiating effects of DNCs in particular, provides 
additional support other than craving or urge alleviation for the use of SMR in treatment. 
Given that DNCs still contain tobacco, there may be concerns over prolonged DNC use and 
this may pose a barrier to utilisation in smoking-cessation treatment. It is important to note 
then, the reduction in use of DNCs over time and in comparison to conventional cigarettes, 
reported in these longer-term studies. 
 
3.2.2.5 Acute effects of de-nicotinised cigarettes: Additional data from the 
Balanced Placebo Design paradigm 
 
Evidence in support of SMR with DNCs also derives from studies examining the role of 
nicotine expectancy. The results of these studies with respect to main effects of dose 
expectancies and interactions with actual nicotine intake were described earlier (see 
theoretical background), but with the use of a balance placebo design (BPD), these studies 
also offer direct comparisons between conventional nicotine cigarettes and DNCs. Nicotine 
cigarettes were reported to better alleviate craving (Juliano et al., 2011, Kelemen and 
Kaighobadi, 2007, Juliano and Brandon, 2002, Darredeau et al., 2013); were rated higher 
than DNCs on satisfaction, liking, and other subjective rewarding effects (Perkins et al., 
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2008, Perkins et al., 2004, Kelemen and Kaighobadi, 2007, Juliano et al., 2011, Juliano and 
Brandon, 2002, Darredeau et al., 2013); reduced anxiety to a greater extent (Juliano and 
Brandon, 2002) and improved mood (Juliano et al., 2011). Two studies, in contrast, 
reported no differences between the two cigarettes on craving (Perkins et al., 2004, Perkins 
et al., 2008), and few main effects of nicotine were found with regard to withdrawal 
measures (Perkins et al., 2004, Juliano and Brandon, 2002), with the exception of one study 
(Perkins et al., 2008).  
In terms of objective measures, the number of puffs earned on a progressive ratio task was 
greater with nicotine cigarettes (Perkins et al., 2004). In another study, latency to first puff 
did not differ between DNCs and nicotine cigarettes (Perkins et al., 2008), and Darredeau et 
al (2013), also reported no main effect of actual nicotine content on various indicators on a 
progressive ratio task.   
These studies (with the exception of one, detailed below) did not include a ‘no smoking’ 
control group, thus the effects of smoking per se, independent of nicotine content or dose 
expectancies are unknown. The effects of DNCs in comparison to no intervention or control 
conditions such as sham smoking were summarised previously, but one BPD study adds to 
this literature (Perkins et al., 2008). In exploratory analyses, Perkins et al compared a no-
smoking control group to the DNC group (i.e. both those told placebo and told nicotine). 
Following either positive or negative mood inducement, DNCs reduced craving vs. no 
smoking. Additionally, following negative mood inducement, DNCs also reduced negative 
affect and withdrawal. The DNC group was also compared to a sham smoking control group 
(puffing on an unlit cigarette). Following negative mood inducement, DNCs again reduced 
craving and negative affect, but no effects were found on withdrawal or positive affect. The 
sham smoking control group was not tested under positive mood inducement. 
In summary, this line of research adds to the literature on the acute effects of DNCs, firstly 
in comparison to no intervention and to conventional cigarettes, but as outlined previously, 
also suggests that the expectation of receiving nicotine may boost the reinforcing efficacy 
of DNCs (Juliano et al., 2011, Juliano and Brandon, 2002, Perkins et al., 2004). Thus some of 
the reinforcing effects reported in previous (blinded) studies with DNCs may be a result of 
nicotine expectancy and/or conditioned sensorimotor stimulation. As Perkins et al (2003) 
points out, many of the (non-BPD) studies examining DNC effects employed double or 
single blind designs, in which participants were given vague information on nicotine 
content. Thus stimulus expectancies (i.e. the belief that they are getting nicotine) may vary 
between participants, and may impact upon outcome. Indeed one non-BPD study found 
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that those participants who could discriminate between nicotine cigarettes and DNCs, rated 
nicotine cigarettes more positively (e.g. more satisfying, stronger) than DNCs (Strasser et 
al., 2007). Amongst those who could not discriminate nicotine content, DNCs and nicotine 
cigarettes were rated the same. Together with the BPD literature, this suggests that 
nicotine expectancy may have some role to play in the reinforcing efficacy of DNCs.     
 
3.2.2.6 Combining de-nicotinised cigarettes with nicotine delivery 
 
A handful of experimental studies have examined the effects of combining DNCs with 
nicotine delivery, either with a nicotine patch or intravenously (IV). Combining DNCs with 
nicotine should prove most beneficial as both primary and secondary reinforcers of tobacco 
addiction are addressed simultaneously. These studies have shown that a combination of 
the two reduced craving the most compared to IV nicotine, saline or DNCs alone (Rose et 
al., 2010), and produced effects similar to conventional cigarettes (Rose et al., 2000, 
Westman et al., 1996b, Rose et al., 2003). A study which combined DNCs with the nicotine 
patch also reported no differences in urges and withdrawal symptoms in comparison to 
smoking own brand cigarettes (Tidey et al., 2012). Donny and Jones (2009), included a 
further two conditions in their study examining the use of DNCs over 6 days - DNCs with 
either a 7mg or 21mg patch - but few consistent effects of either patch type or cigarette 
type were found on withdrawal symptoms.  
 
In addition to the above, one study found a reduction in craving when participants smoked 
DNCs in combination with a nicotine patch, in comparison to craving calculated as an 
average of their baseline craving and craving after 2 weeks of own brand smoking (Rose et 
al., 2007). Withdrawal symptoms were not affected. This study, however, was designed 
primarily to examine brain correlates of nicotine dependence, and the study procedures 
make it difficult to interpret the data for the purposes of this review. For example, 
conditions were not counterbalanced: all participants completed baseline measures, used 
DNCs and patches for 2 weeks, and then smoked their usual cigarettes for 2 weeks; no 
control group was included, thus any effects could be due to the nicotine patch alone; and 
some participants continued to smoke their usual cigarettes during the 2 weeks of DNC use 
(on average 18 per day), though it is not clear whether or not participants were instructed 
to smoke only DNCs during this period.  
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DNCs have also been combined with NRT in smoking cessation trials; the findings of these 
studies and others are discussed next. 
 
3.2.2.7 De-nicotinised cigarettes and smoking cessation 
 
In the past few years, research with DNCs has begun to focus on their clinical utility in 
smoking cessation. As reported above, DNCs appear to offer some acute craving/urge relief 
during abstinence, and therefore may aid cessation by helping to moderate urges to smoke 
if used as a replacement following the quit day. They could also aid cessation through 
extinction, that is, extinguishing the previously learnt associations between nicotine and 
the behaviour and sensations of smoking. In support of this, it has been proposed that the 
process of extinction may be more effective when the reinforcing effects of a drug are 
removed, as opposed to the drug-taking behaviour (Conklin and Tiffany, 2002). 
Furthermore, as DNCs can be smoked in the same situations and environments as regular 
cigarettes, extinction can occur in a wide variety of contexts, and ‘renewal’ effects are 
theoretically less likely to occur. If used prior to quitting, extinction could aid cessation in a 
number of ways, such as reducing the enjoyment and/reward of cigarettes and dependence 
in the lead up to the quit day, and in turn, potentially easing urges to smoke and 
withdrawal during abstinence. Extinction may occur not only for the sensorimotor aspects 
of smoking, thus devaluing smoking itself, but also for other external/internal conditioned 
stimuli which trigger urges to smokes and/smoking behaviour.  
 
In three smoking cessation trials, DNCs have been utilised in this way, i.e. for several weeks 
prior to the quit date but not after it. The first of these trials randomised 96 participants 
into 6 conditions in a three (DNCs; ‘light’ cigarettes; own brand) by two (nicotine patch; 
placebo) design (Rose et al., 2006). Following the quit day, participants then received either 
42mg, 21mg or placebo patch in combination with mecamylamine. There was no effect of 
DNCs on abstinence rates at 1 and 6 months, although there was an effect of pre-cessation 
nicotine patch. It is likely that the study was underpowered to detect any differences 
between the cigarette conditions. DNCs did however significantly reduce urges to smoke 
compared to own brand smoking over the two weeks prior to quitting, as well as on the 
quit day and one week post-quit; but there were no differences at four weeks post-quit. 
Following the quit day, DNCs also had an effect on ‘habit’ withdrawal ratings and negative 
affect. Habit withdrawal was significantly lower compared to those using own brand 
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cigarettes before the quit day, and negative affect was reduced in comparison to those 
using the ‘light’ cigarettes. Dependence scores, as measured by the Fagerstrom Test of 
Nicotine Dependence (FTND; Heatherton et al., 1991), were also reduced over the 2 weeks 
prior to quitting, indicating a potential reduction in dependence, but again there was only a 
main effect of pre-cessation nicotine patch with no additional benefit evident with the 
DNCs.  
 
In the second trial (Rezaishiraz et al., 2007), 98 participants were given nicotine patches and 
were randomised to smoke DNCs or low-nicotine cigarettes for 2 weeks before quitting. 
After the quit day all participants received eight weeks of nicotine patch treatment. Self-
reported point-prevalence abstinence rates at 3 and 6 months did not differ significantly 
between groups, but craving was significantly lower in the DNC group, both before the quit 
day and at 2 weeks post-quit. No differences between groups in other withdrawal 
symptoms were evident. 
 
Finally, in a larger trial, participants (N=346) used cigarettes with gradually reduced nicotine 
content over 6 weeks until DNCs were smoked in the final two weeks (Becker et al., 2008). 
Participants were also randomized to use either a placebo or nicotine patch, before and 
after the quit day. A control group smoked normal cigarettes during the pre-quit period 
with a placebo patch 2 weeks pre-quit day, and subsequently used a nicotine patch 
following the quit day. All groups were asked to stop smoking all cigarettes after the target 
quit date. Four week CO-validated continuous abstinence rates were significantly higher in 
the DNC plus nicotine patch group vs. controls (33% vs. 22%, respectively, p < 0.05), but the 
DNC plus placebo patch group did not differ in outcome relative to controls (22% vs. 16%, 
respectively, ns). Differences between the two DNC groups were not reported. By 3 and 6 
months, no differences in abstinence rates were present. Effects on urges to smoke and 
withdrawal were not reported in the study. Use of DNCs in both conditions increased 
slightly in comparison to the amount of cigarettes smoked in the first week, but this change 
was not significantly different to the change in cigarettes smoked in the control group. 
Finally, regular cigarettes in the control condition were rated as significantly more satisfying 
than DNCs in either condition. 
 
Four studies have examined the use of DNCs following the quit day. In the first (Hatsukami 
et al., 2010), DNCs were compared to the nicotine lozenge and to low-nicotine cigarettes. 
Participants (N=165) used their assigned products ad-libitum for a period of 6 weeks 
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starting on their target quit day. Continuous CO-validated quit rates at four weeks after 
discontinuation of the products (though use of lozenge was permitted) did not differ across 
conditions, but the trend favoured the DNC group (43%, 35%, and 21% for DNC, lozenge, 
and low-nicotine cigarettes, respectively).  
 
With respect to other effects, at one week following the quit day, withdrawal symptoms 
increased compared to baseline for all groups, though the increase was significantly less for 
the DNC group vs. lozenge and marginally less vs. the low-nicotine cigarette group. Craving 
scores did not change in any of the groups. Following cessation of the products however, 
craving increased significantly for the two cigarette groups in comparison to the previous 
week, though withdrawal symptoms only increased in the low-nicotine cigarette group. In 
comparison to the number of cigarettes smoked at baseline, daily smoking of DNCs 
significantly reduced following 2 weeks of use, whereas use of the low-nicotine cigarettes 
was significantly greater vs. baseline at each time-point. At 6 weeks post-quit day, the 
number of DNCs smoked daily was lower than the number of low-nicotine cigarettes 
smoked. Dependence, measured with the FTND, decreased over the 6 weeks in both the 
lozenge and DNC groups, but not for the low-nicotine cigarette intervention, with the 
lowest levels reported in the lozenge group. 
 
In the second trial (Walker et al., 2012), participants (N=1,410) were randomised to either 
standard care (NRT and behavioural support for 8 weeks) or standard care alongside DNC 
use for a period of 6 weeks after the quit day. Abstinence rates reported at 3 and 6 weeks 
and 3 and 6 months were higher in the DNC group at all follow-up points. At 6 months for 
example, continuous self-reported abstinence rates were 23% vs. 15% in the DNC and 
control condition, respectively (p < 0.001). Time to first lapse was also significantly longer 
for those in the DNC group vs. controls.  Abstinence however was not biochemically verified 
at any time point. There were no differences between groups in urge to smoke and other 
withdrawal symptoms from baseline to 6 weeks post-quit. The number of DNCs smoked 
weekly reduced over the 6 week period, although subjective ratings of the cigarettes (e.g. 
satisfaction, craving relief, psychological reward, aversion, enjoyment of sensations) did not 
change from week 3 to week 6.  
 
Recently, Hatsukami et al (2013b), reported on a trial comparing the effects of DNCs, 
nicotine patch and a combination of the two, on smoking behaviour, withdrawal symptoms 
and long term abstinence rates. Participants (N= 235) were randomised to one of the three 
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interventions, and provided with the products for 6 weeks, alongside brief behavioural 
support for 12 weeks. From baseline to one week during the intervention phase, craving 
decreased in all groups, while withdrawal symptoms increased. The increase in withdrawal 
was significantly less in the combined DNC and patch group compared to patch alone. At 
week 7 (i.e. one-week after cessation of the products) craving increased for all groups from 
week 6. There were also changes in withdrawal from weeks 6 to 7, with the patch-only 
group reporting lower withdrawal ratings, and both DNC groups reporting elevated 
symptoms; differences between treatment groups however were not significant.  
 
During the intervention phase, those in the combined DNC and patch group were 
significantly less likely to smoke conventional cigarettes compared to the other groups. For 
example, at week 6, 33% and 43% in the DNC and patch only groups, respectively, reported 
smoking conventional cigarettes in the previous week, compared to just 14% in the 
combined DNC and patch group (p= 0.002). These reports however were point-prevalence 
and self-report only. The number of DNCs smoked per day over 6 weeks reduced, but the 
reduction was significantly greater in the DNC plus patch group vs. DNCs alone. Follow-ups 
at 12, 24 and 36 weeks revealed no differences in continuous, CO and cotinine verified 
abstinence rates between groups. Thus, despite there being some benefit of combined 
treatment early on, these effects did not appear to translate to long term abstinence 
success, though it should be noted that abstinence analyses were exploratory only, and the 
trial was underpowered to detect such long term effects.     
 
Finally, in a trial conducted at our unit, we randomised 200 participants to either use DNCs 
for two weeks post-quit day, in combination with standard NHS-SSS treatment 
(NRT/varenicline and weekly behavioural support), or standard treatment alone (McRobbie 
et al., 2013). Participants using the DNCs reported significantly reduced frequency of urges 
in the first week post-quit day, although intensity of urge and other withdrawal symptoms 
did not differ between groups. Continuous, CO-verified abstinence from two weeks post-
quit day, was significantly higher in the DNC group at 4 weeks (58% vs. 43%, p= 0.034), but 
by 12 weeks, abstinence rates were similar in the two groups (39% vs. 31%, ns). The 
findings therefore point to some benefit of SMR though the effects may be short lived. 
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3.2.2.8 Summary 
 
The existing evidence suggests that DNCs can acutely alleviate urges to smoke and some 
withdrawal symptoms; in some cases these effects may extend over longer periods of 
abstinence. Objective measures have shown them to be as reinforcing as nicotine cigarettes 
in some short-term studies, but it is not clear for how long they can remain reinforcing. 
Studies utilising the BPD have further added to the DNC literature and have shown, 
unsurprisingly, that under double-blind conditions nicotine cigarettes are more acutely 
rewarding than DNCs. Importantly, merely having the expectation of smoking a nicotine 
cigarette can have an impact on the rewarding effects of smoking. There is some evidence 
that dose expectancies may have interactive effects with nicotine pharmacology on urge 
reduction and smoking behaviour, in that the expectation of nicotine decreases urge when 
DNCs are smoked, but adds little to the effect of nicotine (Juliano et al., 2011).  
DNCs appear to have little impact on smoking cessation if used prior to quitting, although 
data is only available from three trials (Rose et al., 2006, Becker et al., 2008, Rezaishiraz et 
al., 2007), which may have been underpowered to detect any differences in cessation 
outcomes. Additionally, in all three studies, DNCs were only used for 2 weeks prior to 
quitting. It is likely that a longer period of use would be needed to facilitate any potential 
extinction processes. It may be that DNCs offer more utility for cessation when used post-
quit and alongside NRT, possibly because this could offer a way of both extinguishing the 
associations between sensorimotor factors and nicotine and at the same time providing a 
way of alleviating urges to smoke in the first few weeks post-quit. However, the evidence is 
far from conclusive as studies have reported mixed findings of DNC effects on general 
craving during the quit attempt (Walker et al., 2012, Hatsukami et al., 2010, Hatsukami et 
al., 2013b). Also, whether or not DNCs extinguish or at least diminish the effects of other 
conditioned stimuli has not been empirically tested.    
Although it is unlikely that people can become dependent upon DNCs (given that the 
primary reinforcer has been removed), there may be some concerns with using DNCs in 
treatment. Since they do still contain tobacco, use of DNCs in treatment may appear 
counterintuitive to patients and still harmful to health; these concerns may however be 
mitigated by presenting DNCs as a temporary tool, and a ‘stepping stone’ towards complete 
tobacco abstinence. Importantly, current data show that DNC use gradually reduces over 
time, and the amount smoked per day is less than baseline cigarette consumption 
 51 
 
(McRobbie et al., 2013, Walker et al., 2012, Hatsukami et al., 2010, Hatsukami et al., 
2013b).   
Secondly, DNCs may prevent people from habituating to life without cigarettes. One 
experimental study found that smokers who smoked DNCs following 4 days of abstinence, 
relapsed back to normal smoking quicker than those who were in the ‘no lapse’ condition 
(Juliano et al., 2006). Furthermore, the finding that craving increased following cessation of 
DNCs (Hatsukami et al., 2010, Hatsukami et al., 2013b), may reflect the loss of a coping tool. 
The main concerns raised by participants using DNCs in treatment were that they were 
harmful to health (31%), that they may encourage them to smoke conventional cigarettes 
again (12%), and that they were habit forming (6%; Walker et al., 2012). Nevertheless, in 
general, DNCs were acceptable; 90% stated they would recommend DNCs for others 
wanting to quit, and only 11% of participants raised the above concerns. This may reflect 
some bias however, as responses were from those participants remaining in the trial at 6 
weeks. Overall though, there is some evidence that DNCs, especially when combined with 
existing treatments, may have a benefit in smoking-cessation treatment at least early on, 
and further trials are warranted.  
 
3.2.3 Electronic Cigarettes 
 
Electronic cigarettes (ECs) are tobacco-free, battery powered devices, where with each puff 
a visible vapour or mist is created which resembles smoke. They are comprised of a battery, 
atomizer and cartridge containing propylene glycol/glycerine and other flavourings, and can 
be purchased with differing levels of nicotine, including nicotine-free. EC technology has 
quickly evolved; early models of ECs (so called ‘first-generation’ devices) typically resemble 
conventional cigarettes in appearance. Second-generation devices are more advanced and 
allow more choice with respect to nicotine strength and flavours. Third-generation ECs, also 
known as ‘mods’, are ECs which have been modified by the user (e.g. battery voltage can be 
controlled). ECs are a potentially useful tool for assessing the sensorimotor aspects of 
smoking as they provide sensorimotor stimuli fairly close to smoking (e.g. throat scratch, 
inhaling/exhaling), and as they can be used with or without nicotine, they offer a way of 
examining the contribution of SMR per se to smoking behaviour.  
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3.2.3.1 Experimental studies with Electronic Cigarettes 
 
In two studies of nicotine ECs, two different brands (NPRO and Hydro) were compared with 
own brand cigarettes and a sham smoking control condition, after overnight abstinence 
(Eissenberg, 2010, Vansickel et al., 2010). As expected, own brand cigarettes were found to 
reduce craving to a greater extent than ECs. ECs were reported to reduce cravings relative 
to baseline and sham smoking, at some time points (Vansickel et al., 2010). Furthermore, 
the ECs were rated as more pleasant and satisfying vs. sham smoking, and these ratings 
increased compared to baseline, as did ratings of ‘taste good’, ‘calm’, ‘concentration’, 
‘awake’, and ‘reduce hunger’, at several time points. Ratings of ‘smoke another cigarette 
right now’ increased at all time points in the EC conditions, but only increased 30-45 
minutes post administration with the nicotine-cigarette conditions. In the other trial they 
showed little impact on baseline craving or difference from sham smoking (Eissenberg, 
2010). It should be noted that both of these early studies allowed only 10 puffs of the EC 
and no increases in plasma nicotine levels were observed. Any effects in these two studies 
may therefore be attributed to sensorimotor stimulation rather than nicotine. 
 
In a direct comparison of a nicotine and placebo EC, (Bullen et al., 2010), significantly 
greater reductions in craving over one hour were evident with the nicotine EC. However, 
the placebo EC also reduced craving initially, with the differences between the two arms 
only becoming apparent at 25 minutes post product use and onwards. This study also 
compared the ECs to own brand cigarettes and a nicotine inhalator. As before, own brand 
cigarettes reduced craving to a greater extent than all other products, but no differences 
were found between the ECs and inhalator. Additionally, there were no differences in other 
withdrawal symptoms (irritability, restlessness, poor concentration) between the two ECs, 
or between the nicotine EC and inhalator. Following a day’s use of the products, the 
nicotine EC was rated as more pleasant than the inhalator, but they were both comparable 
in satisfaction ratings. The nicotine EC was also rated better than the other products at 
helping to keep participants from smoking, and more likely to be used as a potential 
quitting aid and be recommended to a friend who wanted to stop smoking.  
 
Dawkins et al also compared placebo and nicotine ECs on acute effects (Dawkins et al., 
2012, Dawkins et al., 2013a). In the first study (Dawkins et al., 2012), there were no 
differences between groups from baseline to 5 minutes, but both ECs significantly reduced 
desire to smoke over 20 minutes compared to a control condition where participants were 
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asked to only hold the EC. The reduction was greater for the nicotine EC vs. placebo in 
males but no differences between ECs were evident in females. Some reduction in 
withdrawal symptoms was also reported. At 5 minutes, both ECs reduced anxiety in males 
vs. controls, but for females only the placebo EC showed reductions in comparison to 
controls. Over 20 minutes, anxiety, poor concentration, irritability, and restlessness 
reduced in males using the nicotine EC vs. placebo and control group; for females, only 
depression reduced significantly in both EC groups vs. controls over 20 minutes. The 
findings of this study highlight some potential gender differences in SMR effects (i.e. that 
SMR may be of more benefit for women), though the findings are somewhat inconsistent in 
this respect. Gender differences have also emerged within the DNC literature (Barrett, 
2010). Participants however, were required to remain abstinent for only 1-2 hours prior to 
starting the study; the effect of the ECs over a longer period of abstinence is therefore 
unknown. In the second study, Dawkins et al (2013a) reported greater withdrawal symptom 
ratings and desire to smoke (at 15 minutes following ad-libitum EC use, after overnight 
abstinence) during the placebo EC condition vs. nicotine EC.   
 
In two recent studies with experienced EC users (Vansickel and Eissenberg, 2012, Dawkins 
and Corcoran, 2013), nicotine-containing ECs significantly reduced craving and some 
withdrawal symptoms following 10 puffs, and following ad-libitum use of the EC for 60 
minutes. Furthermore, positive effects of the EC such as pleasantness, satisfaction, and 
good taste, increased following use, and peaked during the ad-libitum period (Vansickel and 
Eissenberg, 2012). Vansickel et al (2012), also found effective withdrawal and craving relief 
following 6 bouts of 10 puffs with a nicotine EC in naïve users. Finally, Nides et al (2014), 
examined nicotine EC use acutely in the laboratory and over one week outside of the study 
centre in naïve users not seeking treatment. Craving reduced acutely during the 
experimental sessions, and the majority of participants reported medium to high craving 
relief in general, when used over the course of the week. Withdrawal symptoms were low 
at baseline prior to laboratory testing and thus were not examined, with the exception of 
anxiety which reduced following EC use. 
 
These four studies focused on nicotine EC effects only and there were no control groups 
included, thus the contribution of sensorimotor effects alone cannot be interpreted, 
though in one study, a reduction in craving and withdrawal was observed after each bout 
despite nicotine levels only increasing significantly after the fourth (Vansickel et al., 2012). 
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3.2.3.2 Smoking Cessation and Reduction  
 
At present, one study has been published regarding the use of ECs in smoking cessation 
treatment (Bullen et al., 2013). Here, participants (N= 657) were randomised to one of 
three groups: nicotine or placebo EC, or nicotine patch, and were also able to access 
telephone support throughout their quit attempt. Comparisons were made between the 
nicotine EC and patch, but also to the placebo EC, enabling an indication of the contribution 
of sensory and behavioural aspects. Verified, continuous abstinence rates at 1, 3 and 6 
months post-quit day were in favour of the nicotine EC. At 6 months these were 7.3% for 
the nicotine EC, 5.8% for placebo EC, and 4.1% for nicotine patch. Differences between 
groups were not significant, although with low abstinence rates across the groups, the trial 
was underpowered to detect these. Time to relapse also favoured the nicotine EC 
compared to the other products. There were similar reductions in smoking in those who did 
not remain abstinent across the two EC groups, with 57% of participants using the nicotine 
EC reducing smoking by at least 50%, and 45% reducing smoking in the placebo EC group. 
For the nicotine patch this was lower, with 41% reducing their smoking. The data therefore 
show some support for SMR, particularly with regard to smoking reduction; it is probable 
though that treatment effects with the nicotine EC would be more pronounced given more 
effective nicotine delivery with new-generation ECs and when combined with intensive 
behavioural support.  
Several surveys of EC users have also reported that the majority of respondents have 
replaced their usual cigarettes with ECs, either partially or completely (Etter and Bullen, 
2011, Etter, 2010, Foulds et al., 2011, Heavner et al., 2009, Goniewicz et al., 2012, Dawkins 
et al., 2013b, Adkison et al., 2013, Etter and Bullen, 2014) and two qualitative studies with 
ex-smokers have provided further anecdotal support for the use of ECs in smoking 
cessation (Barbeau et al., 2013, Farsalinos et al., 2013). Some of these surveys have been 
conducted on current EC users, and therefore may be biased in their favour. One survey of 
Quitline users in the U.S. (Vickerman et al., 2013), reported that EC users were less likely to 
have quit than never-users, though this may reflect the fact these participants appeared to 
be harder to treat in general. 
In a recent survey conducted on a representative sample in Britain, it was reported that 
most EC users were current or ex-smokers, with an estimated 170,000 (1.1%) ex-smokers 
having replaced smoking with ECs (Dockrell et al., 2013). In a pilot survey study of 
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participants purchasing cigarettes as opposed to EC users (Kralikova et al., 2012), 26% (253) 
had tried the EC at least once, and of these, around 27% were now using them regularly. 
The main reasons why those who had ever tried one were not using them were because 
they did not find them satisfying (33%) or they did not like the taste (32%). A larger study of 
the same design (Kralikova et al., 2013) found that smoking reduction was the main reason 
for EC use, with 60% of regular users reporting the EC enabled them to do this. As before 
the main reasons for those not continuing with regular EC was lack of satisfaction and taste. 
In a population-based survey in the U.S., approximately 55% of respondents having tried 
the EC did so for smoking cessation purposes (Zhu et al., 2013). 
In addition to survey data, case reports and observational studies have also been 
conducted. A mean reduction of 39% in cigarettes per day (CPD) over one week was 
reported in 89% of participants using nicotine ECs, and a 50% reduction in 32% of 
participants (Nides et al., 2014). Successful cessation with ECs for at least 6 months in highly 
dependent smokers who were previously hard to treat has also been reported (Caponnetto 
et al., 2011c), and in those with a history of depression (Caponnetto et al., 2011b). One 
prospective study gave participants who were not seeking to quit smoking, ECs to use ad-
libitum for 6 months. At 6 months, 22.5% had quit smoking (Polosa et al., 2011), and when 
followed up at 2 years, 16 of the 40 participants were either abstinent (N=5) or had reduced 
their CPD by at least 50% (Polosa et al., 2013). In a similar study design with heavy smokers 
diagnosed with schizophrenia, half of the sample (7 of 14) reduced their smoking by 50% at 
one year follow-up (Caponnetto et al., 2013a).   
Caponnetto and colleagues also recently conducted a randomised controlled trial (RCT) of 
nicotine and nicotine-free ECs for harm reduction in non-treatment seeking smokers 
(Caponnetto et al., 2013b). Participants (N= 300) were randomised to one of three groups: 
nicotine EC (7.2mg) for 12 weeks; nicotine EC (7.2mg for 6 weeks and 5.4mg for the 
remaining 6 weeks); or nicotine-free EC for 12 weeks. With respect to cigarette reduction 
(excluding abstainers), there were no differences between the nicotine and nicotine-free EC 
groups in the number of participants reducing their CPD by at least 50% since baseline, at 
12 (23% vs. 21%, respectively) and 52 weeks (14.5% vs. 12%, respectively). There were 
however, significant differences between groups in smoking cessation (CO-verified, not a 
single puff since last visit) at both time-points, in favour of the nicotine EC groups (14% vs. 
4% at 12 weeks; 11% vs. 4% at 52 weeks, respectively).  
Some subjective measures were also completed, though at 24 and 52 weeks these were 
only reported by participants still using the products, and thus may be biased. Here, there 
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were no differences between the three groups on ratings of satisfaction vs. own brand 
cigarettes, which were relatively low overall; missing own-brand (moderate); and how likely 
they were to recommend the product to a friend/relative (moderate). The occurrence of 
withdrawal symptoms was recorded, though the authors only report on the overall number 
of participants experiencing each symptom, which was low. Although the results 
unsurprisingly show some favour for the nicotine ECs at least for abstinence rates, the 
authors note that the brand of EC used in this study was not particularly efficient at 
delivering nicotine, and instead believe their findings reflect greater satisfaction with the 
flavour/taste of the nicotine cartridges. If true, this suggests that these findings could be a 
result of the sensorimotor input from ECs; salivary cotinine levels, however, were 
measurable in abstainers in the nicotine EC group, thus the contribution of nicotine cannot 
be completely dismissed.    
 
3.2.3.3 Summary  
 
As ECs are a relatively new product, data are currently limited, but there is some evidence 
that they can acutely alleviate craving and withdrawal. The efficacy of ECs in smoking 
cessation is as yet unknown, but considering findings from the first trial published, survey 
data, observational studies, and evidence of harm reduction, there is clearly potential, and 
these findings warrant further research. Given the limited, or negligible nicotine delivery, 
particularly with earlier EC models, some of these effects may be attributed to 
sensorimotor input, and at least anecdotally, the sensorimotor aspects are perceived by 
users as a part of their efficacy in smoking cessation (Barbeau et al., 2013).   
 
3.3 Conclusions and further research 
 
Of the three SMR products investigated to date, DNCs seem to provide the most support 
for the SMR hypothesis; despite variable results with withdrawal symptom alleviation, they 
show good evidence of acute urge relief, and often in comparison to conventional 
cigarettes; plus their effects may extend over longer periods of time. There is also some 
suggestion that when coupled with current treatments such as NRT, DNCs may enhance 
cessation, though the mechanism of action may not necessarily be via moderation of urges 
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to smoke and withdrawal. Their superior effects are most likely due to the fact that they are 
the closest replacement to conventional cigarette smoking, and thus offer the most 
sensorimotor input. Of course, effects may also be enhanced by other chemicals and 
substances present in tobacco smoke.  As they do still contain tobacco, their use may be 
problematic and unacceptable. In contrast to DNCs, the evidence from flavoured non-
nicotine inhalators/aerosols is weaker and somewhat mixed, and this may reflect the level 
of sensorimotor input (or lack of it) provided by these products. ECs may offer a middle 
ground; they provide sensorimotor stimulation closer to smoking than inhalators/aerosols 
(though not as close to DNCs) and are tobacco-free. Although data are currently limited, 
they may be the most promising of the three approaches as they can combine nicotine 
delivery contingent on sensorimotor input.  
Some methodological issues have emerged from the studies reviewed. Firstly, the majority 
have been experimental/laboratory studies conducted following overnight, or a given 
period of abstinence, with few studies examining the longer-term effects of SMR, and 
outside of a laboratory setting. Research findings between different assessments measuring 
the same constructs within a study have often conflicted, making it difficult to formulate 
conclusions. For example Rose et al (2000) and Westman et al (1996b), both reported 
greater craving relief with DNCs in comparison to no smoking on one measure, but no 
group differences on the Shiffman-Jarvik craving subscale. Smoking cessation trials have not 
always complied with the Russell Standard (West et al., 2005), for example, not reporting 
continuous abstinence or validating self-reported quitters. Another important design 
feature which may moderate sensorimotor effects is whether or not nicotine content (or 
lack of it) is blinded from participants; studies utilising the BPD with DNCs have shown that 
nicotine expectancy may have a role to play. 
There are several areas which require further investigation with SMR. Firstly, it is not clear 
to what extent the effects of SMR can surpass simple distraction. Although previous 
research has compared products to placebos or to no intervention, no study has used a 
distraction control condition which provides no conditioned sensorimotor stimulation. The 
effects of distraction are important to consider as previous research indicates that cognitive 
and behavioural techniques (including distraction techniques) may, for example, help to 
alleviate cue-induced cravings (Ferguson and Shiffman, 2009). From a practical standpoint, 
if SMR does not add anything above and beyond the effects of distraction, there would be 
little justification of its use in treatment Secondly, what level of SMR is required is unclear. 
Theoretically, SMR which is closer to real smoking should be more effective, and evidence 
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from the DNC literature seems to support this, but direct comparisons have not been made. 
Until the arrival of the EC, no SMR products have been available that could rival the DNC; a 
direct comparison of the two products could not only have theoretical implications and 
address the issue of a potential dose-response, but clinical ones also. If for example, ECs 
were as effective as DNCs, there may be a preference to integrate ECs into treatment, 
rather than a tobacco product, which may not be deemed acceptable by all. There is also 
some suggestion in the literature that SMR may be of most benefit for a certain sub-group 
of smoker. In one study (Caponnetto et al., 2011a), exploratory examination of the data 
found that SMR aided cessation only in participants who were deemed to be highly 
‘behaviourally dependent’, and other research has pointed to a benefit for those who 
smoke more/are generally more dependent (Brauer et al., 2001, Behm et al., 1993). 
 
The current project therefore aimed to answer the following research questions: 
 
1. Can SMR surpass simple distraction effects? 
2. Are sensorimotor effects ‘dose-dependent’? 
3. Are smokers who are ‘behaviourally dependent’ more likely to benefit from SMR in 
treatment? 
 
These questions were examined via three separate research studies, which focused on two 
non-nicotine SMR products, ECs and DNCs. To answer whether SMR could surpass 
distraction effects, a nicotine-free EC was compared to a stress ball in Study 1. The EC, as 
opposed to DNC, was chosen for this purpose as it does not contain tobacco and smoke 
constituents, which themselves could have reinforcing effects. As such, this would provide a 
clearer indication as to the contribution of conditioned sensorimotor stimuli per se, without 
the contamination of tobacco smoke constituents. In addition, there is currently limited 
experimental research with ECs, and the study would therefore contribute not only to the 
wider literature on non-nicotine and sensorimotor aspects of smoking behaviour, but also 
provide data on ECs, a topic currently of high interest. To examine whether sensorimotor 
effects are dose-dependent, the nicotine-free EC, which provides some level of 
sensorimotor input, was compared with the DNC that gives a virtually complete 
replacement to conventional cigarette smoking.  As noted previously, these products 
showed the most promise for SMR, and a direct comparison of the two would have 
theoretical and clinical implications. Data for the final research question was collected as 
part of an existing randomised controlled trial, examining the effect of DNCs in combination 
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with standard NHS-SSS treatment (McRobbie et al., 2013). The trial provided an 
opportunity to replicate the novel findings of a recent trial which reported favourable 
results with SMR in combination with standard treatment, but only in a sub-group of 
smokers who scored highly on the GN-SBQ measure at baseline (Caponnetto et al., 2011a). 
There has been little empirical work conducted with the GN-SBQ which purports to 
measure behavioural dependence to smoking, and what is available is mixed (Nerín et al., 
2005, Bullen et al., 2013, Rath et al., 2013); the final study would therefore not only add to 
the evidence base on potential moderators of SMR treatment effects,  but would also allow 
an examination of the measures’ general clinical utility. 
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4 Study 1: Can sensorimotor replacement with 
the electronic cigarette surpass behavioural 
distraction?  
 
4.1 Methodology 
4.1.1  Aims 
 
The aim of the first study was to examine whether sensorimotor stimuli delivered by 
nicotine-free ECs could help alleviate urges to smoke and withdrawal symptoms compared 
to a behavioural distraction control condition (stress ball; SB).  
 
4.1.2 Hypotheses  
 
Since ECs provide some level of SMR, it was hypothesised that ECs would be more effective 
at alleviating urges and withdrawal symptoms and would be perceived as more satisfying 
and helpful than SBs.  
 
4.1.3 Research approach and Design 
 
In order to examine any potential effects of SMR, this study employed a controlled 
experimental/‘laboratory’ approach. Such an approach has been previously used to 
evaluate potentially reduced exposure products such as DNCs, the Accord, Eclipse (Breland 
et al., 2002, Buchhalter et al., 2001), and more recently with ECs (Bullen et al., 2010, 
Eissenberg, 2010, Vansickel et al., 2010, Vansickel et al., 2012, Dawkins et al., 2012, Nides 
et al., 2014). Laboratory methods for evaluating such products/aids are usually conducted 
in the following way: participants attend the study centre following a period of abstinence 
(typically overnight abstinence). Baseline measures (e.g. withdrawal) are completed, and 
participants then use the allocated product for a set period of time (e.g. 5 minutes) or a 
particular number of times (e.g. 10 puffs from a cigarette). Following this, measures 
completed at baseline are then repeated at particular time points. In some designs the 
product will be used once, and measures completed over the following hour; in other 
designs, the product may be administered again after 30 minutes or 1 hour, and the 
measures repeated as before.  
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The product of interest will often be compared to a conventional cigarette and/or another 
similar product or control condition (e.g. sham smoking). Thus, this method typically 
employs a cross-over design, where the sequence of conditions is counterbalanced and 
randomised to prevent order effects, and different conditions are completed following a 
period of ‘wash-out’. With a cross-over design, individual variability can be reduced. 
 
The main advantage of this method is that it can help to reveal whether a product/ 
intervention etc., is effective in principle, before time, money and other resources are spent 
on large clinical outcome trials. It can also provide an indication of user acceptability and 
adverse effects etc., which may be barriers to use. Importantly, this method also allows the 
examination of changes over time, and interactions between time and product or 
intervention type.  
 
An important drawback of this method when evaluating potential aids for withdrawal relief 
is that the setting is highly controlled and artificial, meaning results may not necessarily 
generalise to use of the products or interventions in a ‘real-life’ setting. This is especially 
poignant given that smoking behaviour is highly contextual and associated with many 
different cues, which are undoubtedly lacking in a controlled laboratory environment. 
Furthermore, laboratory methods typically assess acute effects (e.g. up to 1 hour), though it 
could be possible that any treatment benefits dissipate over time as withdrawal symptoms 
intensify or as novelty effects disappear. Another problem concerns the use of repeated 
measurement over time, which in some studies is repeated as often as every 5 minutes. 
This may be of particular concern with questionnaires of self-reported craving or urges as 
there has been some suggestion that they may be subject to reactivity bias, whereby the 
act of answering questions about craving may inadvertently cue craving (Sayette et al., 
2000). Research into this has not necessarily supported these claims though. Shadel et al 
(2001), for example, found that the QSU at least, was not related to higher craving vs. a 
questionnaire unrelated to smoking and a time-based control condition. Significant 
increases in craving were however reported for the time-based control condition, leading to 
a suggestion that a task which is structured and focused (such as a questionnaire, 
regardless of content) may supress craving via distraction.   
 
Despite these limitations, using a controlled laboratory method is appropriate for the aims 
of the present study, and can offer important information on the acute effects of SMR. 
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Given the limitations, the present study combined controlled experimental methods with 
ad-libitum use of SMR products outside of the study centre. This approach was used in 
previous studies with ECs (Bullen et al., 2010, Nides et al., 2014), and NRT (McRobbie et al., 
2010), and enables examination of both immediate effects under controlled conditions as 
well those in a naturalistic setting. Additionally, the controlled experiment was conducted 
both after overnight abstinence and abstinence over the day. In this way, possible effects 
over a longer period of time and after familiarity with the products could be evaluated. 
Repeated questionnaire measures completed over the hour were kept to a minimum to 
avoid possible reactivity bias.  
 
The present study also employed cue-exposure methods to not only help amplify urges to 
smoke and withdrawal prior to assessment, but also to increase external validity by 
exposing participants to a smoking trigger typically experienced in a ‘real world’ setting. In 
addition, the impact of SMR on cue-induced urges to smoke could also potentially be 
assessed, something which is currently lacking in the literature. Cue-induced craving/urge 
refers to the intense craving triggered by stimuli (e.g. lighters, seeing someone smoke, 
smoking environments), which have become associated with smoking via conditioning. The 
general finding from the cue-reactivity literature is that smoking cues generate significant 
increases in craving compared to neutral cues, inferring that smokers are reactive to these 
stimuli (Carter and Tiffany, 1999). Recently, the clinical relevance of cue-reactivity has been 
called into question (Perkins, 2009, Sayette and Tiffany, 2012), but there is some evidence 
to suggest that smoking-related cues may have implications for relapse, in that lapses are 
often related to situational cues (Ferguson and Shiffman, 2009). Thus, an intervention 
which could target both background and cue-induced craving may have added benefit in 
treatment. In their review, Ferguson and Shiffman (2009), reported little evidence that cue-
exposure therapy and chronically administered medications such as the nicotine patch, 
varenicline and bupropion, had much effect on alleviating cue-induced cravings. In contrast, 
acutely administered NRT such as nicotine gum and lozenge were reported to be effective, 
as were behavioural or cognitive interventions aimed at helping people cope with ‘high risk’ 
situations. It is possible, therefore, that there may be scope for SMR products to ease these 
cravings.  
 
In summary, this study used a randomised cross-over design. Participants took part in two 
conditions (EC and SB, order counterbalanced), with a minimum of 2 days in between. For 
each condition, participants were required to attend two 1-hour controlled experiments on 
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the same day (one in the morning following overnight abstinence, one in the evening 
following abstinence over the day).  
 
4.1.4 Participants 
4.1.4.1 Recruitment 
 
Participants were recruited from patients attending the Royal London Hospital Smokers’ 
Clinic, via advertisements in London newspapers and through advertisements in staff 
bulletins at Queen Mary, University of London (see Appendix 1). 
 
4.1.4.2 Inclusion/exclusion 
 
Participants were included in the study if they were aged 18 or over, smoked at least 10 
CPD, and smoked within the first hour of waking. Participants were excluded if they were 
pregnant/breast feeding, had an acute psychiatric illness, were taking part in other 
research, or were currently using an EC or NRT. 
 
4.1.5 Measures and Outcomes 
 
A copy of the clinical records form used to collect all data (excluding baseline measures) is 
shown in Appendix 2. 
 
4.1.5.1 Baseline measures  
 
At baseline, participants completed the standard Royal London Smokers’ Clinic baseline 
questionnaire (see Appendix 3), containing questions regarding demographic details, health 
status and smoking history. The questionnaire also includes the Fagerstrom Test of Nicotine 
Dependence (FTND; Heatherton et al., 1991), a widely used measure for assessing the 
severity of nicotine dependence.  
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4.1.5.2 Withdrawal symptoms and urges to smoke 
 
Withdrawal symptoms during the one hour controlled experiments were measured by 
asking participants to rate on an 11-point scale from 0 (“not at all”) to 10 (“extremely”), 
how they felt “right now”. Three items were adapted from the Minnesota Nicotine 
Withdrawal Scale (MNWS; Hughes and Hatsukami, 1986): irritability, restlessness, and 
difficulty concentrating, and were used in a previous study assessing the acute effects of 
ECs (Bullen et al., 2010). Other withdrawal symptoms such as hunger, depression and sleep 
problems were not included as they would not be experienced in this short time frame. 
Urge to smoke was measured with a single item; “Right now, how strong is your urge to 
smoke?”, also on the same 11-point scale. A single-item measure for urge to smoke was 
chosen, as a lengthy multi-item questionnaire would not be appropriate to the study deign 
and could give rise to distraction effects or reactivity bias. Single-item measures have been 
shown to be as reliable and sensitive as multi-item questionnaires such as the QSU (West 
and Ussher, 2010). 
 
Withdrawal symptoms experienced over the course of the day were measured with the 
Mood and Physical Symptoms Scale (MPSS; West and Hajek, 2004), a widely used measure 
of withdrawal and urges. The MPSS required participants to indicate if they had felt 
depressed, irritable, restless, hungry, or had difficulty concentrating over the course of the 
day. These items were rated on a 5-point scale (“not at all”, “slightly”, “somewhat”, “very” 
or “extremely”). The MPSS also includes two items on a 6-point scale assessing frequency of 
urges (“not at all”, “a little of the time”, “some of the time”, “a lot of the time”, “almost all 
of the time”, or “all of the time”) and strength of urges (“no urges”, “slight”, “moderate”, 
“strong”, “very strong” or “extremely strong”).  
 
4.1.5.3 Product perceptions and use 
 
Participants were asked to complete a questionnaire regarding product satisfaction and 
helpfulness, adapted from previous work with ECs and NRT (Bullen et al., 2010, Hajek et al., 
1989, McRobbie et al., 2010). This asked participants on  5-point scales how satisfying their 
product was in comparison to smoking their usual cigarettes (“much less”, “a little less”, 
“the same”, “a little more”, “much more”); how helpful it was in enabling them to keep 
from smoking, how pleasant it was to use, and how embarrassing it was to use (“not at all”, 
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“slightly”, “somewhat”, “very”, “extremely”); the extent to which they would use the 
product to help them quit, and if they would recommend it to a friend as an aid to quitting 
(“definitely not”, “probably not”, “maybe”, “probably”, “definitely”).  
 
Open questions were used to capture any further information about the products, and 
asked participants to list what they liked most and least about the products. Any adverse 
effects experienced were also listed, and rated on strength (“weak”, “moderate”, “strong”). 
At the final session, participants completed a product preference questionnaire, where they 
were asked to indicate which of the two products they liked better, found easier to use, less 
embarrassing to use, more helpful, and which they would use to help them quit and 
recommend to a friend for help in quitting.  
 
Frequency of product use was measured by asking participants to record how often they 
used the product each hour throughout the day. Instead of recording every squeeze of the 
SB or puff of the EC, one ‘use’ of the SB was defined as using the SB for a period of time 
where they squeezed it at least 15 times, and for EC, using the EC for a period of time 
where they took at least five puffs. Participants were encouraged to record their use 
throughout the day, to ensure more reliable data collection and avoid retrospective 
recording. Participants were also asked if they had smoked any of their usual cigarettes 
over the course of the day (“not a puff”, “a few puffs”, “1-5 cigarettes”, “more than 5 
cigarettes”). Abstinence was verified with CO reading of <10ppm, using a Bedfont CO 
monitor.  
 
4.1.5.4 Cue exposure and reactivity 
  
Participants took part in a cue exposure procedure prior to the one hour controlled 
experiments, where they were asked to light and hold a conventional cigarette for one 
minute, without smoking it. This method of cue exposure is widely used (Ferguson and 
Shiffman, 2009), though in the present study all participants were provided with the same 
brand of cigarettes (Marlboro Lights), as opposed to their preferred brand. This procedure 
has been shown to induce cigarette craving (Niaura et al., 1998). The impact of the cue 
exposure was examined by participants completing ratings of withdrawal symptoms and 
urges (detailed above) pre and post exposure. Since smoking cues have consistently shown 
to increase cravings compared to neutral cues (Carter and Tiffany, 1999), and a 
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baseline/pre-exposure rating was completed, a neutral cue condition was deemed not 
necessary for the present study. 
 
4.1.5.5 Outcomes 
 
The primary outcome of interest was the difference between the two conditions in change 
in urge to smoke from post-cue to 10 minutes post-product use, following overnight 
abstinence. Secondary outcomes were to compare the EC and SB on (i) urges and 
withdrawal symptoms over one hour, in the morning and evening; (ii) urges and withdrawal 
symptoms over one day; and (iii) product satisfaction and preferences. 
 
4.1.6 Sample size 
 
A sample of 40 participants was required to detect a minimum difference of 1.6 (at a 
significance level of 0.05, with 80% probability), on change in urge to smoke from post-cue 
to 10 minutes post-product use, on an 11-point scale. This was based on previous data 
(Bullen et al., 2010), where the within-patient standard deviation of the response variable 
was 2.6. 
 
4.1.7 Products 
 
The EC used in this study was the Smoker’s Angel Halo Electronic Cigarette, purchased from 
www.thesmokersangel.co.uk (see Figure 4.1). At the time of study set-up, first generation 
ECs were more common, and this EC was chosen firstly because a nicotine-free version was 
available, and secondly because of its appearance and ease of use: unlike other brands and 
models, it closely resembled a conventional cigarette in size and appearance, with a white 
battery and orange coloured tip; and used ‘cartomizers’ (where the cartridge and atomizer 
are combined), enabling easy assembly and use for participants (i.e. participants were only 
required to screw in the cartridge to the battery) Participants were provided with 2 fully 
charged batteries and 2 cartomizers for use throughout the day.  
 
SBs were purchased from an online retailer and were plain and of standard size (70mm in 
diameter). Participants were provided with one SB to use throughout the day. 
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Figure 4.1: The Halo Electronic Cigarette 
 
 
Figure 4.1: The Halo Electronic Cigarette comprises of a (a) battery and (b) a cartomizer (cartridge with atomizer 
combined). 
 
4.1.8 Procedures 
 
Participants interested in taking part were initially screened on the telephone, and if 
eligible, were posted study information (see Appendix 4), the baseline questionnaire, and 
booked to attend the first study day. Participants were required to attend the study centre 
in the morning (following overnight abstinence) and evening, on two separate days, with a 
minimum of 2 days in between sessions (where they were asked to smoke as normal). 
Morning sessions were scheduled to begin at 9am, and evening at 5pm, though timings 
were flexible (up to 30 minutes either side) to allow for participants’ work commitments, 
travel disruptions etc. On one of the days participants were given the SB to use, and the 
other day the EC. The order of conditions was randomised and counterbalanced.  
 
Participants were re-screened and consented (see Appendix 5) at the first morning session 
and baseline measures were collected. Overnight abstinence was confirmed with a CO 
reading (cut-off point of 15ppm), as used in previous studies (Bullen et al., 2010, McRobbie 
et al., 2010). Six participants had readings between 16 and 18ppm at either morning 
session, and one participant had an average reading of 22.5ppm across the two mornings; 
exceptions were granted to these participants as they were either heavy smokers (>30 
CPD), or reported heavy smoking the night before. Sensitivity analysis of the primary 
outcome, with these participants removed, revealed similar results between this sub-
(a) (b) 
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sample and the whole sample that completed the study (see Appendix 6). Anyone who 
reported smoking overnight or in the morning was rescheduled to another day. Following 
consent and confirmation of overnight abstinence, participants were allocated to their first 
product. 
 
During each morning and evening session, participants took part in a 1-hour controlled 
experiment. Withdrawal symptom ratings and urges to smoke were completed pre and 
post the cue-exposure task. Participants were then given 5 minutes to use their allocated 
product. When using the EC, participants were asked to take at least 5 puffs and for the SB, 
to squeeze it at least 15 times, but otherwise they could use their products as they wished 
over the 5 minutes. Participants then rated their withdrawal and urges at 5, 10, 30 and 60 
minutes following initiation of product use. 
 
After the morning session, participants were asked to use their allocated product 
throughout the day with at least the same frequency as they would normally smoke, to 
record their product use, and to abstain from their usual cigarettes. Participants returned in 
the evening and repeated the 1-hour experiment. They also completed the MPSS and 
questionnaires regarding product perceptions and adverse effects. Self-reported abstinence 
throughout the day was verified with a CO reading (< 10ppm). At the final evening session, 
the product preference questionnaire was also completed, participants were paid £40 
towards their travel expenses, and offered a referral for smoking cessation treatment. 
Table 4.1 provides a summary of the procedures and measures.  
 
The study was approved by the National Research Ethics Service committee (Clinical Trials 
Registration Number: NCT01414998 [www.clinicaltrials.gov]) and ran from May 2012 until 
October 2012.  
 
4.1.9 Data analysis 
4.1.9.1 Cue-exposure effects 
 
To examine the impact of the cue-exposure procedure on MNWS ratings, a product (EC vs. 
SB) by time (baseline vs. post-cue) repeated measures analysis of variance (ANOVA) was 
conducted on urges and withdrawal items, in the morning and evening.  
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Table 4.1: Summary of Study 1 Procedures and Measures 
 
These analyses were conducted on the sample of participants who complied with study 
procedures and abstained over the day in both conditions (‘abstainers’), and then 
separately on the sample of participants who fully completed the study, regardless of 
abstinence over the day (‘whole sample’). 
 
4.1.9.2 Urge and withdrawal symptoms over 1 hour 
 
To provide an overview of the effects of the products during the experimental sessions, 
MNWS ratings over the full hour were analysed with a repeated measures ANOVA (product 
x time) where time had 5 levels (post cue, 5, 10, 30 and 60 minutes), for both the morning 
and evening sessions. ANOVAs were conducted for each item separately, as well as a 
composite withdrawal score (irritability, restlessness and difficulty concentrating, 
averaged). Where assumptions of sphericity were not met, the Greenhouse-Geisser statistic 
was reported. Any significant interactions were followed up with simple contrasts 
Procedure/measure Session 1  
 
 
 
 
 
 
Rest 
period 
min.  
2 days 
Session 2 
 Morning Day  Evening Morning Day Evening 
Screening + Consent X      
Baseline 
demographics 
X      
CO X  X X  X 
Product allocation X      
Cue-exposure X  X X  X 
1-hour post-product 
use MNWS ratings 
X  X X  X 
Product use 
recording 
 X   X  
MPSS   X   X 
Product rating 
questionnaire 
  X   X 
Product preference 
questionnaire 
     X 
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comparing ratings at each time-point to post-cue, as differences between products in 
change from post-cue were of interest. Analyses were conducted on both the abstainer 
sample and the whole sample. 
 
4.1.9.3 Primary outcome: Acute effects on urge to smoke following overnight 
abstinence 
 
The primary outcome concerned the acute effect of the products on urge to smoke after 
overnight abstinence. Urge to smoke change scores, from post-cue to 10 minutes post-
product use rated in the morning session, were computed for each condition. The Wilcoxin 
Signed Ranks Test was used to test for any differences between the products (data were 
not normally distributed). The analysis was conducted on the whole sample.   
 
4.1.9.4 Urge and withdrawal symptoms over the day 
 
Differences between products in MPSS scores were analysed with paired sample t-tests, or 
where data was not normally distributed, with the Wilcoxin Signed Ranks Test. These were 
conducted on individual items and composite scores (depression, irritability, restlessness, 
difficulty concentrating and hunger averaged for composite withdrawal; urge strength and 
urge frequency averaged for composite urge). Data was analysed for both abstainers and 
the whole sample.   
 
4.1.9.5 Product use, perceptions, and abstinence 
 
Differences between products in amount of use (defined as total amount of times used 
over the day), product satisfaction and other user ratings were also analysed with paired 
samples t-tests/Wilcoxin. For the open questions, where participants were asked what they 
liked most and least about the products they used, responses were categorised, and 
frequencies reported. Any adverse effects listed were reported, along with their strength 
(averaged across participants if n>1). Chi-square tests were used to examine if there were 
any differences in the amount of participants choosing one product over the other in the 
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product preference questionnaire. Differences in abstinence rates over the day were 
examined with the McNemar test. These analyses were conducted on the whole sample. 
 
4.2 Results 
 
4.2.1 Participant characteristics 
 
Forty-eight participants consented to take part in the study, and 40 of these were 
randomised and completed the first session (the remaining eight did not return for their 
first session). Three participants did not attend the second session (N= 1 for EC, N= 2 for 
SB), and two participants did not fully complete the second evening session (both during 
the SB condition). A total of 35 participants therefore completed the full study. Participant 
demographics and baseline characteristics of those who completed are listed in Table 4.2. 
 
4.2.2 Compliance with abstinence 
 
During the EC condition, 22 of the 35 (62.9%) participants who completed the study 
abstained (CO validated) from cigarettes during the day, and 21 of 35 abstained (60%)  
during the SB condition. There was no significant difference in abstinence rates between 
conditions (p= 1.00). Seventeen participants were abstinent during both conditions, and 
thus made up the ‘abstainer’ sample. 
 
4.2.3 Product use 
 
There was a significant difference in the amount of product use over the course of the day 
between the two conditions (z= -2.42, p= 0.015). The EC was used on average 15.9 times 
(SD= 21.5), and SB, 10.2 times (SD= 12.8). 
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Table 4.2: Study 1 Participant Characteristics 
Demographics and baseline characteristics % (N= 35) 
Gender  
   Male 
 
65.7 
Ethnicity 
  Caucasian  
  Mixed/other 
  Don’t wish to answer 
 
68.6 
25.5 
5.7 
Employment status  
   Employed 
   Unemployed 
   Student 
   Other (e.g. retired, sick/disabled) 
 
54.3 
14.3 
5.7 
25.7 
Education  
   Higher 
   Secondary or none 
 
57.1 
42.9 
 Mean (SD) 
Age 40.9 (15.5) 
CPD* 19.0 (7.2) 
FTND 5.8 (2.1) 
*Cigarettes per day 
 
 
 
4.2.4 Primary outcome: Acute effects on urges to smoke after overnight 
abstinence 
 
The hypothesis that the EC would reduce urge to smoke to a greater extent than the SB 
following overnight abstinence, was examined by comparing change scores from post-cue 
to 10 minutes in the two conditions. Since all participants were abstinent during the 
morning sessions, the analysis was conducted on the sample of participants who completed 
the study. Both the EC and SB reduced urge to smoke from post-cue to 10 minutes (Mean 
reduction: EC= 1.20 (SD= 1.92); SB= 0.63 (SD= 1.26), but the difference in change was only 
marginally higher for the EC condition vs. the SB (z= -1.87, p= 0.062).  
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4.2.5 Cue exposure effects  
 
The mean ratings of urge to smoke and withdrawal symptoms pre and post cue-exposure 
for each condition are shown in Table 4.3 (abstainer sample) and Table 4.4 (whole sample), 
together with a summary of ANOVA analyses.  
Ratings during both morning and evening sessions on the whole were fairly moderate. With 
regards to the impact of the cue-exposure (i.e. main effects of time), in abstainers, the cue-
exposure procedure seemed to have some impact on urges (F (1, 16) = 9.07, p= 0.008), 
restlessness (F (1, 16) = 6.67, p= 0.020) and difficulty concentrating (F (1, 16) = 9.30, p= 
0.008) during the morning session, and on urges (F (1, 16) = 9.00, p= 0.008) and irritability 
(F (1, 16) = 5.88, p= 0.028) in the evening session, indicating increases from pre-cue to post-
cue. For the whole sample of participants, no main effects of time were evident. 
 
The repeated measures ANOVA also revealed significant main effects of product for some 
items, particularly in the morning sessions; since participants were aware of which 
condition they would be participating in on that morning prior to commencing the cue-
exposure task, these findings may reflect participants’ expectancies of the EC and SB. In the 
sample of participants who abstained throughout the study, ratings for urge to smoke and 
difficulty concentrating were on the whole lower when participants were told they would 
be using the EC vs. the SB (urge to smoke: F (1, 16) = 6.97, p= 0.018; difficulty 
concentrating: F (1, 16) = 7.73, p= 0.013). There was also a trend for lower ratings of 
irritability and restlessness in the morning, but this did not reach significance. There was, 
however, a significant interaction between time and product for restlessness in the 
morning, suggesting that the increase was larger when participants were aware they would 
be using the SB than EC (F (1, 16) = 4.92, p= 0.041). No main effects of product were evident 
during the evening sessions. 
 
For the whole sample (i.e. those who completed the study, regardless of abstinence 
throughout the day), ratings of urges and irritability in the morning were also lower when 
participants knew they would be using the EC compared to the SB (urge to smoke: F (1, 34) 
= 10.26, p= 0.003; irritability: (F (1, 34) = 6.46, p= 0.016). The same pattern was evident for 
restlessness and difficulty concentrating, but it did not reach significance. Urge to smoke 
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was also on the whole lower in the evening when participants were to use the EC vs. SB (F 
(1, 34) = 5.02, p= 0.032). 
Table 4.3:  Mean ratings and summary of ANOVA analysis of urges and withdrawal 
symptoms pre and post cue-exposure in abstainers. 
 
 
Table 4.4: Mean ratings and summary of ANOVA analysis of urges and withdrawal 
symptoms pre and post cue-exposure (whole sample). 
 Mean rating (SD) F [1, 16] (p)  
 N= 17 EC 
baseline 
EC post-
cue 
SB 
baseline 
SB post-
cue 
Time Product Time x 
Product 
Morning      
Urges 5.94 
(2.73) 
6.53 
(2.83) 
6.88 
(2.62) 
7.29 
(2.37) 
9.07 
(0.008) 
6.97 
(0.018) 
0.46 
(0.508) 
 
Irritability 4.59 
(2.79) 
4.94 
(2.90) 
5.47 
(2.70) 
5.53 
(3.00) 
2.86 
(0.110) 
3.72 
(0.072) 
1.74 
(0.206) 
 
Restlessness 4.94 
(2.95) 
5.00 
(2.81) 
5.47 
(2.79) 
6.00 
(2.72) 
6.67 
(0.020) 
3.97 
(0.064) 
4.92 
(0.041) 
 
Difficulty 
concentrating 
4.24 
(2.66) 
4.65 
(2.83) 
5.06 
(2.82) 
5.24 
(2.66) 
9.30 
(0.008) 
7.73 
(0.013) 
1.36 
(0.260) 
Evening   
Urges 6.24 
(2.66) 
6.76 
(2.80) 
6.29 
(2.69) 
6.88 
(2.89) 
9.00 
(0.008) 
0.04 
(0.837) 
0.09 
(0.773) 
 
Irritability 5.00 
(2.65) 
5.53 
2.65) 
5.00 
(2.94) 
5.24 
(3.07) 
5.88 
(0.028) 
0.13 
(0.728) 
3.13 
(0.096) 
 
Restlessness 
 
 
4.88 
(2.60) 
5.06 
(2.90) 
5.06 
(2.70) 
5.24 
(2.99) 
1.42 
(0.251) 
0.21 
(0.655) 
0  
(1.00) 
 
Difficulty 
concentrating 
4.94 
(2.73) 
4.94 
(2.73) 
5.24 
(2.88) 
5.41 
(2.94) 
1.31 
(0.269) 
1.04 
(0.323) 
1.31 
(0.269) 
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 Mean rating (SD) F [1, 34] (p)  
 N= 35 EC 
baseline 
EC post-
cue 
SB 
baseline 
SB post-
cue 
Time Product Time x 
Product 
Morning      
Urges 5.51 
(3.37) 
5.66 
(2.95) 
6.63 
(2.90) 
6.80 
(2.93) 
0.66 
(0.421) 
10.26 
(0.003) 
0.01 
(0.934) 
 
Irritability 4.14 
(3.46) 
4.31 
(3.26) 
5.26 
(3.13) 
5.11 
(3.42) 
0.01 
(0.937) 
6.46 
(0.016) 
1.56 
(0.221) 
 
Restlessness 4.26 
(3.00) 
4.57 
(2.98) 
5.06 
(2.91) 
5.20 
(3.06) 
1.83 
(0.160) 
3.74 
(0.061) 
0.28 
(0.597) 
 
Difficulty 
concentrating 
3.63 
(2.95) 
3.94 
(2.97) 
4.40 
(2.86) 
4.54 
(3.00) 
1.51 
(0.228) 
3.56 
(0.071) 
0.28 
(0.597) 
Evening   
Urges 5.69 
(3.12) 
5.71 
(3.30) 
6.37 
(2.95) 
6.63 
(3.25) 
0.53 
(0.474) 
 
5.02 
(0.032) 
 
0.53 
(0.473) 
 
Irritability 4.23 
(2.79) 
4.34 
(2.95) 
4.69 
(3.09) 
4.83 
(3.36) 
0.78 
(0.383) 
1.72 
(0.199) 
0.02 
(0.905) 
 
Restlessness 
 
 
4.46 
(2.76) 
4.46 
(3.04) 
4.91 
(2.61) 
5.17 
(2.82) 
0.93 
(0.342) 
3.03 
(0.091) 
1.08 
(0.305) 
 
Difficulty 
concentrating 
4.17 
(2.77) 
4.14 
(2.96) 
4.17 
(2.99) 
4.46 
(3.08) 
1.49 
(0.230) 
0.23 
(0.633) 
1.74 
(0.196) 
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4.2.6 Urges to smoke and withdrawal symptoms over 1 hour 
 
 A repeated measures ANOVA was used to examine the pattern of urges and withdrawal 
symptoms over the course of the hour following the cue exposure, during morning and 
evening sessions. Table 4.5 (abstainer sample) and Table 4.6 (whole sample) present a 
summary of the results. Mean scores and standard deviations for each item by condition 
can be found in Appendices 7-11.  
 
In those who abstained throughout the study, there was a main effect of product during 
the morning session, indicating that urges and withdrawal symptoms were significantly 
lower overall during the EC condition (urge to smoke: F (1, 16) = 20.59, p< 0.001; irritability: 
F (1, 16) = 8.32, p= 0.011; restlessness: F (1, 16)= 14.22, p= 0.002; difficulty concentrating: F 
(1, 16) = 5.07, p= 0.039; and composite withdrawal: F (1, 16) = 13.35, p= 0.002). 
 
There was also a significant main effect of time in the morning for urge to smoke (F (4, 64) = 
9.29, p< 0.001), irritability (F (2.24, 35.83) = 5.63, p= 0.006), restlessness (F (1.94, 31.03) = 
6.18, p= 0.006), and composite withdrawal (F (1.81, 28.97) = 5.71, p= 0.010), with 
reductions from post-cue evident at 5 and 10 minutes post-product use (see Figures 4.2, 
4.3, 4.4 and 4.6, respectively, top panel). There were no significant interactions between 
product and time, for any items, though restlessness tended to decrease to a greater extent 
early on in the EC condition vs. SB (F (4, 64) = 2.43, p= 0.057).  
 
A different pattern of results emerged during the evening session; there was only a 
significant effect of time evident for urge to smoke (F (2.44, 38.98) = 6.80, p= 0.002). All 
other withdrawal symptoms remained stable over time, with no differences between 
products. Figures 4.1-4.5 (top panel) show the ratings for all items by condition, over 1 
hour, in those who abstained. 
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Table 4.5: Summary of ANOVA analysis for urges and withdrawal ratings over 1 hour in 
abstainers. 
 Product Time Product x Time 
 N= 17 F (df), p value 
Morning  
Urge to smoke 20.59 (1, 16) 
p< 0.001 
 
9.29 (4, 64) 
p< 0.001 
1.51 (2.42, 38.73) 
p= 0.230 
Irritability 8.32 (1, 16) 
p= 0.011 
 
5.63 (2.24, 35.83) 
p= 0.006 
0.74 (4, 64) 
p= 0.568 
Restlessness 14.22 (1, 16) 
p= 0.002 
 
6.18 (1.94, 31.03) 
p= 0.006 
2.43 (4, 64) 
p= 0.057 
Difficulty 
Concentrating 
5.07 (1, 16) 
p= 0.039 
 
1.69 (1.95, 31.23) 
p= 0.201 
0.30 (4, 64) 
p= 0.878 
Composite 
withdrawal 
13.35 (1, 16) 
p= 0.002 
5.71 (1.81, 28.97) 
p= 0.010 
0.92 (4, 64) 
p= 0.457 
Evening     
Urges to smoke 0.008 (1, 16) 
p= 0.932 
 
6.80 (2.44, 38.98) 
p= 0.002 
1.23 (2.44, 39.02) 
p= 0.312 
Irritability 0.05 (1, 16) 
p= 0.831 
 
1.97 (1.38, 22.07) 
p= 0.172 
1.17 (4, 64) 
p= 0.332 
Restlessness 0.52 (1, 16) 
p= 0.480 
 
0.95 (1.33, 21.21) 
p= 0.367 
0.26 (4, 64) 
p= 0.902 
Difficulty 
Concentrating 
 
0.54 (1, 16) 
p= 0.475 
1.02 (1.23, 20.71) 
p= 0.347 
0.79 (4, 64) 
p= 0.534 
Composite 
withdrawal 
0.42 (1, 16) 
p= 0.525 
1.26 (1.27, 3.17) 
p= 0.286 
0.30 (4, 64) 
p= 0.903 
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Table 4.6: Summary of ANOVA analysis for urges and withdrawal ratings over 1 hour (whole 
sample) 
 Product Time Product x Time 
 N= 35 F (df), p value 
Morning  
Urge to smoke 14.14 (1, 34) 
p= 0.001 
 
17.18 (3.15, 106.97) 
p< 0.001 
3.65 (2.71, 92.08) 
p= 0.019 
Irritability 8.08 (1, 34) 
p= 0.008 
 
5.29 (2.14, 72.88) 
p= 0.006 
0.62 (2.43, 82.54) 
p= 0.573 
Restlessness 12.96 (1, 34) 
p= 0.001 
 
11.78 (1.92, 65.34) 
p< 0.001 
2.02 (2.41, 81.83) 
p= 0.130 
Difficulty 
Concentrating 
4.82 (1, 34) 
p= 0.035 
 
3.09 (2.63, 89.43) 
p= 0.037 
0.57 (2.81, 95.61) 
p= 0.625 
Composite 
withdrawal 
10.77 (1, 34) 
p= 0.002 
9.10 (2.11, 2.52) 
p< 0.001 
1.19 (2.52, 85.71) 
p= 0.316 
Evening     
Urges to smoke 4.41 (1, 34) 
p= 0.043 
 
11.69 (2.69, 91.48) 
p< 0.001 
1.37 (2.66, 90.58) 
p= 0.258 
Irritability 2.50 (1, 34) 
p= 0.123 
 
1.89 (1.98, 67.32) 
p= 0.159 
1.81 (2.52, 85.65) 
p= 0.160 
Restlessness 3.21 (1, 34) 
p= 0.082 
 
4.49 (1.96, 66.76) 
p= 0.015 
1.15 (2.10, 71.35) 
p= 0.326 
Difficulty 
Concentrating 
 
0.43 (1, 34) 
p= 0.517 
 
2.35 (1.94, 65.99) 
p= 0.105 
0.27 (2.11, 71.66) 
p= 0.775 
Composite 
withdrawal 
2.48 (1, 34) 
p= 0.125 
3.52 (1.81, 61.44) 
p= 0.040 
1.19 (2.24, 76.07) 
p= 0.315 
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Figure 4.2: Mean urge to smoke ratings over 1 hour 
Abstainers (N= 17)  Morning       Evening 
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Figure 4.2 shows the 
mean urge to smoke 
during morning and 
evening sessions over 
one hour, rated on a 
scale of 0 (not at all) 
to 10 (extremely). 
Product was 
administered post-
cue exposure (PC). *, 
** and † indicate 
significant effects of 
Time, Product and a 
Time x Product 
interaction, 
respectively (p≤ 0.05) 
Whole sample (N= 35) 
Time point (minutes) 
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Figure 4.3: Mean irritability ratings over 1 hour 
Abstainers (N= 17)  Morning      Evening 
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Figure 4.3 shows 
mean irritability 
during morning and 
evening sessions over 
one hour, rated on a 
scale of 0 (not at all) 
to 10 (extremely). 
Product was 
administered post-
cue exposure (PC). * 
and ** indicate 
significant effects of 
Time and Product 
respectively (p≤ 0.05) 
Time point (minutes) 
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Figure 4.4: Mean restlessness ratings over 1 hour 
Abstainers (N= 17)   Morning      Evening   
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Figure 4.4 shows 
mean restlessness 
during morning and 
evening sessions over 
one hour, rated on a 
scale of 0 (not at all) 
to 10 (extremely). 
Product was 
administered post-
cue exposure (PC). * 
and ** indicate 
significant effects of 
Time and Product 
respectively (p≤ 0.05) 
Whole sample (N= 35) 
Time point (minutes) 
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Figure 4.5 Mean ratings of difficulty concentrating over 1 hour 
Abstainers (N= 17)   Morning        Evening   
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Figure 4.5 shows 
mean difficulty 
concentrating during 
morning and evening 
sessions over one 
hour, rated on a scale 
of 0 (not at all) to 10 
(extremely). Product 
was administered 
post-cue exposure 
(PC). * and ** 
indicate significant 
effects of Time and 
Product respectively 
(p≤ 0.05) 
Time point (minutes) 
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Figure 4.6: Mean composite withdrawal ratings over 1 hour 
Abstainers (N= 17)   Morning       Evening  
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Figure 4.6 shows 
mean composite 
withdrawal during 
morning and evening 
sessions over one 
hour, rated on a scale 
of 0 (not at all) to 10 
(extremely). Product 
was administered 
post-cue exposure 
(PC). * and ** 
indicate significant 
effects of Time and 
Product respectively 
(p≤ 0.05) 
Time point (minutes) 
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For the whole sample of participants, all items overall were rated significantly lower during 
the EC condition vs. SB in the morning (urge to smoke: F (1, 34) = 14.14, p= 0.001; 
irritability: F (1, 34) = 8.08, p= 0.008; restlessness: F (1, 34) = 12.96, p= 0.001; difficulty 
concentrating: F (1, 34) = 4.82, p= 0.035; and composite withdrawal: F (1, 34) = 10.77, p= 
0.002). There were also significant changes over time (urge to smoke: F (3.15, 106.97) =  
17.18, p< 0.001; irritability: F (2.14, 72.88) = 5.29, p= 0.006; restlessness: F 1.92, 65.34) = 
11.78 , p< 0.001; difficulty concentrating: F (2.63, 89.43) = 3.09, p= 0.037; and composite 
withdrawal: F (2.11, 2.52) = 9.10, p< 0.001), with reductions mostly evident within the first 
5-10 minutes after product use (see Figures 4.2-4.6, bottom panel).  
 
There was also a significant interaction for urge to smoke (F (2.71, 92.08) = 3.65, p= 0.019); 
contrasts comparing each time-point to post-cue revealed only a trend for a greater 
reduction in urge from post-cue to 10 minutes during the EC vs. SB condition (F (1, 34) = 
3.28, p= 0.079; see Appendix 12 for a summary of results). This interaction is perhaps more 
likely explained by the steeper increase in urge during the EC condition from 10 minutes 
onwards (see Figure 4.2, bottom panel).  
 
In the evening, urge to smoke was rated significantly lower during the EC condition (F (1, 
34) = 4.41, p= 0.043), and changes over time were apparent for urges (F (2.69, 91.48) = 
11.69, p< 0.001) , restlessness (F (1.96, 66.76) = 4.49, p= 0.015) and composite withdrawal 
scores (F (1.81, 61.44) = 3.52, p= 0.040); although there were no significant interactions, 
mean scores are indicative of reductions at 5-10 minutes after product use during the EC 
condition, with scores during SB use remaining more stable (see Figures 4.2, 4.4 and 4.6, 
respectively, bottom panel). 
 
4.2.7 Supplementary analyses: Acute effects on urges to smoke and withdrawal 
 
The pattern of symptom ratings over the course of the hour indicated that any effects of 
the products and potential differences between them were immediate and relatively short-
lived. The primary outcome analysis suggested some advantage for the EC. To examine 
theses acute effects more closely, urge scores and composite withdrawal were entered into 
a two-by-two repeated measures ANOVA (product [EC vs. SB] by time [post-cue vs. 10 
minutes]). To simplify the analysis further, differences from post-cue to 10 minutes for each 
of the products separately were examined via paired samples t-test (or Wilcoxin Signed 
Ranks Test where data was not normally distributed).  
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In addition, area under the curve (AUC) analysis was also conducted for the first 10 minutes 
post-product use. This approach was used in earlier studies examining both ECs and NRT, 
with a similar design to the present study (Bullen et al., 2010, McRobbie et al., 2010), and 
has an advantage over the traditional repeated measures ANOVA approach. It provides a 
combined summary of the two types of information generated by a repeated measure 
design: the magnitude of effect and change over time. This simplifies the analysis and 
reduces the number of statistical comparisons. AUC was calculated from change scores 
(post-cue minus each time point [5 minutes and 10 minutes]) for urge to smoke and 
composite withdrawal. Alongside AUC, the greatest reduction in ratings (Rmax) and time at 
which this occurred (Tmax) were also computed. Paired samples t-test/Wilcoxin was used 
to test for any differences in these values between products.  
 
These analyses were conducted for both morning and evening sessions, on the sample of 
participants who abstained throughout the study, and for the whole sample who 
completed the study. 
 
4.2.7.1 Results: Abstainer sample 
 
Separate analyses for each product revealed that both the SB and EC significantly reduced 
urge to smoke at 10 minutes, during both the morning (SB: t= 2.55, p= 0.022; EC: z= -2.90, p 
= 0.004) and evening sessions (SB: t= 3.89, p= 0.001; EC: t= 2.40, p= 0.029; see Figure 4.7, 
top panel). The ANOVA however revealed a significant interaction for the morning session,
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Figure 4.7: Acute effects of products on urge to smoke in abstainers    
(N= 17)   Morning        Evening 
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Figure 4.7 Top panel 
shows the mean urge to 
smoke pre-product use 
and at 10-minutes post-
product use. Product 
was administered post 
cue-exposure. * and ** 
indicate a significant 
change from post-cue 
to 10 minutes for EC 
and SB respectively, 
and † a significant 
interaction. Bottom 
panel shows reduction 
from post-cue in urge to 
smoke over 5 and 10 
minutes post-product 
use. * and ** indicate a 
significant difference 
between products in 
AUC and Rmax, 
respectively. Analysis 
conducted on 
abstainers only; 
significance level p ≤ 
0.05. Time point (minutes) 
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indicating that reduction with EC was greater than SB (M= 1.82 (2.04) vs. 0.82 (1.33), 
respectively; F (1, 16) = 8.00, p= 0.012). This interaction was not evident during the evening 
session. Table 4.7 provides a summary of the repeated measures ANOVA analysis. 
 
AUC analyses were in accordance with these results. During the morning session, mean 
AUC and Rmax were significantly larger for the EC condition (AUC: z= -2.06, p= 0.040; Rmax: 
z= -2.25, p= 0.024), with no differences between products apparent in the evening (see 
Table 4.8). Figure 4.6, bottom panel, shows the mean reduction in urge to smoke over 10 
minutes by condition, during morning and evening sessions. 
 
Composite withdrawal scores showed a similar pattern, with the EC significantly reducing 
withdrawal in the morning (t= 2.73, p= 0.015) and evening (t= 2.70, p= 0.016), as did the SB 
(morning: t= 2.41, p= 0.028; evening: t= 2.63, p= 0.018; see Figure 4.7, top panel). The 
ANOVA revealed no significant interaction for either the morning or evening session, 
indicating no difference in magnitude of reduction between products (see Table 4.7). There 
were no differences in mean AUC between the products during morning and evening 
sessions for withdrawal scores. Maximum reduction was significantly larger for the EC 
condition in the morning only (z= -1.99, p= 0.046; see Table 4.8).  
 
Table 4.7: Summary of ANOVA analysis on the acute effects of products on urges and 
withdrawal ratings in abstainers. 
 Product Time Product x Time 
N= 17 F (df) p value 
Morning  
Urge to smoke 13.79 (1, 16) 
p= 0.002 
12.23 (1, 16) 
p= 0.003 
8.00 (1, 16) 
p= 0.012 
 
Composite 
withdrawal 
10.23 (1, 16) 
p= 0.006 
9.96 (1, 16) 
p= 0.006 
1.05 (1, 16) 
p= 0.322 
Evening     
Urges to smoke 0.006 (1, 16) 
p= 0.940 
12.46 (1, 16) 
p= 0.003 
1.21 (1, 16) 
p= 0.289 
 
Composite 
withdrawal 
0.26 (1, 16) 
p= 0.616 
11.15 (1, 16) 
p= 0.004 
1.24 (1, 16) 
p= 0.729 
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Time to maximum reduction was not significantly different at either session (see Table 4.8). 
Figure 4.7, bottom panel, shows the mean reduction in composite withdrawal over 10 
minutes by condition, during morning and evening sessions. 
 
4.2.7.2 Results: Whole sample  
 
When the analyses were repeated on the whole sample, a similar pattern emerged for urge 
to smoke, in that the EC reduced urge to smoke during both sessions (morning: t= 3.69, p= 
0.001; evening: (z = -2.78, p= 0.005), as did the SB (morning: z= -2.74, p= 0.006; evening: -
2.73, p= 0.006; see Figure 4.8, top panel).  
 
 
Table 4.8: Mean area under the curve (AUC), reduction maximum (Rmax), and time to 
Rmax (Tmax) values and summary test statistics for acute urges and withdrawal ratings in 
abstainers. 
N= 17 EC SB EC vs. SB 
Morning  Mean (SD) Test statistic Sig. (p) 
Urge to smoke      
  AUC 
  Rmax 
  Tmax 
13.68 (15.89) 
2.35 (2.09) 
6.47 (2.94) 
7.65 (10.17) 
1.41 (1.37) 
5.00 (3.06) 
z= - 2.06 
z= -2.25 
z= -1.29 
0.040 
0.024 
0.197 
Composite withdrawal 
  AUC 
  Rmax 
  Tmax 
6.62 (7.21) 
1.12 (0.94) 
5.29 (2.78) 
3.48 (4.49) 
0.75 (0.70) 
5.29 (4.13) 
t= -1.83 
z= -1.99 
z= 0 
0.085 
0.046 
1.00 
Evening     
Urge to smoke      
  AUC 
  Rmax 
  Tmax 
5.29 (9.18) 
1.06 (1.14) 
3.53 (3.43) 
6.91 (5.63) 
1.18 (0.88) 
5.29 (3.29) 
z= -0.91 
z= -0.28 
z= -1.51 
0.362 
0.776 
0.130 
Composite withdrawal 
  AUC 
  Rmax 
  Tmax 
3.09 (5.89) 
0.63 (0.73) 
5.29 (4.13) 
2.99 (3.17) 
0.63 (0.62) 
5.88 (3.64) 
z= -0.78 
z= -0.48 
z= -0.42 
0.938 
0.634 
0.674 
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Figure 4.8: Acute effects of products on composite withdrawal in abstainers  
(N= 17) 
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Figure 4.8 Top panel 
shows the mean 
composite withdrawal 
score pre-product use 
and at 10-minutes 
post-product use. 
Product was 
administered post 
cue-exposure. * and 
** indicate a 
significant change 
from post-cue to 10 
minutes for EC and SB 
respectively. Bottom 
panel shows 
reduction from post-
cue in composite 
withdrawal over 5 
and 10 minutes post-
product use. ** 
indicates a significant 
difference between 
products in Rmax. 
Analysis conducted on 
abstainers only; 
significance level p ≤ 
0.05. 
Time point (minutes) 
 90 
 
Figure 4.9: Acute effects of products on urge to smoke (whole sample) 
(N= 35)            Morning        Evening 
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Figure 4.9 Top panel 
shows the mean urge 
to smoke pre-product 
use and at 10-minutes 
post-product use. 
Product was 
administered post 
cue-exposure. * and 
** indicate a 
significant change 
from post-cue to 10 
minutes for EC and SB 
respectively. Bottom 
panel shows reduction 
from post-cue in urge 
to smoke over 5 and 
10 minutes post-
product use. ** 
indicates a significant 
difference between 
products in Rmax. 
Analysis includes non-
abstainers; 
significance level p ≤ 
0.05. 
Time point (minutes) 
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Reduction in the morning tended to be larger for the EC, but the interaction did not reach 
significance (F (1, 34) = 3.28, p= 0.079; see Table 4.9). 
 
Similarly, there was no difference in urge to smoke AUC between products, during the 
morning and evening, though AUC for the EC in the morning tended to be larger (z= -1.77, 
p=0.077). Reduction maximum in the morning was significantly larger for the EC (z= -2.59, 
p= 0.010; see Table 4.10). Figure 4.9, bottom panel, shows the mean reduction in urge to 
smoke over 10 minutes by condition, during morning and evening sessions. 
 
Composite withdrawal scores followed a slightly different pattern of results. The EC 
reduced withdrawal acutely in the morning (z= -3.20, p= 0.001), but the reduction was not 
significant during the evening session (t= 1.47, p= 0.151). In contrast, the SB had no effect 
during the morning, (t= 1.08, p= 0.288) but reduced withdrawal significantly in the evening 
(t= 2.16, p= 0.038), though the reduction was modest (see Figure 4.10, top panel). 
Interactions between product and time in the morning did not quite reach significance (F 
(1, 34) = 3.53, p= 0.069; see Table 4.9). 
 
 
Table 4.9: Summary of ANOVA analysis on the acute effects of products on urges and 
withdrawal ratings (whole sample). 
 
 Product Time Product x Time 
N= 35 F (df) p value 
Morning  
Urge to smoke 15.46 (1, 34) 
p< 0.001 
 
16.51 (1, 34) 
p< 0.001 
3.28 (1, 34) 
p= 0.079 
Composite 
withdrawal 
10.45 (1, 34) 
p= 0.003 
9.43 (1, 34) 
p= 0.004 
3.53 (1, 34) 
p= 0.069 
Evening     
Urges to smoke 4.91 (1, 34) 
p= 0.034 
 
15.30 (1, 34) 
p< 0.001 
0.004 (1, 34) 
p= 0.947 
Composite 
withdrawal 
6.24 (1, 34) 
p= 0.017 
0.004 (1, 34) 
p= 0.952 
3.39 (1, 34) 
p= 0.919 
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Table 4.10: Mean area under the curve (AUC), reduction maximum (Rmax), and time to 
Rmax (Tmax) values and summary test statistics for acute urges and withdrawal ratings 
(whole sample).  
 
 N= 35 EC SB EC vs. SB 
Morning  Mean (SD) Test statistic Sig. (p) 
Urge to smoke      
  AUC 
  Rmax 
  Tmax 
9.14 (14.35) 
1.80 (1.78) 
5.29 (3.42) 
5.14 (9.23) 
1.03 (1.20) 
4.00 (3.60) 
z= -1.77 
z= -2.59 
z= -1.48 
0.077 
0.010 
0.139 
Composite withdrawal     
  AUC 
  Rmax 
  Tmax 
6.02 (9.67) 
1.14 (1.14) 
5.00 (3.43) 
1.93 (7.81) 
0.69 (0.81) 
4.43 (4.16) 
z= -2.16 
z= -2.01 
z= -0.71 
0.031 
0.044 
0.477 
Evening     
Urge to smoke      
  AUC 
  Rmax 
  Tmax 
5.93 (11.91) 
1.17 (1.34) 
3.57 (3.34) 
4.29 (8.57) 
1.00 (1.14) 
4.43 (3.98) 
z= -0.48 
z= -0.57 
z= -1.10 
0.628 
0.589 
0.273 
Composite withdrawal     
  AUC 
  Rmax 
  Tmax 
2.71 (6.17) 
0.60 (0.72) 
4.43 (3.98) 
1.69 (5.64) 
0.55 (0.67) 
4.71 (4.19) 
z= -0.64 
z= -0.11 
z= -0.29 
0.520 
0.991 
0.771 
 
 
Differences between products were more apparent with AUC analyses (Table 4.10). AUC 
and Rmax values for composite withdrawal scores were significantly larger for the EC during 
the morning session (AUC: z= -2.16, p= 0.031; Rmax: z= -2.01, p= 0.044) but any differences 
were not significant during the evening. Figure 4.10, bottom panel, shows the mean 
reduction in urge to smoke over 10 minutes by condition, during morning and evening 
sessions. 
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Figure 4.10: Acute effects of products on composite withdrawal (whole sample) 
(N= 35)            Morning        Evening 
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Figure 4.10 Top 
panel shows the 
mean composite 
withdrawal score 
pre-product use and 
at 10-minutes post-
product use. Product 
was administered 
post cue-exposure. * 
and ** indicate a 
significant change 
from post-cue to 10 
minutes for EC and 
SB respectively. 
Bottom panel shows 
reduction from post-
cue in composite 
withdrawal over 5 
and 10 minutes post-
product use.* and ** 
indicate a significant 
difference between 
products in AUC and 
Rmax, respectively. 
Analysis includes 
non-abstainers; 
significance level p ≤ 
0.05. Time point (minutes) 
 94 
 
 
4.2.8 Urges to smoke and withdrawal symptoms during the day 
 
Table 4.11 shows the mean composite MPSS withdrawal and urge scores completed in the 
evening. In general, participants reported moderate levels of withdrawal and urges over the 
course of the day. In abstainers, there were no differences between conditions in 
composite withdrawal scores, but composite urge score was significantly lower in the EC 
condition (t= -2.26, p= 0.038). When individual urge items were analysed, participants 
experienced the same frequency of urges in both conditions, but the strength of these 
urges tended to be lower with EC than SB  (z= -1.94, p= 0.052). With respect to individual 
MPSS items (depression, irritability, restlessness, difficulty concentrating and hunger), there 
were no differences between conditions on any items. A summary of the analysis can be 
found in Appendix 13. 
 
When the whole sample was analysed, composite MPSS and urge scores showed a similar 
pattern, in that there were no differences in MPSS scores, but significantly lower urges to 
smoke in the EC condition (t= -4.01, p< 0.001; see Table 4.11). 
 
 
Table 4.11: Mean scores and summary test statistics for composite MPSS and urges to 
smoke. 
 MPSS Urge to 
smoke 
Urge Frequency Urge Strength 
Abstainers (N= 17) M (SD) 
EC 2.52 (0.76) 3.26 (0.71) 3.35 (1.00) 3.18 (0.81) 
SB 2.51 (0.68) 3.65 (1.14) 3.71 (1.21) 3.59 (1.18) 
Test statistic 
Sig. (p) 
t= 0.09 
0.933 
t= -2.26 
0.038 
z= -1.60 
0.109 
z= -1.94 
0.052 
Whole Sample  
(N= 37)* 
 
EC  2.37 (0.78) 3.28 (0.89) 3.44 (1.07) 3.26 (0.94) 
SB 2.46 (0.77) 3.82 (1.17) 3.87 (1.23) 3.76 (1.20) 
Test statistic 
Sig. (p) 
t= -1.02 
0.314 
t= -4.01 
<0.001 
t= -2.59 
0.010 
t= -3.51 
<0.001 
*Two participants who did not attend the evening session gave responses via telephone 
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Frequency and urge strength were also significantly lower in the EC condition (z= -2.59, p= 
0.01; z= -3.51, p< 0.001, respectively). Irritability was found to be significantly lower for the 
EC condition (z= -2.08, p= 0.038) though the magnitude of this difference was small (EC: M= 
2.49, SD= 1.17; SB: M= 2.84, SD= 1.39). Depression tended to be greater with the EC 
(M=2.00, SD= 1.20) vs. SB (M= 1.70, SD= 0.88), but ratings for depression were low in both 
conditions and the difference did not reach significance (z= -1.81, p= 0.070). A summary of 
the analysis can be found in Appendix 13.  
 
4.2.9 Supplementary analyses: Baseline ratings during morning and evening 
sessions 
 
To further examine the effect of the products over the course of the day, analyses were 
conducted to compare morning and evening baseline ratings for MNWS items, urge to 
smoke and composite withdrawal. Paired samples t-tests/Wilcoxin were used to compare 
ratings separately for each product, and data were entered into a two-by-two repeated 
measures ANOVA (product [EC vs. SB] by time [morning vs. evening]) to ascertain any 
interactional effects. Results are reported for the sample of abstainers, and the whole 
sample. 
 
4.2.9.1 Results: Abstainer sample 
 
Separate analyses showed that for the EC condition, mean baseline urge to smoke did not 
change significantly over the course of the day (morning: 5.94 (SD= 2.73), evening: 6.24 
(SD= 2.66); t= -0.52, p= 0.611). This was also true for the SB condition (morning: 6.88 (SD= 
2.62), evening: 6.29 (SD= 2.69); t= 0.97, p= 0.347; see Figure 4.11, top left panel). The 
repeated measures ANOVA revealed no significant interactions (see Table 4.12). The same 
pattern of results was evident for composite withdrawal scores (see Figure 4.11, bottom 
left panel), with no changes for the EC over the day (morning: 4.59 (SD= 2.60), evening: 
4.94 (SD= 2.44); t= -0.71, p= 0.486) or SB (morning: 5.33 (SD= 2.51), evening: 5.10 (SD= 
2.71); t= 0.55, p= 0.591). Accordingly, the interaction was not significant (see Table 4.12). 
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Figure 4.11: Mean baseline ratings of urge to smoke and composite withdrawal in the morning and evening  
Abstainers (N= 17)       Whole sample (N= 35) 
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Figure 4.11 shows the 
mean baseline ratings 
of urge to smoke (top 
panel) and composite 
withdrawal score 
(bottom panel) during 
morning and evening 
sessions, rated on a 
scale of 0 (not at all) to 
10 (extremely), prior to 
commencing cue-
exposure. There were 
no significant changes 
or interactions for 
either measure.  
Session time 
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Table 4.12: Summary of ANOVA analysis on baseline urge and withdrawal ratings in the 
morning and evening. 
 Product Time Product x Time 
Abstainers  
(N=17) 
F (df) p value 
Urge to smoke 2.03 (1, 16) 
p= 0.173 
0.076 (1, 16) 
p= 0.786 
3.22 (1, 16) 
p= 0.092 
 
Composite 
withdrawal 
3.62 (1, 16) 
p= 0.075 
0.020 (1, 16) 
p= 0.890 
2.16 (1, 16) 
p= 0.161 
Whole sample 
(N= 35) 
   
Urges to smoke 11.03 (1, 34) 
p= 0.002 
 
0.01 (1, 34) 
p= 0.912 
0.83 (1, 34) 
p= 0.370 
Composite 
withdrawal 
6.24 (1, 34) 
p= 0.017 
0.00 (1, 34) 
p= 0.952 
3.39 (1, 34) 
p= 0.074 
 
 
4.2.9.2 Results: Whole sample 
 
Analysis conducted on the whole sample revealed the same results, with no changes in 
mean urge to smoke evident from morning to evening for either the EC (morning: 5.51 (SD= 
3.37), evening: 5.69 (SD= 3.12); z= -0.05, p= 0.959) or SB (morning: 6.63 (SD= 2.90), evening: 
6.37 (SD= 2.95); z= -0.37, p= 0.710; see Figure 4.11, top right panel). This was also the case 
for mean composite withdrawal (see Figure 4.11, bottom right panel) for the EC (morning: 
4.01 (SD= 2.90), evening: 4.29 (SD= 2.58); t= -0.79, p= 0.436) and SB (morning: 4.90 (SD= 
2.61), evening: 4.59 (SD= 2.69); t= 0.90, p = 0.375), and again no significant interaction was 
evident (see Table 4.12).  
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4.2.10 Product perceptions, preferences and adverse effects 
 
Table 4.13 shows the mean product ratings and percentage of participants choosing each 
product. Overall, participants perceived the EC more positively than the SB. The ECs were 
rated as more satisfying (z= -3.01, p= 0.003), and of more help in enabling participants to 
keep from smoking (z= -4.54, p< 0.001). Satisfaction with the EC still low however. They 
were also deemed to be less embarrassing to use (z= -2.56, p= 0.011); participants were 
more likely to use ECs as an aid to quitting in the future (z= -4.83, p< 0.001), and to 
recommend them to others who wanted to quit smoking (z= -4.59, p< 0.001). There was 
however no difference between the products in ratings of pleasantness (z= -0.77, p= 0.443).  
 
When participants were asked to choose between the two products, the majority of 
participants favoured the EC than SB. Significantly more participants liked the EC (  = 
22.73, p< 0.001), reported it was easier to use (  = 22.11, p= 0.011), more helpful in 
keeping them from smoking (  = 22.73, p< 0.001), less embarrassing    = 26.81, p= 0.001), 
and more likely to use the EC in their own quit attempt    = 22.73, p< 0.001) as well as 
recommend to others for quitting (  = 22.73, p< 0.001). 
 
Seven participants reported adverse effects from the EC. These were moderate throat 
irritation/sore throat (N= 3); EC becoming hot on the lips/mouth (weak-moderate, N= 2); 
weak chest irritation (N= 1); moderate stomach ache (N= 1); and a strong feeling of 
dizziness (N= 1). For the SB condition, two participants reported strong pain from squeezing 
the ball.  
 
Table 4.14 shows the responses participants gave regarding what they liked most and least 
about the EC and SB. Most participants liked the EC because of the sensory and behavioural 
replacement it provided (N= 17), and its similarity to cigarettes (N= 8), though the taste was 
the least liked aspect (N= 13), followed by the weight and size (N= 10). For the SB, the 
majority of participants were indifferent, and did not like or dislike anything about the 
product (N= 17 and 8, respectively). Some did report that the SB was pleasant to use (N= 
10), and helped to provide a behavioural distraction (N= 5). The least liked aspects were 
that it gave no craving or urge relief (N= 9), and that it was impractical (N= 8).  
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Table 4.13: Mean product ratings and preferences. 
Product ratings EC SB Sig. (p) 
N = 37† Mean (SD) 
Satisfaction compared to 
usual cigarette 
1.77 (0.96) 1.29 (0.80) 0.003 
Helpful in keeping from 
smoking 
2.69 (1.10) 1.55 (0.65) <0.001 
Pleasantness 2.69 (0.95) 2.55 (0.72) 0.433 
Embarrassing to use 1.72 (0.92) 2.26 (1.13) 0.011 
Would use to quit 
smoking 
3.36 (1.14) 1.68 (0.74) <0.001 
Would recommend to 
others for quitting 
3.38 (1.09) 1.89 (0.92) <0.001 
Product preferences  % of participants  
Liked more 89.2 10.8 <0.001 
Easier to use* 71.4 28.6 0.011 
More helpful in keeping 
from smoking 
89.2 10.8 <0.001 
More embarrassing to 
use** 
20.6 79.4 0.001 
More likely to use for 
quitting smoking 
89.2 10.8 <0.001 
More likely to 
recommend to others for 
quitting 
89.2 10.8 <0.001 
†
Two participants who did not attend the evening session gave responses via telephone. *N= 2 and **N= 3 did 
not choose between the two products.  
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Table 4.14: Open responses to questions “What did you like most/least about the product 
you used today?” 
Liked Most  Liked Least  
EC N*  N* 
Sensorimotor replacement 17 Taste 13 
Similarity to real cigarettes 8 Weight/size/shape 10 
Helped with 
cravings/prevented smoking 
5 No craving relief/satisfaction 5 
Less harmful/‘clean’/no 
smell 
4 No nicotine rush or ‘hit’ 4 
Taste/flavour 4 Technical problems 1 
Can be used anywhere 3 Throat irritation 1 
Easy to carry around 1 Increased urge to smoke 1 
Nothing 3 Not acceptable to use everywhere 1 
  Difficult to puff on 1 
  Nothing 7 
SB    
Pleasant to use/felt 
nice/soft 
10 No craving relief 9 
Behavioural 
replacement/distraction 
5 Size/impractical to use 8 
Calming/relaxing 3 No sensory replacement 4 
Helpful for keeping from 
smoking 
1 Embarrassing/felt self-conscious 2 
Convenient size 1 Difficult/painful to squeeze 2 
Nothing 17 Too dissimilar to smoking 1 
  Made more irritable/annoyed 1 
  Increased urge to smoke 1 
  Everything 1 
  Nothing 8 
*N refers to the frequency of responses. Some participants gave more than one answer. 
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4.3 Discussion 
 
The aim of the present study was to investigate whether SMR effects could surpass simple 
distraction. Here, the nicotine-free EC was compared to a SB on urges to smoke and 
withdrawal following overnight abstinence and abstinence over one day. Both the EC and 
SB alleviated urge to smoke and most withdrawal symptoms acutely, following overnight 
abstinence. Ratings were generally lower with the EC over the hour, most likely reflecting 
lower ratings at baseline. Urge to smoke, the primary outcome of interest, reduced to a 
lesser extent with the SB, but analysis of change scores at 10 minutes between products did 
not reach significance. The change seen here with the EC was smaller compared to a 
previous similar study; Bullen et al (2010), reported a mean reduction of 2.8 units with the 
nicotine-free EC from baseline to 10 minutes following overnight abstinence, compared to 
1.82 (‘abstainer’ sample), and 1.20 (whole sample), seen in the present study. It may be 
that effects were somewhat diminished as ratings of urge to smoke were slightly lower in 
the EC condition to begin with compared to SB.  
 
 
When the data were examined more closely however, and in those who had abstained 
throughout the study, the EC was more effective in alleviating urges acutely compared to 
the SB. This was further confirmed with AUC analyses, whereby AUC values and mean 
reduction maximum were significantly larger for the EC vs. SB. Nevertheless, the magnitude 
of difference was still fairly modest. Differences between products for composite 
withdrawal on the other hand were less pronounced. 
 
After participants had used the products throughout the day and continued to abstain, 
there was a small benefit of the EC with respect to urge to smoke over the course of the 
day (MPSS ratings), and in particular the intensity of these. As before, the differences 
between products were modest. Over the course of the hour, there were few changes in 
urges to smoke and withdrawal, except for a slight dip in urges at 5 and 10 minutes. This 
occurred regardless of product used, and additional analyses confirmed that both products 
reduced urges and withdrawal at 10 minutes to a similar extent. This lack of difference 
appeared to be a result of reduced EC effectiveness, as opposed to an improvement with 
the SB. These findings suggest that SMR may only have an effect early on in the treatment 
phase. A similar finding was also reported with the citric acid aerosol, whereby treatment 
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effects were only evident at the start of the study, and dissipated quickly after repeated use 
and prolonged abstinence (Levin et al., 1990).  
 
There may be a number of potential explanations for these findings. Firstly, the novelty of 
using a device which resembles a cigarette and retains similar behaviours to smoking may 
have been enough to alleviate symptoms when first used, but not after continued use. 
Related to this is the possibility that the sensorimotor input from the EC was inadequate or 
even unpleasant. Indeed, the taste of the EC was the most disliked aspect reported by 
participants, and this may have reduced adherence to the product particularly in the 
evening when novelty effects had worn off. It should also be considered that ratings of 
symptoms are also highly subjective and participants may simply have perceived the EC to 
be more effective in the morning. 
 
With regards to the impact of the cue-exposure procedure, in abstainers at least, the 
procedure seemed to increase urges, restlessness and difficulty concentrating during the 
morning session, and urges and irritability in the evening to a modest extent. Interestingly, 
symptom ratings were on the whole lower in the morning prior to product use, when 
participants were told they would be using the EC vs. the SB. Furthermore, restlessness 
increased to a greater extent following cue-exposure, when participants were told they 
would be using the SB rather than the EC. These findings are suggestive of an expectancy 
effect; that is, participants may have had the expectation that the EC would be of more 
help than the SB, resulting in lower symptom ratings.  
 
Overall, there is some evidence that conditioned SMR may surpass distraction effects, but 
the small differences between products, particularly after continued use, suggest that this 
effect may be short-lived. On the other hand, the finding that participants had a strong 
preference for the EC, and primarily reported they liked it because it provided sensorimotor 
input (in particular the vapour, being able to inhale and exhale) and its similarity to 
cigarettes, suggest there is an important role for sensorimotor input, if anything at least in 
terms of user acceptability. Thus, despite somewhat limited EC effects in urge and 
withdrawal relief, the sensorimotor aspects gave it added appeal over simple behavioural 
distraction. One notion which should be considered (and would have implications for the 
central SMR hypothesis), is that these contradictory findings could imply that sensorimotor 
factors are less involved in urge alleviation than previously hypothesised; smokers may still 
find ECs helpful, perhaps as a coping tool during abstinence, but this may not necessarily 
mean that they work by alleviating the urge to smoke.  
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It also could be possible that the sensorimotor input from the EC was insufficient or 
inadequate. The next step was to ascertain whether SMR requires a certain level of input or 
‘dose’ to be effective. There is indication in the literature that SMR more proximal to 
conventional cigarettes would be more effective - and certainly this would hold 
theoretically - but this has not been empirically tested. The aim of Study 2 was therefore to 
compare the nicotine-free EC with the DNC, with the same design and procedures used 
here. Given the modest impact of the EC in this study, this would then also allow 
comparison between studies, to see how nicotine-free EC effects would compare in a 
different sample of smokers.  
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5 Study 2: Are sensorimotor effects ‘dose’ 
dependent? 
 
5.1 Methodology 
5.1.1 Aims 
 
The aim of Study 2 was to assess whether sensorimotor effects were ‘dose-dependent’. 
Here, the nicotine-free EC and DNC were compared directly to examine whether the 
proximal SMR delivered by DNCs, would be more effective at reducing urges to smoke and 
withdrawal symptoms than the EC. 
 
5.1.2 Hypotheses  
 
Since DNCs provide a greater level of SMR (i.e. real tobacco smoke), it was hypothesised 
that DNCs would be more effective at alleviating urges and withdrawal symptoms and 
would be perceived as more satisfying and helpful than ECs.  
 
5.1.3 Design 
 
This study followed the same design and procedures as that of Study 1. Participants took 
part in two conditions (DNC and EC, order counterbalanced), with a minimum of 2 days in 
between, and attended 2 one-hour controlled experiments on the same day (morning and 
evening).    
 
5.1.4 Participants 
5.1.4.1 Recruitment 
 
Participants were recruited from patients attending the Royal London Hospital Smokers’ 
Clinic, via advertisements in London newspapers, and through advertisements in staff 
bulletins at Queen Mary, University of London (see Appendix 1). 
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5.1.4.2 Inclusion/exclusion 
 
Participants were included in the study if they were aged 18 or over, smoked at least 10 
cigarettes per day, and smoked within the first hour of waking. Participants were excluded 
if they were pregnant/breast feeding, had an acute psychiatric illness, were taking part in 
other research, or were currently using an EC, NRT, or smoking nicotine-free cigarettes (e.g. 
herbal cigarettes). 
 
5.1.5 Measures and Outcomes 
5.1.5.1  Measures 
 
The present study used the same measures as those in Study 1, listed below. A detailed 
description of the measures used is given in the Study 1 methodology. A copy of the clinical 
records form and baseline questionnaire can be found in Appendices 2 and 3, respectively.  
1. Smokers Clinic Baseline Questionnaire: This is the standard Royal London Hospital 
baseline questionnaire that includes demographic details, health status, smoking 
history and the FTND (Heatherton et al., 1991). 
2. Minnesota Nicotine Withdrawal Scale (MNWS; Hughes and Hatsukami, 1986): 
Measure of urges to smoke and withdrawal symptoms (irritability, restlessness, 
difficulty concentrating).  
3. Mood and Physical Symptoms Scale (MPSS; West and Hajek, 2004): Measure of 
urges to smoke and withdrawal symptoms over the day. 
4. Cue-reactivity: Measure of reactions to smoking-related cues. 
5. Abstinence from conventional cigarettes: Measured with a Bedfont CO monitor, cut 
off <10ppm. For the DNC condition, abstinence over the course of the day was self-
report only. 
6. Product questionnaire: Measure of satisfaction, helpfulness, acceptability, and 
preferences adapted from previous work (Hajek et al., 1989, Bullen et al., 2010, 
McRobbie et al., 2010).  
7. Adverse effects: Description of any adverse effects and strength of these. 
8. Product use: Record of how often the product was used during the day (note one 
‘use’ was defined as taking at least 5 puffs from the EC or DNC). 
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5.1.5.2 Outcomes 
 
The primary outcome of interest was the difference between the two conditions in change 
(from post-cue) in urge to smoke at 10 minutes post-product use, following overnight 
abstinence. Secondary outcomes were to compare the DNC and EC on (i) urges and 
withdrawal symptoms over one hour, in the morning and evening; (ii) urges and withdrawal 
symptoms over the course of a day; and (iii) product satisfaction and preferences. 
 
5.1.6 Sample size 
 
As Study 1 used the same design and procedures as the present study, the sample size was 
calculated from those data, in order to obtain a more accurate idea of how the nicotine-
free EC would affect acute urge scores following overnight abstinence. Data from Study 1 
showed that the EC generated a mean reduction of 1.20 units (SD= 1.92) from post-cue to 
10 minutes post-product use. The present study therefore required 40 participants in order 
to detect a minimum difference between the two conditions of 1.2 units, with 80% power, 
at a significance level of 0.05. Taking into account that three participants from Study 1 did 
not complete the second study session, the total sample size for Study 2 was increased to 
45 to allow for some drop-out between sessions.  
 
 
5.1.7 Products  
 
The EC used in Study 1 was also used for the present study (Smoker’s Angel Halo Electronic 
Cigarette, purchased from www.thesmokersangel.co.uk) with nicotine-free cartomizers.  
DNCs (XODUS brand) were purchased from 22nd Century Group Inc., USA. These cigarettes 
contain extremely low levels of nicotine, about 95% reduced compared to most US brands 
(Xie et al., 2004). The machine yields of nicotine under ISO smoking conditions are 
approximately 0.088 mg nicotine/cigarette.  
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5.1.8 Procedures 
 
This study followed the same procedures as Study 1, whereby participants attended the 
study centre on two separate days, following overnight abstinence. A copy of the 
participant information sheet is shown in Appendix 14. Two participants had CO readings 
between 18 and 20ppm during both morning sessions, but exceptions were granted as one 
participant was a heavy smoker (>40 CPD), and the other smoked heavily the night before. 
Sensitivity analysis of the primary outcome, with these participants removed, revealed 
similar results between this sub-sample and the whole sample that completed the study 
(see Appendix 15). Participants were allocated the EC on one day, and DNC the other 
(randomised, counterbalanced). As before, on each day, participants took part in two 1-
hour controlled experiments (morning and evening), and used their allocated product 
throughout the day whilst remaining abstinent from their conventional cigarettes. The 
same cue-exposure procedures as those of Study 1 were also used for the present study.  
The study was approved by the National Research Ethics Service committee (Clinical Trials 
Registration Number: NCT01414998 [www.clinicaltrials.gov]), and ran from October 2012 
until March 2013. 
 
5.1.9 Data analysis 
 
Due to the same study design and procedures, the same sets of analyses outlined 
previously for Study 1 were conducted for the present study comparing the EC and the 
DNC.  
In summary, these were: 
1. Cue-exposure effects on urges and MNWS ratings: Repeated measures ANOVA 
(Product [DNC vs. EC] x Time [baseline vs. post-cue]) for morning and evening 
sessions. 
2. Urges and MNWS ratings over 1 hour: Repeated measures ANOVA (Product [DNC 
vs. EC] x Time [post-cue, 5, 10, 30 and 60 minutes]) for morning and evening 
sessions. Any significant interactions were followed up with simple contrasts 
(comparing each time point to post-cue).  
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3. Acute effects of products on urge to smoke following overnight abstinence (primary 
outcome): paired sample t-test/Wilcoxin Signed Rank Test on change scores 
(calculated from post-cue to 10 minutes post-product use).  
4. Urge to smoke and withdrawal symptoms over the day (MPSS scores): Paired 
samples t-test/Wilcoxin Signed Rank Test. 
5. Differences between products in amount of product use (defined as total us over 
the day) and product ratings: Paired samples t-test/Wilcoxin Signed Rank Test. 
6. Differences in abstinence over the day: McNemar Test. 
7. Product preferences: Chi-square test. 
8. Open responses to questions “liked most/least about the product used”: 
Categorised and frequencies of responses reported. 
9. Adverse effects: Frequency reported along with strength rating (averaged across 
participants if N>1). 
 
5.2 Results  
 
5.2.1  Participant characteristics 
 
Forty-five participants consented to take part in the study, and all were randomised and 
completed the first session. Four participants did not attend the second session (N= 3 for 
DNC; N= 1 for EC). Participant demographics and baseline characteristics of those who 
completed the study are listed in Table 5.1. 
 
5.2.2 Compliance with abstinence 
 
During the EC condition, 28 of 41 participants (68.3%) abstained (CO validated) from 
cigarettes during the day, and 38 of 41 (92.7%) abstained during the DNC condition (self-
reported). The difference in abstinence rates between the two conditions was significant 
(p= 0.002). Twenty-eight participants were abstinent during both conditions, and made up 
the ‘abstainer’ sample.  
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Table 5.1: Study 2 Participants Characteristics.   
Demographics/baseline characteristics  % (N= 41) 
Gender  
   Male 
 
53.7 
Ethnicity 
  Caucasian  
  Mixed/other 
  Don’t wish to answer 
 
65.9 
34.1 
0 
Employment status  
   Employed 
   Unemployed 
   Student 
   Other (e.g. retired, sick/disabled) 
 
41.5 
26.8 
7.3 
24.4 
Education  
   Higher 
   Secondary or none 
 
58.5 
41.5 
 Mean (SD) 
Age 42.9 (15.6) 
CPD 20.6 (9.7) 
FTND 5.6 (1.9) 
 
 
5.2.3 Product use 
 
There was a significant difference in the amount of product use over the course of the day 
between the two conditions (z= -2.39, p= 0.017). The EC was used on average 13.9 times 
(SD= 13.8), and DNC, 9.4 times (SD= 4.1).  
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5.2.4 Primary outcome: Acute effects on urges to smoke after overnight 
abstinence 
 
Urge to smoke change scores (from post-cue to 10 minutes) in the two conditions, 
following overnight abstinence were compared in order to test the primary hypothesis that 
the DNC would be more effective compared to the EC. This analysis was conducted on the 
full sample of participants who completed the study, as all participants were abstinent in 
the morning session. Both the EC and DNC reduced urge to smoke following product use, 
(M= 2.95, SD= 2.82 for EC change; M= 3.10, SD= 2.72 for DNC change), but there were no 
significant differences in magnitude of reduction between the two conditions (z= -0.76, p= 
0.448). 
 
5.2.5 Cue-exposure effects  
 
The mean ratings of urge to smoke and withdrawal symptoms pre and post cue-exposure 
for each condition are shown in Table 5.2 (abstainer sample) and Table 5.3 (whole sample), 
together with a summary of ANOVA analyses.  
On the whole, ratings in the morning prior to product use were fairly moderate. In both 
samples, the cue-exposure only had a significant impact on ratings of difficulty 
concentrating (abstainer sample: F (1, 27) = 4.57, p= 0.042; whole sample: (F (1, 40) = 5.53, 
p= 0.024), whereby these ratings increased following cue-exposure. In the whole sample, 
there was also a trend for an increase in urge to smoke post cue-exposure (F (1, 40) = 3.32, 
p= 0.076), 
Although there were no significant main effects of product in the morning in either of the 
samples analysed, there were some interactions between product and time. As in Study 1, 
participants were aware of which product they would be using prior to completing baseline 
and post-cue ratings, and as such these interactions could indicate a moderating role of 
product expectancy on cue reactivity.  For the whole sample, there was a significant 
interaction for restlessness (F (1, 40) = 4.30, p= 0.045), and a marginal interaction for 
irritability (F (1, 40) = 3.88, p= 0.056), with mean scores reflecting an increase when 
participants were told they would be using the EC, and no change when they knew they 
would be using the DNC 
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There was also a suggestion of an interaction for urge to smoke in the abstainer sample; 
here, post-cue urge tended to reduce prior to DNC use, but increased prior to EC use (F (1, 
27) = 3.71, p= 0.065).  
Table 5.2: Mean ratings and summary of ANOVA analysis of urges and withdrawal 
symptoms pre and post cue-exposure in abstainers. 
 Mean rating (SD) F [1, 27] (p) 
N= 28 EC 
baseline 
EC post-
cue 
DNC 
baseline 
DNC 
post-
cue 
Time Product Time x 
Product 
Morning      
Urges 6.89 
(2.81) 
7.54 
(2.77) 
7.14 
(2.19) 
6.89 
(2.78) 
 
0.49 
(0.489) 
0.18 
(0.678) 
3.71 
(0.065) 
Irritability 4.89 
(3.06) 
5.57 
(3.12) 
5.07 
(2.45) 
4.96 
(2.84) 
 
0.98 
(0.330) 
0.14 
(0.708) 
2.40 
(0.133) 
Restlessness 
 
5.07 
(2.96) 
5.64 
(2.95) 
4.96 
(2.59) 
4.96 
(2.81) 
 
1.54 
(0.226) 
0.72 
(0.404) 
2.78 
(0.107) 
Difficulty 
concentrating 
4.46 
(2.72) 
5.04 
(3.09) 
4.18 
(2.78) 
4.29 
(2.79) 
4.57 
(0.042) 
0.99 
(0.329) 
2.17 
(0.152) 
Evening   
Urges 6.57 
(2.67) 
6.29 
(3.00) 
4.75 
(3.22) 
5.00 
(3.50) 
 
0.01 
(0.935) 
4.97 
(0.034) 
1.82 
(0.188) 
Irritability 5.43 
(3.21) 
5.29 
(3.45) 
3.43 
(3.36) 
3.54 
(3.36) 
 
0.02 
(0.896) 
6.54 
(0.016) 
1.42 
(0.244) 
Restlessness 4.89 
(3.26) 
4.96 
(3.23) 
3.43 
(3.28) 
3.61 
(3.51) 
 
1.34 
(0.257) 
4.91 
(0.035) 
0.35 
(0.558) 
Difficulty 
concentrating 
4.36 
(3.26) 
4.36 
(3.39) 
2.93 
(2.89) 
3.14 
(3.26) 
0.81 
(0.375) 
3.92 
(0.058) 
1.13 
(0.297) 
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Table 5.3: Mean ratings and summary of ANOVA analysis of urges and withdrawal 
symptoms pre and post cue-exposure (whole sample). 
 Mean rating (SD) F [1, 40] (p)  
N= 41 EC 
baseline 
EC post-
cue 
DNC 
baseline 
DNC 
post-
cue 
Time Product Time x 
Product 
Morning      
Urges 6.80 
(2.87) 
7.41 
(2.78) 
6.85 
(2.52) 
7.05 
(2.76) 
 
3.32 
(0.076) 
0.19 
(0.662) 
1.33 
(0.256) 
Irritability 4.61 
(3.08) 
5.32 
(3.16) 
4.88 
(2.70) 
4.83 
(2.85) 
 
2.35 
(0.134) 
0.07 
(0.796) 
3.88 
(0.056) 
Restlessness 
 
4.98 
(3.11) 
5.59 
(2.95) 
4.98 
(2.78) 
4.95 
(2.77) 
 
2.20 
(0.146) 
0.82 
(0.371) 
4.30 
(0.045) 
Difficulty 
concentrating 
4.54 
(2.81) 
5.05 
(3.06) 
4.32 
(2.91) 
4.51 
(2.79) 
5.53 
(0.024) 
0.99 
(0.326) 
1.03 
(0.317) 
Evening   
Urges 6.41 
(2.76) 
6.49 
(2.97) 
4.98 
(3.33) 
5.07 
(3.42) 
 
0.16 
(0.696) 
7.09 
(0.011) 
0 
(0.948) 
Irritability 5.02 
(3.09) 
4.95 
(3.29) 
3.34 
(3.24) 
3.46 
(3.16) 
 
1.35 
(0.812) 
8.83 
(0.005) 
1.35 
(0.253) 
Restlessness 4.85 
(3.05) 
4.95 
(3.10) 
3.44 
(3.06) 
3.63 
(3.35) 
 
1.62 
(0.210) 
8.69 
(0.005) 
0.42 
(0.523) 
Difficulty 
concentrating 
4.32 
(3.17) 
4.54 
(3.26) 
2.80 
(2.74) 
2.95 
(3.05) 
2.57 
(0.117) 
9.12 
(0.004) 
0.11 
(0.746) 
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There was no evidence that the cue-exposure had a significant impact on any of the 
symptom ratings (i.e. no main effects of time were evident), following abstinence 
throughout the day. Ratings in general were of a moderate level, but somewhat lower for 
the DNC condition in comparison to the EC. Accordingly, the ANOVA revealed a main effect 
of product for urge to smoke (F (1, 27) = 4.97, p= 0.034), irritability (F (1, 27) = 6.54, p= 
0.016) and restlessness (F (1, 27) = 4.91, p= 0.035), and a marginal effect for difficulty 
concentrating (F (1, 27) = 3.92, p= 0.058).  
There was a similar pattern of results when all participants were included in the analysis; 
for all items there was a main effect of product in that urges (F (1, 40) = 7.09, p= 0.011), 
irritability (F (1, 40) = 8.83, p= 0.005), restlessness (F (1, 40) = 8.69, p= 0.005) and difficulty 
concentrating (F (1, 40) = 9.12, p= 0.004) were all significantly higher during the EC 
condition compared to the DNC.  
 
5.2.6 Urges to smoke and withdrawal symptoms over 1 hour 
 
Data were analysed with a repeated measures ANOVA to examine the effect of the 
products over the course of the hour, during the morning and evening session. Table 5.4 
(abstainer sample) and Table 5.5 (whole sample) provide a summary of the ANOVA 
analyses. Mean ratings and standard deviations for each item by condition are shown in 
Appendices 16-20. 
In the sample of participants who abstained throughout the study, there was a significant 
main effect of product for urge to smoke in the morning (F (1, 27) = 4.54, p= 0.042), and a 
marginal effect for composite withdrawal scores (F (1, 27) = 4.11, p= 0.053), whereby 
ratings were lower overall during the DNC condition. Irritability and difficulty concentrating 
also tended to be lower overall during the DNC condition, but did not reach significance (F 
(1, 27) = 3.77, p= 0.063; F (1, 27) = 3.57, p= 0.070, respectively). For both products, there 
were significant effects of time for all items (urge to smoke: F (2.47, 66.76) = 21.36, p< 
0.001; irritability: F (2.27, 61.22) = 11.35, p< 0.001; restlessness: F (2.25, 60.71) = 15.91, p< 
0.001; difficulty concentrating: F (1.97, 52.81) = 6.95, p= 0.002; and composite withdrawal: 
F (2.07, 55.84) = 13.64, p< 0.001). Mean ratings indicated both products alleviated all 
symptoms acutely (within 5-10 minutes), and these did not necessarily increase back to 
post-cue levels at 60 minutes, particularly with urge to smoke (see Figures 5.1- 5.5, top 
panel). The lack of interaction indicated these reductions occurred regardless of product.  
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A similar pattern emerged for the evening session, with both products alleviating symptoms 
acutely and to a similar extent, with the exception of difficulty concentrating which 
remained relatively stable over the hour (urge to smoke: F (2.34, 63.30) = 18.76, p< 0.001; 
irritability: F (2.23, 60.17) = 4.68, p= 0.010; restlessness: F (1.50, 40.45) = 3.67, p= 0.046; 
and composite withdrawal: F (1.58, 42.62) = 4.01, p= 0.034). For all items there were also 
significant main effects of product, with the DNC generating lower ratings overall compared 
to the EC (urge to smoke: F (1, 27)= 5.73, p= 0.024; irritability: F (1, 27) = 5.25, p= 0.030; 
restlessness: F (1, 27) = 5.67, p= 0.025; difficulty concentrating: F (1, 27) = 4.35, p= 0.047; 
and composite withdrawal: F (1, 27) = 5.45, p= 0.027). This is reflective of the fact that post-
cue ratings were lower in the DNC condition to begin with (see Figures 5.1-5.5, top panel). 
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Table 5.4: Summary of ANOVA analysis for urges and withdrawal ratings over 1 hour in 
abstainers. 
 Product Time Product x Time 
N= 28 F (df), p value 
Morning  
Urge to smoke 4.54 (1,27) 
p= 0.042 
 
21.36 (2.47, 66.76) 
p< 0.001 
0.28 (2.03, 54.86) 
p= 0.763 
Irritability 3.77 (1, 27) 
p= 0.063 
11.35 (2.27, 61.22) 
p< 0.001 
0.14 (1.95, 52.60) 
p= 0.861 
 
Restlessness 2.18 (1, 27) 
p= 0.151 
15.91 (2.25, 60.71) 
p< 0.001 
0.67 (2.19, 59.24) 
p= 0.530 
 
Difficulty 
concentrating 
3.57 (1, 27) 
p= 0.070 
6.95 (1.97, 52.81) 
p= 0.002 
0.17 (2.82, 76.01) 
p= 0.907 
 
Composite 
withdrawal 
4.11 (1, 27) 
p= 0.053 
13.64 (2.07, 55.84) 
p< 0.001 
0.28 (2.17, 58.49) 
p= 0.778 
Evening  
Urge to smoke 5.73 (1, 27) 
p= 0.024 
 
18.76 (2.34, 63.30) 
p< 0.001 
0.37 (2.98, 80.34) 
p= 0.772 
Irritability 5.25 (1, 27) 
p= 0.030 
 
4.68 (2.23, 60.17) 
p= 0.010 
1.05 (2.73, 73.75) 
p= 0.373 
Restlessness 5.67 (1, 27) 
p= 0.025 
 
3.67 (1.50, 40.45) 
p= 0.046 
0.75 (2.60, 70.20) 
p= 0.507 
Difficulty 
Concentrating 
4.35 (1, 27) 
p= 0.047 
 
1.93 (1.70, 46.01) 
p= 0.162 
0.435 (2.49, 67.09) 
p= 0.692 
Composite 
withdrawal 
5.45 (1, 27) 
p= 0.027 
4.01 (1.58, 42.62) 
p= 0.034 
0.72 (2.56, 69.14) 
p= 0.521 
 
 116 
 
Table 5.5: Summary of ANOVA analysis for urges and withdrawal ratings over 1 hour (whole 
sample). 
 Product Time Product x Time 
N= 41 F (df), p value 
Morning  
Urge to smoke 3.60 (1, 40) 
p= 0.065 
 
32.82 (2.50, 100.03) 
p< 0.001 
0.48 (2.16, 86.25) 
p= 0.635 
Irritability 2.07 (1, 40) 
p= 0.158 
 
16.51 (2.46, 98.57) 
p< 0.001 
0.21 (2.12, 84.84) 
p= 0.823 
Restlessness 3.07 (1, 40) 
p= 0.088 
 
22.44 (2.59, 103.64) 
p< 0.001 
0.43 (2.21, 88.31) 
p= 0.675 
Difficulty 
concentrating 
4.65 (1, 40) 
p= 0.037 
 
13.46 (2.25, 90.12) 
p< 0.001 
0.13 (2.75, 109.94) 
p= 0.929 
Composite 
withdrawal 
3.96 (1, 40) 
p= 0.053 
21.13 (2.39, 95.55) 
p< 0.001 
0.21 (2.23, 88.99) 
p= 0.833 
Evening  
Urge to smoke 6.41 (1, 40) 
p= 0.015 
 
21.65 (2.54, 101.54) 
p< 0.001 
0.711 (3.01, 120.31) 
p= 0.547 
Irritability 4.83 (1, 40) 
p= 0.034 
 
6.11 (2.27, 90.75) 
p= 0.002 
1.58 (2.82, 112.96) 
p= 0.201 
Restlessness 6.74 (1, 40) 
p= 0.013 
 
5.73 (1.85, 74.00) 
p= 0.006) 
1.60 (2.54, 101.56) 
p= 0.201 
Difficulty 
Concentrating 
7.78 (1, 40) 
p= 0.008 
 
3.84 (1.85, 74.16) 
p= 0.029 
1.64 (2.44, 97.77) 
p= 0.193 
Composite 
withdrawal 
7.36 (1, 40) 
p= 0.010 
6.17 (1.74, 69.55) 
p= 0.005 
1.96 (2.57, 102.77) 
p= 0.134 
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Figure 5.1: Mean urge to smoke ratings over 1 hour 
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Figure 5.1 shows the 
mean urge to smoke 
during morning and 
evening sessions over 
one hour, rated on a 
scale of 0 (not at all) 
to 10 (extremely). 
Product was 
administered post 
cue-exposure (PC). * 
and **  indicate 
significant effects of 
Time and Product, 
respectively (p≤ 0.05) 
Time point (minutes) 
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Figure 5.2: Mean irritability ratings over 1 hour 
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Figure 5.2 shows 
mean irritability 
during morning and 
evening sessions over 
one hour, rated on a 
scale of 0 (not at all) 
to 10 (extremely). 
Product was 
administered post 
cue-exposure (PC). * 
and ** indicate 
significant effects of 
Time and Product, 
respectively (p≤ 0.05) 
Time point (minutes) 
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Figure 5.3: Mean restlessness ratings over 1 hour 
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Figure 5.3 shows 
mean restlessness 
during morning and 
evening sessions over 
one hour, rated on a 
scale of 0 (not at all) 
to 10 (extremely). 
Product was 
administered post 
cue-exposure (PC). * 
and ** indicate 
significant effects of 
Time and Product, 
respectively (p≤ 0.05) 
Time point (minutes) 
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Figure 5.4: Mean ratings of difficulty concentrating over 1 hour  
Abstainers (N= 28)   Morning       Evening  
  
  
0
1
2
3
4
5
6
7
8
Baseline PC 5 10 30 60
M
e
an
 d
if
fi
cu
lt
y 
co
n
ce
n
tr
at
in
g     * 
0
1
2
3
4
5
6
7
8
Baseline PC 5 10 30 60
EC
DNC
** 
0
1
2
3
4
5
6
7
8
Baseline PC 5 10 30 60
M
e
an
 d
if
fi
cu
lt
y 
co
n
ce
n
tr
at
in
g  *  ** 
0
1
2
3
4
5
6
7
8
Baseline PC 5 10 30 60
*  ** 
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Figure 5.4 shows 
mean difficulty 
concentrating during 
morning and evening 
sessions over one 
hour, rated on a scale 
of 0 (not at all) to 10 
(extremely). Product 
was administered 
post cue-exposure 
(PC). * and ** 
indicate significant 
effects of Time and 
Product, respectively 
(p≤ 0.05) 
Time point (minutes) 
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Figure 5.5: Mean composite withdrawal ratings over 1 hour 
Abstainers (N= 28)   Morning       Evening  
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Figure 5.5  shows 
mean composite 
withdrawal during 
morning and evening 
sessions over one 
hour, rated on a scale 
of 0 (not at all) to 10 
(extremely). Product 
was administered 
post cue-exposure 
(PC). * and ** 
indicate significant 
effects of Time and 
Product, respectively 
(p≤ 0.05) 
Time point (minutes) 
 122 
 
When the analysis was conducted on the whole sample, an almost identical pattern of 
results emerged. Main effects of product in the morning were evident for difficulty 
concentrating in favour of the DNC, (F (1, 40) = 4.65, p= 0.037), and urge to smoke and 
composite withdrawal scores tended to be lower overall for the DNC condition (F (1, 40) = 
3.60, p= 0.065; F (1, 40) = 3.96, p= 0.053, respectively). There were again significant effects 
of time for all items in the morning (urge to smoke: F (2.50, 100.03) = 32.82, p< 0.001; 
irritability: F (2.46, 98.57) = 16.51, p< 0.001; restlessness: F (2.59, 103.64) = 22.44, p< 0.001; 
difficulty concentrating: F (2.25, 90.12), 13.46, p< 0.001; and composite withdrawal: F (2.39, 
95.55) = 21.13, p< 0.001), but no interactions were evident (see Figures 5.1-5.5, bottom 
panel).  
In the evening all items were overall significantly lower during the DNC condition (urge to 
smoke: F (1, 40) = 6.41, p= 0.015; irritability: F (1, 40) = 4.83, p= 0.034; restlessness: F (1, 
40)= 6.74, p= 0.013; difficulty concentrating: F (1, 40) = 7.78, p= 0.008; and composite 
withdrawal: F (1, 40) = 7.36, p= 0.010), and there were again significant main effects of time 
for all items (urge to smoke: F (2.54, 101.54) = 21.65, p< 0.001; irritability: F (2.27, 90.75) = 
6.11, p= 0.002; restlessness: F (1.85, 74.00) = 5.73, p= 0.006); difficulty concentrating: F 
(1.85, 74.16) = 3.84, p= 0.029; and composite withdrawal: F (1.74, 69.55) = 6.17, p= 0.005). 
There were no significant interactions (see Figures 5.1-5.5, bottom panel). 
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5.2.7 Supplementary analyses: Acute effects on urges to smoke and withdrawal  
 
As with Study 1, a further set of analyses were conducted to examine the acute effects of 
the products more closely on urges to smoke and composite withdrawal. The same set of 
analyses in Study 1 were conducted here: comparisons (t-test/Wilcoxin) from post-cue to 
10 minutes for each product separately in each session; repeated measures ANOVA to test 
for any interactional effects between time (post cue vs. 10 minutes) and products; and 
differences between products on area under the curve (AUC), maximum reduction (Rmax) 
and time to maximum reduction (Tmax) on data obtained over the first 10 minutes post 
product use. 
Analyses were run on those who abstained throughout the study, and on the whole sample. 
 
5.2.7.1 Results: Abstainer sample 
 
Separate analysis for each product revealed that both the EC and DNC reduced urge to 
smoke at 10 minutes, during both the morning (EC: z= -3.93, p< 0.001; DNC: z= -4.06, p< 
0.001) and evening sessions (EC: t= 4.45, p< 0.001; DNC: z= -3.22, p= 0.001; see Figure 5.6, 
top panel). The ANOVA revealed no interaction between time and product indicating a 
similar magnitude of reduction between products (see Table 5.6).  
The comparable effects between products were confirmed with AUC analyses, which 
showed no differences between products on AUC values, Rmax or Tmax during both 
sessions (see Table 5.7). Figure 5.6, bottom panel, shows the mean reduction scores in 
urges to smoke over 10 minutes. 
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Figure 5.6: Acute effects of products on urge to smoke in abstainers  
(N= 28)  Morning        Evening 
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Figure 5.6 Top panel 
shows the mean urge to 
smoke pre-product use 
and at 10-minutes post-
product use. Product 
was administered post 
cue-exposure. * and ** 
indicate a significant 
change from post-cue 
to 10 minutes for EC 
and DNC respectively. 
Bottom panel shows 
reduction from post-cue 
in urge to smoke over 5 
and 10 minutes post-
product use. Analysis 
conducted on 
abstainers only; 
significance level p ≤ 
0.05. 
Time point (minutes) 
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Table 5.6: Summary of ANOVA analysis on the acute effects of products on urges and 
withdrawal ratings in abstainers. 
 Product Time Product x Time 
N= 28 F (df) p value 
Morning  
Urge to smoke 2.66 (1, 27) 
p= 0.115 
44.48 (1, 27) 
p< 0.001 
0.051 (1, 27) 
p = 0.823 
 
Composite 
withdrawal 
3.07 (1, 27) 
p= 0.091 
33.46 (1, 27) 
p< 0.001 
0.31 (1, 27) 
p = 0.580 
Evening     
Urges to smoke 4.39 (1, 27) 
p = 0.046 
43.07 (1, 27) 
p< 0.001 
0.21 (1, 27) 
p= 0.651 
 
Composite 
withdrawal 
5.61 (1, 27) 
p= 0.025 
28.71 (1, 27) 
p< 0.001 
0.92 (1, 27) 
p= 0.346 
 
 
Composite withdrawal scores also reduced significantly at 10 minutes following use of both 
products in the morning (EC: t= 4.24, p< 0.001; DNC: t= 5.14, p< 0.001) and evening (EC: t= 
3.77, p= 0.001; DNC: z= -2.21, p= 0.027; see Figure 5.7, top panel). As with urges, reductions 
between products were comparable in both sessions (see Table 5.6), and there were no 
differences between products with respects to AUC and Rmax, though time to maximum 
reduction tended to be longer with the DNC than EC in the morning (z= -1.93, p= 0.053; see 
Table 5.7). Figure 5.7, bottom panel, shows the mean reduction scores in composite 
withdrawal over 10 minutes. 
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Table 5.7: Mean area under the curve (AUC), reduction maximum (Rmax), and time to 
Rmax (Tmax) values and summary test statistics for acute urges and withdrawal ratings in 
abstainers. 
N= 28 EC DNC EC vs. DNC 
Morning  Mean (SD) Test statistic Sig (p) 
Urge to smoke      
  AUC 
  Rmax 
  Tmax 
 
21.70 (20.59) 
3.61 (3.02) 
5.36 (3.58) 
 
22.41 (20.59) 
3.43 (2.66) 
5.71 (3.25) 
t= -0.18 
z= -0.09 
z= -0.45 
0.857 
0.927 
0.653 
Composite 
withdrawal 
    
  AUC 
  Rmax 
  Tmax 
13.24 (16.70) 
2.18 (2.26) 
5.00 (3.85) 
10.71 (12.73) 
1.94 (1.63) 
6.79 (3.39) 
z= -0.31 
z= -0.38 
z= -1.93 
0.755 
0.706 
0.053 
Evening     
Urge to smoke      
  AUC 
  Rmax 
  Tmax 
13.48 (14.71) 
2.21 (2.22) 
4.82 (3.46) 
12.95 (12.80) 
2.07 (1.78) 
4.46 (3.43) 
z =-0.01 
z= -0.07 
z= -0.36 
0.989 
0.946 
0.723 
Composite 
withdrawal 
    
  AUC 
  Rmax 
  Tmax 
8.45 (10.26) 
1.41 (1.51) 
5.71 (3.53) 
4.46 (9.30) 
0.89 (1.22) 
4.29 (4.24) 
z= -1.17 
z= -1.13 
z= -1.29 
0.244 
0.257 
0.198 
 
5.2.7.2 Results: Whole sample 
 
When the analysis was repeated on the whole sample, a similar picture emerged, with 
significant reductions in urge to smoke following both products in the morning (EC: z= -
4.93, p< 0.001; DNC: z= -4.87, p< 0.001) and evening (EC: z= -4.70, p< 0.001; DNC: z= -3.62, 
p< 0.001; see Figure 5.8, top panel).  
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Figure 5.7: Acute effects of products on composite withdrawal in abstainers  
(N= 28)  Morning        Evening 
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Figure 5.7 Top panel 
shows the mean 
composite withdrawal 
pre-product use and at 
10-minutes post-
product use. Product 
was administered post 
cue-exposure. * and ** 
indicate a significant 
change from post-cue 
to 10 minutes for EC 
and DNC respectively. 
Bottom panel shows 
reduction from post-cue 
in composite 
withdrawal over 5 and 
10 minutes post-
product use. Analysis 
conducted on 
abstainers only; 
significance level p ≤ 
0.05). 
Time point (minutes) 
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Figure 5.8: Acute effects of products on urge to smoke (whole sample) 
 (N= 41)    Morning        Evening 
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Figure 5.8 Top panel 
shows the mean urge to 
smoke pre-product use 
and at 10-minutes post-
product use. Product 
was administered post 
cue-exposure. * and ** 
indicate a significant 
change from post-cue 
to 10 minutes for EC 
and DNC respectively. 
Bottom panel shows 
reduction from post-cue 
in urge to smoke over 5 
and 10 minutes post-
product use. Analysis 
includes non-
abstainers; significance 
level p ≤ 0.05. 
Time point (minutes) 
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There was no indication that the magnitude of reduction differed, from both the ANOVA 
analysis (see Table 5.8) and examination of AUC (see Table 5.9). Figure 5.8, bottom panel, 
shows the mean reduction scores in urges to smoke over 10 minutes. 
For composite withdrawal, there were again significant reductions during both conditions in 
the morning (EC: z= -4.57, p< 0.001; DNC: z= -4.66, p< 0.001) and evening sessions (EC: t= 
4.74, p< 0.001; DNC: z= -2.29, p= 0.022; see Figure 5.9, top panel). The ANOVA revealed no 
significant interaction for either session, though during the evening, withdrawal tended to 
decrease to a greater extent for the EC (F (1, 40) = 3.29, p= 0.077; see Table 5.8). This was 
also evident with AUC analysis, in that the maximum reduction was larger for the EC (z = -
1.96, p= 0.05), and AUC values were marginally in favour of the EC (z= -1.89, p= 0.059; see 
Table 5.9). Given the fact that withdrawal ratings were lower at post-cue in the DNC 
condition, these findings likely reflect a floor effect with the DNC. Figure 5.9, bottom panel, 
shows the mean reduction scores in composite withdrawal over 10 minutes. 
 
Table 5.8: Summary of ANOVA analysis on the acute effects of products on urges and 
withdrawal ratings in abstainers (whole sample). 
 Product Time Product x Time 
N= 41 F (df) p value 
Morning  
Urge to smoke 2.22 (1, 40) 
p= 0.144 
71.61 (1, 40) 
p< 0.001 
0.09 (1, 40) 
p= 0.765 
 
Composite 
withdrawal 
4.32 (1, 40) 
p= 0.044 
51.92 (1, 40) 
p< 0.001 
0.04 (1, 40) 
p= 0.836 
Evening     
Urges to smoke 6.35 (1, 40) 
p= 0.016 
52.56 (1, 40) 
p< 0.001 
1.67 (1, 40) 
p= 0.203 
 
Composite 
withdrawal 
8.74 (1, 40) 
p= 0.005 
30.42 (1, 40) 
p< 0.001 
3.29 (1, 40) 
p= 0.077 
 
 
 130 
 
Table 5.9: Mean area under the curve (AUC), reduction maximum (Rmax), and time to 
Rmax (Tmax) values and summary test statistics for acute urges and withdrawal ratings 
(whole sample). 
N= 41 EC DNC EC vs. DNC 
Morning Mean (SD) Test statistic Sig (p) 
Urge to smoke      
  AUC 
  Rmax 
  Tmax 
19.57 (18.21) 
3.22 (2.70) 
5.85 (3.52) 
21.77 (20.03) 
3.37 (2.61) 
5.85 (3.52) 
t= -0.70 
z= -0.53 
z= -0.19 
0.490 
0.596 
0.985 
Composite 
withdrawal 
    
  AUC 
  Rmax 
  Tmax 
12.22 (14.62) 
1.98 (1.99) 
5.49 (3.84) 
10.67 (13.82) 
1.95 (1.72) 
6.71 (3.47) 
z= -0.21 
z= -0.02 
z= -1.67 
0.834 
0.982 
0.094 
Evening     
Urge to smoke      
  AUC 
  Rmax 
  Tmax 
13.84 (13.01) 
2.22 (2.04) 
5.12 (3.44) 
10.18 (15.76) 
1.80 (1.78) 
4.15 (3.34) 
z= -1.06 
z= -0.94 
z= -1.26 
0.288 
0.349 
0.208 
Composite 
withdrawal 
    
  AUC 
  Rmax 
  Tmax 
8.21 (10.25) 
1.39 (1.51) 
5.24 (3.87) 
3.78 (9.38) 
0.80 (1.11) 
3.90 (3.79) 
z= -1.89 
z= -1.96 
z= -1.58 
0.059 
0.050 
0.114 
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Figure 5.9: Acute effects of products on composite withdrawal (whole sample) 
 (N= 41)        Morning        Evening 
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Figure 5.9 Top panel 
shows the mean 
composite withdrawal 
pre-product use and at 
10-minutes post-
product use. Product 
was administered post 
cue-exposure. * and ** 
indicate a significant 
change from post-cue 
to 10 minutes for EC 
and DNC respectively. 
Bottom panel shows 
reduction from post-cue 
in composite 
withdrawal over 5 and 
10 minutes post-
product use. ** 
indicates a significant 
difference between 
products in Rmax. 
Analysis includes non-
abstainers; significance 
level p ≤ 0.05. 
Time point (minutes) 
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5.2.8 Urges to smoke and withdrawal symptoms during the day 
 
Table 5.10 shows the mean composite MPSS urge and withdrawal scores. As a whole, 
participants reported fairly moderate withdrawal symptoms and urges over the course of 
the day. Following abstinence over the day, withdrawal scores and urge scores were 
significantly lower during the DNC condition compared to the EC (z= -3.24, p= 0.001; t= 
2.91, p= 0.007, respectively). 
Individual items, depression (z= -2.22, p= 0.026), difficulty concentrating (z= -3.03, p= 
0.002), urge frequency (z= -2.87, p= 0.004) and urge strength (z= -2.30, p= 0.021), were also 
significantly lower during the DNC condition, and restlessness was marginally lower (z= -
1.93, p= 0.053). These findings suggest that the DNC may have been more effective than 
ECs in supressing urges and withdrawal symptoms over the day, though it should be noted 
that the magnitude of difference between the two was small. A summary of test results and 
mean scores for individual MPSS items is shown in Appendix 21. 
 
Table 5.10: Mean scores and summary test statistics for composite MPSS and urges to 
smoke. 
 
Product MPSS Urge to smoke Urge 
Frequency 
Urge Strength 
Abstainers (N= 28) M (SD) 
EC 2.47 (0.70) 3.46 (0.92) 3.57 (1.00) 3.36 (0.95) 
DNC 2.01 (0.59) 2.88 (0.79) 2.86 (0.85) 2.89 (0.96) 
Test statistic 
Sig. (p) 
z= -3.24 
0.001 
t= 2.91 
0.007 
z= -2.87 
0.004 
z= -2.30 
0.021 
Whole Sample  
(N= 41) 
 
EC  2.45 (0.69) 3.53 (0.90) 3.61 (0.97) 3.43 (0.93) 
DNC 2.05 (0.58) 3.00 (0.86) 2.98 (0.92) 3.02 (1.00) 
Test statistic 
Sig. (p) 
z= -3.50 
< 0.001 
z= -3.47 
0.001 
z= -3.66 
< 0.001 
z= -2.52 
0.012 
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The same pattern of results was evident when the whole sample was analysed (z= -3.50, p< 
0.001 for composite withdrawal; z= -3.47, p= 0.001 for composite urge), and a similar 
pattern was evident for individual items: depression (z = -2.40, p = 0.016), restlessness (z= -
2.43, p= 0.015), difficulty concentrating (z= -3.30, p= 0.001), hunger (z= -2.02, p= 0.043), 
urge frequency (z= -3.66, p< 0.001) and urge strength (z= -2.52, p= 0.012) were all 
significantly lower during the DNC condition. A summary of test results and mean scores for 
individual MPSS items is shown in Appendix 21. 
 
5.2.9 Supplementary analyses: baseline ratings during morning and evening 
sessions 
 
As with Study 1, baseline ratings of urge to smoke and composite withdrawal scores 
completed during the 1 hour experimental sessions were compared from morning to 
evening. Mean baseline ratings in the evening appeared to be lower than in the morning 
but only for the DNC condition, indicating a potentially beneficial effect of DNCs over the 
course of the day in comparison to ECs. Scores from morning to evening were compared, 
for each condition individually, and a repeated measures ANOVA was used to examine this 
potential interaction. 
 
5.2.9.1 Results: Abstainer sample  
 
For the EC, there was no change in urge to smoke from morning to evening (z= -0.71, p= 
0.481), but the DNC condition showed a significant reduction (z= -2.78, p= 0.005; see Figure 
5.10, top left panel). The ANOVA revealed a marginal interaction between product and time 
(F (1, 27) = 3.85, p= 0.060; see Table 5.11). The same pattern of results emerged for 
composite withdrawal scores (see Figure 5.10, bottom left panel), with a reduction in 
withdrawal only evident for the DNC condition (DNC: t= 2.78, p= 0.010; EC: t= -0.18, p= 
0.859), and an interaction which did not quite reach significance (F (1, 27) = 3.36, p= 0.078; 
see Table 5.11). 
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Figure 5.10: Mean baseline ratings of urge to smoke and composite withdrawal in the morning and evening 
Abstainers (N= 28)       Whole sample (N= 41) 
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Figure 5.10 shows the 
mean baseline ratings 
of urge to smoke (top 
panel) and composite 
withdrawal score 
(bottom panel) during 
morning and evening 
sessions, rated on a 
scale of 0 (not at all) to 
10 (extremely), prior to 
commencing cue-
exposure. ** indicates a 
significant reduction for 
DNC from morning to 
evening, and †, a 
significant interaction 
(p≤ 0.05) 
Session time 
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Table 5.11: Summary of ANOVA analysis on baseline urge and withdrawal ratings in the 
morning and evening. 
 Product Time Product x Time 
Abstainers 
 (N= 28) 
F (df) p value 
Urge to smoke 17. 29 (1, 27) 
p= 0.045 
13.66 (, 27) 
p= 0.001 
3.85 (1, 27) 
p= 0.060 
 
Composite 
withdrawal 
5.18 (1, 27) 
p= 0.031 
7.16 (1, 27) 
p= 0.013 
3.36 (1, 27) 
p= 0.078 
Whole sample 
(N= 41) 
   
Urges to smoke 4.60 (1, 40) 
p= 0.038 
12.09 (1, 40) 
p= 0.001 
3.54 (1, 40) 
p= 0.067 
 
Composite 
withdrawal 
7.36 (1, 40) 
p= 0.010 
7.54 (1, 40) 
p= 0.009 
6.47 (1, 40) 
p= 0.015 
 
5.2.9.2 Results: Whole sample 
 
For the whole sample of participants, the findings were identical for urge to smoke (DNC: z= 
-3.08, p= 0.002; EC: z= -0.94, p= 0.345; see Figure 5.10, top right panel) and there was a 
trend for an interaction (F (1, 40) = 3.54, p= 0.067). This was also the case for composite 
withdrawal scores (DNC: z= -3.21, p= 0.001; EC: z= -0.52, p= 0.602; see Figure 5.10, bottom 
right panel), though here, the ANOVA revealed a significant interaction (F (1, 40) = 6.47, p= 
0.015). Table 5.11 provides a summary of the analysis. 
 
  
Figure xx shows the 
mean baseline ratings 
of urge to smoke (top 
panel) and composite 
withdrawal score 
(bottom panel) during 
morning and evening 
sessions, rated on a 
scale of 0 (not at all) to 
10 (extremely), prior to 
commencing cue-
exposure. There were 
no significant changes 
or interactions for 
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5.2.10 Product perceptions, preferences and adverse effects 
 
Table 5.12 shows the mean product ratings and percentages of participants choosing each 
product.  
 
Table 5.12: Mean product ratings and preferences.  
Product ratings EC DNC Sig. (p) 
N= 41 Mean (SD)  
Satisfaction compared 
to usual cigarette 
1.73 (1.07) 1.78 (0.94) 0.752 
Helpful in keeping from 
smoking 
2.76 (0.97) 3.07 (0.91) 0.070 
Pleasantness 2.59 (1.07) 2.15 (1.11) 0.077 
Embarrassing to use 1.66 (0.94) 1.22 (0.53) 0.007 
Would use to quit 
smoking 
3.15 (1.32) 3.17 (1.22) 0.897 
Would recommend to 
others for quitting 
3.39 (1.28) 3.39 (1.30) 0.876 
Product preferences % of participants    (p) 
Liked more 36.6 63.4 2.95 (0.086) 
Easier to use 48.8 51.2 0.02 (0.876) 
More helpful in keeping 
from smoking* 
42.5 57.5 0.90 (0.343) 
More embarrassing to 
use** 
91.2 8.8 23.06  (< 0.001) 
More likely to use for 
quitting smoking** 
45 55 0.40 (0.527) 
More likely to 
recommend to others 
for quitting** 
52.5 47.5 0.10 (0.752) 
*N=7 and **N =1 did not choose between products. 
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There were no differences between the two products in satisfaction ratings (z= -0.32, p= 
0.752), how likely participants were to use them as an aid to quitting (z= -0.13, p= 0.897) 
and likelihood of recommending either product to someone who wanted to quit smoking 
(z= -0.16, p= 0.876). The EC was however rated as more embarrassing to use (z = -2.69, p= 
0.007), but tended to be rated as more pleasant (z= -1.77, p= 0.077); the DNC though 
tended to be rated as more helpful than the EC in enabling participants to keep from 
smoking conventional cigarettes (z= -1.81, p= 0.070). 
Overall, there were no differences in the number of participants choosing one product over 
the other, except that significantly more participants perceived the EC to be more 
embarrassing to use than the DNC (   = 23.06, p< 0.001). 
Thirteen participants reported adverse effects with the DNCs, and 9 participants reported 
adverse effects with the EC. For the DNC, these were moderate to strong nausea (N= 4); 
moderate cough/throat irritation (N= 4); moderate headache (N= 4); weak to moderate 
light headedness (N= 2); and one participant reported feeling moderately ‘shaky’. For the 
EC, these were moderate headache (N= 4); moderate light headedness (N= 2); moderate 
cough/throat irritation (N= 3); and strong burning sensation on lips (N= 1). Additionally, one 
participant reported a mild rash, though this was deemed to be unrelated to the EC.  
Table 5.13 shows the responses participants gave regarding what they liked most and least 
about the products. As in Study 1, participants reported liking most the sensorimotor 
replacement provided by the EC (N= 13). Again, taste was the least liked aspect of the EC 
(N= 16) and also the DNC (N= 22). The similarity to conventional cigarettes was the most 
liked aspect of the DNCs (N= 17).  
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Table 5.13: Open responses to questions “What did you like most/least about the product 
you used today?”  
Liked Most  Liked Least  
EC N*  N* 
Sensorimotor replacement 13 Taste 16 
Taste 9 Weight/size/shape 13 
Similarity to real cigarettes 8 Too ‘weak’/no ‘throat ‘hit’ 6 
Healthier/no smoke 6 No nicotine 5 
Can be used anywhere/ 
around others 
4 Technical problems 4 
Weight/size/shape 2 Too dissimilar to cigarettes 3 
Ease of use/Does not need 
lighting or putting out 
2 Embarrassing  2 
Could be used for cessation  1 Side effects (e.g. coughing, headache) 2 
Everything 1 Difficult to puff/draw on 2 
Nothing 9 No craving relief/satisfaction 1 
  No start or finish 1 
  Nothing 5 
DNC    
Similarity to conventional 
cigarettes 
17 Taste 22 
Still able to smoke 9 Smell 7 
Sensorimotor replacement 6 Too harsh/strong throat ‘hit’ 3 
Taste 3 Increased cough 3 
Reduced nicotine content 3 No satisfaction/enjoyment 3 
Craving relief 2 Too dissimilar to smoking  
Could be used as a cessation 
aid 
1 Still harmful to health 2 
Smell 1 Weaker than conventional 
cigarettes/no ‘hit’ 
2 
Nothing 4 Appearance/design of cigarettes/packet 2 
  Burnt down too quickly 1 
  Still addictive 1 
  Nothing 6 
*N refers to the frequency of responses. Some participants gave more than one answer. 
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5.2.11 Supplementary analyses: Comparison of EC effects across studies 
 
Although the EC alleviated urge to smoke acutely in both studies, there was some 
indication that EC effects were less pronounced in Study 1 compared to Study 2. Mean 
change scores from post-cue to 10 minutes following overnight abstinence, for example, 
were greater in the second study than the first (3.25 vs. 1.82, respectively; abstainer only 
sample).  
To examine whether EC effects differed across studies, a repeated measures ANOVA on 
urge to smoke was conducted for both sessions, where time had two levels (post-cue vs. 10 
minutes) and study (1 vs. 2) was entered as a between-subjects factor. The sample 
comprised of those participants who had abstained throughout their respective study (N= 
17 for Study 1; N= 28 for Study 2). 
 
5.2.11.1  Results 
 
Participant demographics and characteristics by Study are shown in Table 5.14. There were 
no differences between participants with respect to gender (  = 0.54, p= 0.463), age (F (1, 
44) = 0.00, p= 0.973), ethnicity (  = 13.40, p= 0.374), employment status (  = 0.54, p= 
0.307), qualifications (  = 4.35, p= 0.500), CPD (F (1, 44) = 0.12, p= 0.726), FTND scores (F 
(1, 44) = 0.65, p= 0.426) and EC use over the day (F (1, 44) = 0.20, p= 0.658). 
Figure 5.11 shows the mean urge to smoke by Study during morning and evening sessions. 
For the morning session, the ANOVA confirmed previous findings of a significant reduction 
from post-cue to 10 minutes across both studies (F (1, 43) = 33.67, p< 0.001), but there was 
no significant main effect of Study (F (1, 43) = 0.14, p= 0.715) and no interaction between 
time and study, indicating that the EC reduced urge to smoke in both studies to a similar 
extent (F (1, 43) = 2.66, p= 0.110).  
During the evening session, the pattern of results was similar with respect to main effects 
(Time: F (1, 43) = 19.17, p< 0.001; Study: F (1, 43) = 1.66, p= 0.204), except here, the 
interaction was marginal, with mean scores indicating that alleviation of urge tended to be 
greater in the second study compared to the first (F (1, 43) = 4.00, p= 0.052). 
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Table 5.14: Participant characteristics of ‘abstainer’ samples in Studies 1 and 2. 
Demographics/baseline characteristics  Study 1* 
% (N= 17) 
 Study 2* 
% (N= 28) 
Gender  
   Male 
 
64.7 
  
53.6 
Ethnicity 
  Caucasian  
  Mixed/other 
  Don’t wish to answer 
 
70.6 
23.5 
5.9 
  
64.4 
35.6 
0 
Employment status  
   Employed 
   Unemployed 
   Student 
   Other (e.g. retired, sick/disabled) 
 
52.9 
23.5 
5.9 
17.7 
  
46.4 
28.6 
7.1 
17.9 
Education  
   Higher 
   Secondary or none 
 
53 
47 
 
 
 
57.1 
42.9 
 Mean (SD)* 
Age 40.6 (15.5)  40.8 (15.0) 
CPD 18.8 (6.5)  19.5 (6.1) 
FTND 5.4 (1.9)  5.8 (1.4) 
EC use during study day 12.7 (9.4)  14.6 (15.9) 
*There were no significant differences between studies in any participant characteristics.  
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Figure 5.11: Mean ratings of urge to smoke for EC in Studies 1 and 2 in abstainers  
(N= 45)  
Morning session       Evening session 
 
 
Figure 5.11 shows the mean ratings of urge to smoke in the two studies (EC1= Study 1; EC2= Study 2), at post-cue and 10 minutes post-EC use (rated on a scale of 0 
[not at all] to 10 [extremely]), in abstainers only. EC was administered post cue-exposure. Interactions between time and study were not significant at the p≤ 0.05 
level, at either session.  
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5.3 Discussion 
 
This study aimed to examine whether sensorimotor effects were ‘dose’ dependent. 
Specifically, whether more proximal SMR from DNCs would better alleviate urges to smoke 
and withdrawal compared to ECs. Both the EC and DNC reduced urge to smoke and most 
withdrawal symptoms acutely (within 5-10 minutes) following overnight abstinence, with 
little indication of differences between products. Further analyses confirmed that acute 
alleviation of urges to smoke and composite withdrawal was similar for the two products 
during both sessions. 
The comparable acute urge relief evident during the controlled experiments seems to 
suggest that proximity to real smoking may not necessarily be as important as previously 
hypothesised, at least for acute urge relief, so long as key elements of smoking behaviour 
(importantly the smoke - or vapour resembling smoke - puffing, inhaling/exhaling) are 
present.  
One difference that did emerge from this study was the reduction in urges to smoke and 
withdrawal from the morning to the evening session, evident only in the DNC condition. 
This suggests that DNCs may have helped suppress withdrawal and urge to a greater extent 
than the EC over the course of the day. Data from MPSS scores collected at the evening 
session confirm this, as ratings following abstinence were significantly lower with the DNC 
than EC, though the difference was modest.  
These findings point to the possibility that sensorimotor treatment effects may be 
sustained when the sensorimotor input is more proximal to conventional smoking. The DNC 
literature indicates that DNCs’ reinforcing effects can extend over longer periods of time, 
(Baldinger et al., 1995b, Buchhalter et al., 2005, Donny and Jones, 2009, Hatsukami et al., 
2013a). In this way, sensorimotor effects may still be ‘dose-dependent’; a lower level of 
sensorimotor input may be sufficient to alleviate urge to smoke acutely (but perhaps only in 
the early treatment phase), so long as the key sensorimotor factors described above are 
present - to confirm this, a control condition would need to be included, such as a nicotine-
free inhalator, which would offer some sensorimotor input, but not the key sensorimotor 
aspects (i.e. nothing resembling smoke, no inhaling/exhaling). With more proximal input 
however, these sensorimotor factors may remain reinforcing for longer, thus providing help 
for a more prolonged period; they may also impact on both ‘background’ and episodic 
withdrawal discomfort.  
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The cue-exposure procedure had very little impact on urges and withdrawal ratings during 
both the morning and evening sessions across conditions, but there was some evidence to 
suggest that product expectancies may have had an impact on the extent of cue reactivity. 
Some ratings such as restlessness, irritability and urges to smoke, remained relatively stable 
following cue exposure in the morning, when participants were told they would be using 
the DNC, but increased when told they would be using the EC. Thus participants may have 
held the expectation that the DNC would be of more help - given that it is still a tobacco 
cigarette - resulting in lowered reactivity to the cue-exposure procedure. There were few 
differences in product ratings and preferences, except that ECs were considered more 
embarrassing to use, though ratings of embarrassment were low in any case. Similarly to 
Study 1, taste was the least liked aspect of the EC, as well as with the DNC. Despite this, 
participants still reported that the provision of SMR (again having the vapour, being able to 
inhale/exhale etc.) was the most liked aspect of the EC, and that the similarity to normal 
cigarettes was most liked about the DNCs. Interestingly, few participants reported (in 
response to the open questions) that these products helped to alleviate their urges and/or 
withdrawal symptoms, across both studies.  
This again raises the possibility that the alleviation of urge to smoke may not be the central 
mechanism involved in SMR. In this study, however, the effects of the EC on urge alleviation 
were not as small as those seen in Study 1, especially during the evening. Although the 
analysis across studies only revealed a marginal interaction, examination of mean scores 
shows quite marked differences in urge changes from post-cue to 10 minutes (Study 1: 6.76 
to 6.06; Study 2: 6.29 to 4.39, respectively). Without a control condition in the second 
study, the contribution of conditioned sensorimotor input to these effects cannot be 
reliably interpreted. The difference in EC effects across studies is interesting to note and 
may reflect individual variability in responses to SMR. There is already some evidence of 
this in the literature, i.e. that effects may be moderated by characteristics such as gender 
and physical dependence (Brauer et al., 2001, Barrett, 2010, Dawkins et al., 2012, Dawkins 
et al., 2013b). A recent trial also reported a favourable treatment effect for SMR, but only in 
smokers who were categorised as highly ‘behaviourally’ dependent (Caponnetto et al., 
2011a). It is logical to assume that such smokers, who place importance on the 
ritualistic/behavioural aspects of smoking, would find SMR of more benefit, but these 
findings were post-hoc and require replication. The final study therefore investigated the 
possibility that sensorimotor treatment effects may be moderated by behavioural 
dependence.  
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6 Study 3: Are sensorimotor replacement 
treatment effects moderated by ‘behavioural’ 
dependence?  
 
6.1 Study synopsis 
 
This study was part of a randomised controlled trial (RCT) investigating the effects of DNCs 
in combination with standard NHS-SSS treatment (i.e. behavioural and pharmacological 
support; DNC+ST) vs. standard NHS-SSS treatment (ST) alone (McRobbie et al., 2013). 
The primary outcome of the main trial was the difference in urge to smoke between the 
two groups over the first week of abstinence. Secondary outcomes included (i) differences 
between the two groups on change in withdrawal symptoms (MPSS ratings) over four 
weeks of abstinence; (ii) abstinence rates over 12 weeks; (iii) predictors of abstinence at 4 
and 12 weeks post-target quit day (TQD); (iv) effects of medication type (NRT vs. 
varenicline) on abstinence rates between DNC+ST and ST groups; and (v) DNC use, 
satisfaction and sensory ratings, and adverse effect. 
 
6.2 Methodology 
6.2.1 Aims  
 
The aim of this study was to examine whether scores on the Glover-Nilsson Smoking 
Behavioural Questionnaire (GN-SBQ; Glover et al., 2005), which purports to measure 
behavioural dependence, would moderate any effect of SMR on smoking cessation 
outcomes. A secondary aim was to examine whether sensorimotor motives for smoking as 
measured by Sensorimotor subscale of the Motives for Smoking scale (SM-MFS; Russell et 
al., 1974) would also moderate treatment effects.  
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6.2.2 Hypotheses  
 
It was hypothesised that behavioural dependence and/sensorimotor motives, would 
moderate treatment effects, in that abstinence rates would be greater in the DNC+ST vs. ST 
group for those reporting high scores on these measures at baseline, with a different 
pattern of results evident in the low dependence/motives sub-groups.  
 
6.2.3 Design 
 
This study was a RCT where participants were randomised (1:1) to one of two treatment 
groups: DNCs alongside standard NHS-SSS treatment (experimental condition), or to 
standard NHS-SSS treatment only (control condition).  
 
6.2.4 Participants 
6.2.4.1 Recruitment 
 
Smokers seeking treatment were recruited from the Royal London Hospital Smokers Clinic 
and through advertisements in local London newspapers (see Appendix 1). 
 
6.2.4.2 Inclusion/exclusion 
 
Participants were included in the study if they were aged 18 or over and seeking smoking 
cessation treatment. Participants were excluded if they were pregnant/breastfeeding, or 
had an acute psychiatric illness.   
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6.2.5 Procedures 
 
Participants interested in taking part were initially screened on the telephone, and if 
eligible, were posted study information (see Appendix 22), the baseline questionnaire and 
booked to attend the clinic. All participants received standard NHS-SSS treatment (i.e. 
weekly behavioural and pharmacological support). 
At the first session, participants were consented (see Appendix 23) and baseline 
information was collected. Participants were also asked to choose which medication (NRT 
or varenicline, provided on prescription) they wished to use. The second session provided 
guidance on preparing for the TQD, scheduled for the following week. Those choosing 
varenicline were instructed to start taking the medication at the second session, and all 
participants were asked to smoke as normal up until the TQD (session 3).  
On the TQD, participants were randomised to one of the two conditions. In order to 
examine interactional effects with medication type (a secondary outcome of the main trial), 
100 participants using NRT and 100 using varenicline were randomised, resulting in a 50/50 
split in medication type within each treatment group. The randomisation list was computer 
generated, and participants were sequentially allocated to either use the DNCs or continue 
with standard treatment only. Study staff and participants were not blinded to treatment 
allocation. The DNCs used in Study 2 were also used in the present study. Participants were 
given an initial supply of 140 DNCs on the TQD, though anyone reporting baseline cigarette 
consumption greater than 20/day were given extra. Participants could request a further 
supply of DNCs the following week. Those randomised to the DNC+ST group were asked to 
smoke their first DNC, and rate its sensory effects, satisfaction and other user ratings at the 
session. They were instructed to smoke the cigarettes ad-libitum over the following two 
weeks. Those using NRT were instructed to start using their products from the TQD.  
All participants were telephoned 24 hours post-TQD, to assess smoking status, withdrawal 
symptoms and urges, and for the DNC+ST group, to rate the DNCs. Following this, 
participants attended a further 6 sessions for weekly behavioural support. At each session, 
participants completed questionnaires assessing smoking status (with CO validation), 
withdrawal and urges, DNC use and ratings (sessions 4 and 5 only), and adverse effects. All 
participants were followed up at 3 months post-TQD to assess smoking status. Participants 
were paid £20 at session 9 and £10 at the follow up, for travel expenses pertaining to the 3 
extra visits on top of standard treatment (usually only 7 sessions).  
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Table 6.1 gives a summary of the study assessment procedures for the whole trial.  
The study was approved by the National Research Ethics Service Committee (Clinical Trials 
registration Number: NCT01250301 [www.clinicaltrials.gov]) and ran from July 2011 until 
July 2012. 
 
 
Table 6.1: Summary of Study 3 Procedures. 
Measures/ 
procedures 
Weeks Post-TQD 
-2 -1 0 
TQD 
24 hr –
post 
TQD 
phone 
call 
1 2 3 4 5 
 
6 12 
          
Screening + 
consent 
X           
Baseline 
questionnaire 
(including GN-
SBQ and SM-
MFS) 
X           
Randomisation   X         
CO X X X  X X X X X X X 
MPSS X X X  X X X X X X X 
Smoking status X X X X X X X X X X X 
Adverse effects  X X X X X X X X X X 
DNC ratings   X X X X      
DNC urges       X X X X  
Medication/ 
DNC use 
 Varenicline 
 NRT 
          DNC      
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6.2.6 Measures and Outcomes 
6.2.6.1 Behavioural dependence and sensorimotor motives 
 
Participants completed the standard Royal London Hospital Smokers Clinic Baseline 
questionnaire (see Appendix 3), which included demographic details, smoking history and 
the FTND, as in Study 1 and 2 (details provided in Study 1 methodology). This also included 
the Glover-Nilsson Smoking Behavioural Questionnaire (GN-SBQ) which purports to 
measure the construct of behavioural dependence to smoking (Glover et al., 2005). This 
questionnaire was used in a previous study to examine the potential moderating effect of 
behavioural dependence on treatment effects of a non-nicotine inhalator (Caponnetto et 
al., 2011a).   
Two items from this questionnaire asked participants how much they value their cigarette 
habit and the handling/manipulating ritual of smoking, on a 5-point scale (“not at all”, 
“somewhat”, “moderately so”, “very much so” or “extremely so”). The remaining 9 items 
required participants to rate the frequency of behaviours associated with smoking on a 5-
point scale (“never”, “seldom”, “sometimes”, “often”, or “always”). The behaviours, for 
example, include smoking routinely without craving and using smoking as a reward. The 
GN-SBQ classifies smokers into 4 dependence categories based on total scores: mild (<12), 
moderate (12-22), strong (23-33) and very strong (>33), with a maximum score of 44 
possible.  
The GN-SBQ has a strong focus on the ritual of smoking and behaviours associated with it, 
but little attention is paid to the sensory aspects. Thus, in addition, participants also 
completed the Sensorimotor subscale of the Motives for Smoking scale (SM-MFS; Russell et 
al., 1974). This 5-item questionnaire measured the extent to which participants were 
motivated to smoke by sensorimotor aspects. Questions were rated on a 4-point scale 
(“uncertain or not at all”, “a little”, “quite a bit”, “very much so”). Other questionnaires 
with sensorimotor sub-scales exist, such as the Occasions for Smoking scale (Ikard et al., 
1969, Horn and Waingrow, 1966) and Reasons for Smoking scale (McKennell, 1973, 
McKennell, 1970), but there is considerable overlap, and the measure chosen, the SM-MFS, 
combines these two previous scales (Shiffman, 1993).  
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6.2.6.2 Abstinence  
 
Smoking status over the past week was recorded at every visit (“not a single puff”; “a few 
puffs”; “1-5 cigarettes”; “more than 5 cigarettes”). Self-reported abstinence was verified 
with a CO reading (cut off <10ppm). During DNC use, abstinence (from conventional 
cigarettes) was self-report only.  
 
6.2.6.3 Outcomes 
 
The outcomes of interest were the differences between the treatment groups in abstinence 
rates at 4 and 12 weeks post-TQD, within high and low GN-SBQ sub-groups, as per the 
previous study by Caponnetto et al (2011a); specifically, whether DNC treatment effects 
were more apparent in the high vs. low sub-groups. Abstinence was defined as CO-
validated continuous abstinence from 2 weeks post-TQD, and reflected standard NHS-SSS 
outcome criteria at 4 weeks.  
Secondary outcomes included differences in abstinence rates at 4 and 12 weeks post-TQD 
between treatment groups, within the high/low SM-MFS sub-groups; and GN-SBQ and SM-
MFS as predictors of abstinence at 4 and 12 weeks post-TQD.   
 
6.2.7 Sample size 
 
A total of 200 participants were randomised into the trial as it was powered to detect a 
difference in the primary outcome of the main study (i.e. urge to smoke at one-week post-
TQD, measured by the MPSS) of 0.5 (p≤ 0.05, 2-tailed test, 90% power), and thus required 
69 participants in each group. In order to account for an estimated 30% attrition rate 
between the TQD and one week post-quit, the sample size was increased to one hundred 
participants in each condition. This also allowed detection of a 20% difference in 4-week 
validated abstinence rates between groups (p≤ 0.05, 2-tailed test, 80% power).  
In the Caponnetto et al  (2011a) study, abstinence rates in the high GN-SBQ sub-group at 4-
weeks were 67% and 35% in the experimental and control conditions, respectively. To 
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detect a similar difference, a total of 38 participants would be needed in each treatment 
group at a two-sided significance level of 0.05, with 80% power. 
 
6.2.8 Data analysis 
 
Participants were categorised into high or low dependence groups. For the GN-SBQ, high 
dependence was defined as a total score of more than 22, and low dependence as a score 
of 22 or below (Caponnetto et al., 2011a). Similarly, for the SM-MFS sub-scale, a score of 8 
or more was categorised as high and 7 or less as low. Differences in abstinence rates over 4 
and 12 weeks between the DNC+ST and ST groups were examined with chi-square tests, 
within each behavioural dependence/SM-MFS sub-group. In addition, logistic regression 
was used to examine whether GN-SBQ dependence category (mild [<12], moderate [12-22], 
strong [23-33] and very strong [>33]), as per the original questionnaire, and total GN-SBQ 
and SM-MFS scores, predicted abstinence at 4 and 12 weeks within the DNC group only. 
Finally, to explore the general predictive utility of these measures on abstinence, the 
logistic regression was repeated on the whole sample. 
In all analyses, participants lost to follow-up were considered to still be smoking. 
 
6.3 Results 
 
6.3.1 Participant characteristics 
 
A total of 251 participants consented to take part in the study, and 200 were randomised 
(100 in each group). Figure 6.1 shows the flow of participants throughout the study, and 
Table 6.2 reports the baseline characteristics and demographics of the sample. There were 
no significant differences between groups in participant characteristics (all p’s> 0.05; a 
summary of test results is shown in Appendix 24).  
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Figure 6.1: Study 3 Participant flow diagram 
 
    802 provided with study 
information 
(479 responded direct to 
advertisements, 323 
smokers were accessed via 
the Smokers’ Clinic) 
 10 did not meet inclusion 
criteria 
541 did not wish to 
participate 
     
        
 
 
      
     
 
251 consented to take part 
 45 decided not to take part 
5 stopped smoking prior to 
the TQD 
1 not randomised as quota 
reached 
     
              
    200 randomised    
              
 100 allocated to 
DNC+ST 
Allocation 100 Allocated to ST 
only 
   
              
 56 attended session 7 4 weeks 
post-quit 
56 attended session 7    
              
 69 attended follow-up 
at 12 weeks post-quit 
Follow-up 72 attended follow-up 
at 12 weeks post-quit 
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Table 6.2: Study 3 Participant Characteristics   
Baseline 
demographics/characteristics 
% (N= 194- 200)* 
 DNC+ST 
(N= 96-100)* 
ST 
(N= 97-100)* 
Gender  
   Male 
 
56 
 
56 
Ethnicity 
  Caucasian  
  Mixed/other 
  Don’t wish to answer  
 
82 
17 
1 
 
75 
24 
1 
Employment status  
   Employed 
   Unemployed 
   Student 
   Other (e.g. retired,     
sick/disabled) 
 
56 
13 
1 
30 
 
48 
13 
4 
35 
Education  
   Higher 
   Secondary or none 
 
57 
43 
 
60 
40 
Behavioural Dependence/ 
Sensorimotor Motives** 
  High GN-SBQ (N= 67) 
  Low GN-SBQ (N= 128) 
  High SM-MFS (N= 26) 
  Low SM-MFS (N= 173) 
 
 
49.3 
50.8 
42.3 
50.9 
 
 
50.7 
49.2 
57.7 
49.1 
                Mean (SD) 
Age 45.64 (10.53) 47.20 (13.24) 
CPD 19.11 (9.56) 18.82 (8.79) 
FTND 5.23 (2.36) 4.99 (2.47) 
GN-SBQ 19.16 (7.27) 20.31 (6.94) 
SM-MFS 3.70 (2.95) 4.19 (3.26) 
*Ns vary due to missing data    
**Data missing for 6 participants (N= 5 for GN-SBQ; N= 1 for SM-MFS) 
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6.3.2 De-nicotinised cigarette use 
 
Participants in the DNC+ST arm were provided with DNCs for up to 2 weeks post-quit day. 
On average, participants smoked 8.9 (SD= 7.76) DNCs per day in the first week, and 6.4 (SD= 
6.26) per day in the second week. 
 
6.3.3 Smoking cessation  
 
Table 6.3 and Table 6.4 give a summary of abstinence rates at 4 and 12 weeks by GN-SBQ 
and SM-MFS sub-groups, respectively. Overall, 4-week abstinence rates were higher for the 
DNC group compared to controls (58% vs. 43%, respectively; p= 0.034;  McRobbie et al., 
2013). When the analysis was separated by behavioural dependence group, both sub-
groups revealed the same pattern of results (i.e. higher abstinence in the DNC+ST vs. ST 
group), though differences did not reach significance in either sub-group (59% vs. 44%, 
respectively, for low dependence; 54% vs. 41%, respectively, for high dependence). For the 
SM-MFS measure, the majority of participants were categorised into the low motives 
group, and only 26 participants fell into the high category. As a result of this, data from the 
high motives group are difficult to interpret. The pattern of results within the low motives 
group was understandably consistent with the pattern of overall abstinence rates, as this 
sub-group made up almost the whole sample. Accordingly, at 4-weeks, abstinence rates 
were marginally higher for the DNC group vs. controls (57% vs. 42%, respectively, p= 0.057). 
At 12 weeks post-TQD, there were no differences in overall abstinence rates, though rates 
in the DNC+ST group were slightly higher than ST (39% vs. 31%, respectively; p= 0.237; 
McRobbie et al., 2013). A similar pattern of results was found within the respective sub-
groups (see Table 6.3 and Table 6.4). There is therefore little indication that any SMR 
effects are moderated by these baseline characteristics.   
Table 6.3: Abstinence rates within high and low GN-SBQ sub-groups. 
 High GN-SBQ (N= 67) Low GN-SBQ (N= 128) 
Time since 
TQD 
DNC+ST ST Chi-square 
(p) 
DNC+ST ST Chi-square 
(p) % (N) % (N) 
4 weeks  54.4 (18) 41.2 (14) 1.20 (0.273) 58.5 (38) 44.4 (28) 2.12 (0.113) 
12 weeks  33.3 (11) 23.5 (8) 0.79 (0.373) 41.5 (27) 34.9 (22) 0.59 (0.441) 
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Table 6.4: Abstinence rates within high and low SM-MFS sub-groups. 
 High SM-MFS (N= 26) Low SM-MFS (N= 173) 
Time since 
TQD 
DNC+ST ST Chi-square 
(p) 
DNC+ST ST Chi-square 
(p) % (N) % (N) 
4 weeks  63.6 (7) 46.7 (7) 0.74 (0.391) 56.8 (50) 42.4 (36) 3.52 (0.057) 
12 weeks  36.4 (4) 33.3 (5) 0.03 (0.873) 38.6 (34) 30.6 (26) 1.24 (0.266) 
 
 
6.3.4 Predictors of abstinence 
 
Regression analysis revealed that at 4-weeks post-TQD, neither GN-SBQ or SM-MFS total 
scores, nor GN-SBQ category, were significant predictors of abstinence within the DNC 
condition, or for the whole sample. This was also the case for abstinence at 12 weeks post-
TQD. Table 6.5 provides a summary of the analysis.  
 
Table 6.5: Summary of logistic regression analyses for GN-SBQ and SM-MFS as predictors of 
abstinence. 
 4 weeks post-TQD 12 weeks post-TQD 
DNC condition (N= 97)* Wald (p) 
 GN-SBQ total 
 GN-SBQ category** 
 SM-MFS total 
0.13 (0.719) 
0.15 (0.694) 
0.26 (0.608) 
2.67 (0.102) 
1.88 (0.170) 
1.35 (0.246) 
Whole sample (N= 194)*   
 GN-SBQ total 
 GN-SBQ category** 
 SM-MFS total 
0.05 (0.828) 
0.04 (0.842) 
0.30 (0.586) 
0 (0.953) 
0.14 (0.711) 
0.07 (0.787) 
*Data missing for GN-SBQ and SM-MFS measures 
**Category scores: mild (<12), moderate (12-22), strong (23-33) and very strong (>33). 
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6.4 Discussion 
 
The present study examined the possibility that sensorimotor treatment effects may be 
moderated by the GN-SBQ (Glover et al., 2005), which was proposed as a measure of 
behavioural dependence. A recent study reported greater quit rates at 4 and 24-weeks 
post-quit in the experimental group (non-nicotine inhalator and standard treatment) vs. 
controls (standard treatment only) but only in a sub-group of smokers with high GN-SBQ 
scores; in the low scoring group, the pattern was reversed indicating an unfavourable effect 
of SMR for this sub-group (Caponnetto et al., 2011a). This sub-group comparison was 
however post-hoc, and required replication. The results of the present study do not support 
these findings. At four weeks post-TQD, there was a small benefit for those participants 
treated with standard NHS-SSS treatment and DNCs (McRobbie et al., 2013), but there was 
no indication that this outcome was moderated by GN-SBQ scores: both sub-groups 
followed a similar pattern to overall abstinence rates. At 12 weeks, effects of DNCs in 
general were diminished, and again this pattern was reflected in both GN-SBQ sub-groups.  
The different findings could reflect the different sensorimotor products used (i.e. non-
nicotine inhalator vs. DNCs). Caponnetto et al (2011a), speculate that the apparent 
unfavourable effects of the inhalator in the low-dependence group could be a result of 
participants’ expectations (i.e. that the inhalator would help them in quitting) not being 
met. This could then lead to added stress and frustration, which in turn could undermine 
the quit attempt. If this were true, participants in the present study may not have 
encountered this problem because of the more adequate SMR provided by the DNCs, 
compared to the limited input of an inhalator. Indeed, a previous study reported more 
effective craving relief with DNCs vs. a placebo inhalator (Barrett, 2010).  
There were other notable differences between the two studies aside from the treatment 
offered. Firstly, baseline daily cigarette smoking was slightly higher in the Caponnetto study 
(on average ~5 CPD more than the sample in the present study), and participants scored 
somewhat higher on the FTND. This difference reflects the fact that Caponnetto et al only 
included participants who smoked ≥20 CPD for at least 10 years, with a minimum CO 
reading of 10ppm; in the present study, no such restrictions were set. In addition, their 
sample was two thirds male, compared to a more equal gender split in the present study.  
The distribution of high and low GN-SBQ scores were also more equal, with 58% reporting  
low behavioural dependence and, 42%  high dependence; in the current study, the 
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distribution was more skewed towards the low dependence category (66%). These 
differences in sample characteristics, i.e. a predominantly male and more physically and 
behaviourally dependent sample in the Caponnetto study, may have contributed to the 
disparate findings between studies. 
In addition to the GN-SBQ, a second measure, the SM-MFS (Russell et al., 1974), was also 
included. The two measures overlapped slightly, and scores were correlated to a moderate 
extent (r= 0.61, p< 0.001), but the SM-MFS was included as it focused more on the sensory 
aspects and behaviour of smoking per se as opposed to other behaviours associated with 
smoking. As with the GN-SBQ, it was hypothesised that those smokers, who were 
motivated by, and enjoyed the sensorimotor aspects of smoking, would benefit more from 
SMR. Unfortunately, as almost the entire sample was categorised into the low motives 
group, it is difficult to draw any strong conclusions with respect to this. The same pattern of 
results (i.e. higher abstinence rates in the DNC+ST group vs. ST) within the two sub-groups 
again seems to suggest no moderating effects, but this needs to be considered with 
caution. 
In addition to examining quit rates amongst these sub-groups, further analysis revealed 
that total scores on either of these measures, did not predict abstinence rates at 4 or 12 
weeks. This was also true when participants were categorised into the four original 
behavioural dependence groups of the GN-SBQ (mild, moderate, strong, very strong), 
suggesting that abstinence did not vary as a function of these baseline characteristics.     
The notion that smoking cessation treatment can be tailored to the individual based on 
their motivation for smoking or type of dependence, is appealing but not necessarily 
effective. This idea stems back over 40 years, when the concept of smoking typologies, for 
example, was introduced. Questionnaires such as the Motives for Smoking Scale (MFS; 
Russell et al., 1974) were developed in order to categorise smokers by their main 
motivation or reason for smoking, which could then potentially be used to tailor treatment. 
This was also the rationale behind the GN-SBQ (Glover et al., 2005). Although this seems 
like a logical concept, Russell et al (1974), concluded that it would be of more utility to 
classify with regards to level of physical addiction on a single dimension, rather than by 
smoker type. Accordingly, a review of the typology literature at least, revealed little 
evidence that these typologies helped to inform treatment or that matching typology to 
treatment improved cessation (Shiffman, 1993). The results here would seem to be in 
accordance with this. 
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Alternatively, the possibility that the GN-SBQ is not an adequate measure needs to be 
considered. Behavioural dependence reflects patterns of use, and according to the authors, 
includes the rituals of smoking, the relationship between cigarettes and the smoker, and 
perceived benefits that smoking provides with regards to confidence and/feelings of 
security (Glover et al., 2005). There has been little research utilising the GN-SBQ, and only 
recently has its validity and reliability been examined (Rath et al., 2013). In a sample of 
smokers not seeking treatment, the measure showed good consistency and reliability. It 
was not correlated with the FTND; this would suggest that if GN-SBQ were to show a 
relationship to smoking cessation outcome, it may indicate independent contributions of 
physical and behavioural dependence. However, one study of treatment-seeking smokers 
did find a positive relationship between the two measures (Nerín et al., 2005). Moreover, 
the findings reported here, and in a recent trial with the EC (Bullen et al., 2013), found no 
relationship between scores on the GN-SBQ and smoking cessation outcomes, questioning 
its clinical utility.  
The measure could also benefit from some refinement and clarification. For example, the 
statement “I handle and manipulate my cigarette as part of the ritual of smoking” was, at 
least in this sample of participants, difficult to grasp and answer. Handling/manipulating a 
cigarette is an integral part of smoking behaviour (e.g. holding it, flicking ash) for every 
smoker, and may not necessarily reflect ‘behavioural dependence’. Other items also now 
require updating, given Smokefree legislation.    
Some limitations were inherent with the study. Firstly, the cut-offs used to classify 
participants into high and low dependence/motives sub-groups may make it difficult to 
detect differences between smokers at the extreme ends of the scale; removing those with 
moderate-strong scores would reflect ‘high’ and ‘low’ sub-groups more accurately, but 
would substantially diminish the sample size of each sub-group in the present study. 
Alternatively, in another study, smokers were classified into three GN-SBQ groups on the 
basis of the distribution of total scores. Those in the lower (0-16) and upper (23-33) thirds 
were then classified as ‘low’ and ‘high’ dependence groups, respectively, and the middle 
third (17-22) omitted (Rath et al., 2013). This may have been a more appropriate approach, 
but would have compromised comparisons to the Caponnetto et al (2011a) study. 
For the SM-MFS, scores were highly skewed towards the lower end of the scale, meaning 
that the majority of participants were considered to have low sensorimotor motives. The 
distribution of scores seen here was in fact similar to that of the original samples on which 
the questionnaire was developed from (Russell et al., 1974), whereby very few participants 
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responded to items with the “quite a bit” or “very much so” options. It may be that only a 
very small proportion of the population feel motivated to smoke for these reasons. Another 
explanation is that participants were uncertain about their motivations. Russell et al 
instructed participants to select “not at all” if uncertain about their answer, and this was 
also mirrored in the present study with “Uncertain or not at all” presented together as one 
option. It has been proposed previously that smokers may be unaware or misguided about 
their motives and smoking patterns (Shiffman, 1993). In hindsight, it may have been worth 
separating these responses to distinguish between the two.   
In conclusion, SMR combined with standard NHS-SSS treatment may help improve short-
term cessation rates, providing some support for the notion of addressing primary and 
secondary reinforcers of smoking in tandem. This effect, however, does not seem to be 
moderated by baseline levels of GN-SBQ, and it is likely that this is also true with regards to 
levels of sensorimotor motives for smoking.  
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7 General Discussion and Conclusions 
 
Although there is a range of smoking cessation medicines available to assist smokers to 
quit, their efficacy is low and there remains substantial room for improvement. One 
potential problem with current treatments is that they do not address all of the factors 
which contribute to tobacco dependence (Rose, 2006). The aim of the present research was 
to examine more closely the non-nicotine sensorimotor factors which likely play some role 
in the reinforcing effects of smoking, and in particular, whether different types of 
‘sensorimotor replacement’ (SMR) have potential to improve on existing treatments.  
In Chapter 2, the thesis provided an overview of theories and mechanisms which underlie 
the ‘SMR hypothesis’. It is widely believed that sensorimotor stimuli become conditioned 
reinforcers as a result of classical conditioning processes; a neutral stimulus (in this case 
sensorimotor stimuli) may become rewarding if it is closely followed by a real reward (i.e 
nicotine; Rose and Levin, 1991). It follows that a cigarette substitute, which adequately 
replaces the sensory and behavioural aspects of smoking, should theoretically help to 
alleviate urges to smoke and withdrawal, and may additionally offer some enjoyment. If 
combined with current medications, SMR may help enhance treatment by offering a way of 
addressing both primary and secondary reinforcers of tobacco dependence - something 
missing with current smoking cessation treatments.  
In Chapter 3, a review of the literature was presented concerning three types of SMR 
products that had previously been evaluated for their effects on cigarette withdrawal 
symptoms and smoking cessation. These were flavoured non-nicotine inhalators/aerosols, 
de-nicotinised cigarettes (DNCs) and electronic cigarettes (ECs). The review concluded that 
there is some evidence in support of the SMR hypothesis, particularly with DNCs, but there 
were important theoretical questions requiring clarification.   
Firstly, no prior studies had compared SMR to a ‘distraction’ control condition where no 
conditioned sensorimotor stimuli were present. In most cases, products were compared to 
placebo devices (e.g. unflavoured inhalators) or other control conditions such as puffing on 
unlit cigarettes/air etc., which could offer some, albeit limited, sensorimotor input; or they 
were compared to no intervention at all.  
Secondly, whether or not SMR is ‘dose dependent’ had not been examined. In particular, 
how proximal to conventional smoking does sensorimotor input need to be to provide any 
withdrawal relief?  
 160 
 
The final question concerned ‘behavioural dependence’, which was proposed as an 
individual propensity that may moderate sensorimotor effects. A recent study suggested 
that the Glover-Nilsson Smoking Behavioural Questionnaire (GN-SBQ) measures this 
construct and relates to individual reactivity to sensorimotor stimulation, but the findings 
were post-hoc (Caponnetto et al., 2011a). The review identified a need to replicate and 
clarify this result.  
Aside from theoretical considerations, there were also potential clinical implications of the 
research questions posed. If sensorimotor input does not surpass simple distraction, there 
would be little justification for using SMR products in treatment; other tools are available 
that offer a means of distracting away from urges to smoke (e.g. ‘tangles’ or squeeze/stress 
balls often provided with NHS Quit Kits) and cost less than DNCs/ECs. If SMR does enhance 
treatment effects, the next clinical question concerns the type of product to use, i.e. how 
do any DNC and EC effects compare? Finally, identifying smokers who would particularly 
benefit from this approach would have practical implications for tailoring treatments to 
individual needs.  
Following the literature review, three separate studies addressed the three issues discussed 
above. The first two studies used an experimental approach to examine the effects of the 
products on short-term urge and withdrawal relief. In Study 1, a nicotine-free EC was 
compared to a stress ball (SB) to assess the importance of sensorimotor input per se. In 
Study 2, the nicotine-free EC and DNC were compared to examine potential ‘dose’ effects. 
Finally, Study 3 was a RCT comparing the combination of DNCs with standard smoking 
cessation treatment (DNC+ST), vs. standard treatment (ST) alone, and sought to examine 
potential moderating effects of behavioural dependence on abstinence rates.   
The key findings can be summarised as follows, and are discussed in further detail below: 
(i) SMR can surpass behavioural distraction but this effect may be short-lived. 
(ii) SMR more proximal to conventional smoking appears to offer more sustained 
urge and withdrawal alleviation.  
(iii) SMR seems to be of benefit to some but not all smokers, but behavioural 
dependence, as measured by the GN-SBQ, is not a moderator of these effects.   
(iv) SMR may have a more modest effect on acute urge to smoke and withdrawal 
alleviation than previously hypothesised. 
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7.1 Sensorimotor replacement vs. behavioural distraction 
 
Given the sensorimotor stimuli present with the EC, it was hypothesised that the EC would 
alleviate urges to smoke and withdrawal to a greater extent than the SB, and that the EC 
would be rated higher in terms of user acceptability and generally preferred over the SB. 
Overall, there appeared to be a slight benefit for the EC in urge alleviation, acutely and over 
the course of the day, but differences between products were not as large as expected. The 
most pronounced differences between products were evident during the morning session 
following overnight abstinence, in those participants who had complied with the study 
protocol and abstained throughout the study; here, urge reduction from post-cue to 10 
minutes was significantly larger for the EC (mean reduction of 1.82) vs. SB (mean reduction 
of 0.82), despite participants reporting slightly lower baseline urge scores during the EC 
condition. By the evening, these differences diminished, notably due to reduced 
effectiveness of the EC as opposed to an improvement in the effects of the SB. Thus, 
although SMR appeared to surpass distraction, the effects were smaller than expected and 
short-lived.  
It is somewhat surprising that the EC did not generate a greater effect compared to the SB. 
Demand characteristics, especially given a controlled experimental environment, may go 
some way to explaining SB effects, although the same could be expected for the EC. In 
addition, a comparison across the two studies in EC effects indicated that EC effects were 
more pronounced in the second study compared to the first. It may be that the sample of 
participants in Study 1 did not find SMR as beneficial for urges/withdrawal alleviation as 
those in Study 2. This was particularly evident in the evening session where the interaction 
almost reached significance, though even in the morning mean reduction scores from post-
cue to 10 minutes favoured the EC in Study 2 compared to Study 1 (3.25 vs. 1.82, 
respectively). The magnitude of reduction seen in Study 2 was also more in line with data 
from an earlier study, where the nicotine-free EC reduced urge to smoke by 2.8 units (on 
the same scale used here) from baseline to post-cue (Bullen et al., 2010). These findings 
highlight the potential individual variability in SMR effects, as reported previously by others 
(Brauer et al., 2001, Barrett, 2010, Dawkins et al., 2012, Dawkins et al., 2013b). But, since 
there was no behavioural-distraction control condition in Study 2, how this second sample 
would have responded to a SB is unknown. 
EC effects were found to diminish somewhat by the evening in Study 2 also, though to a 
markedly lesser extent than in Study 1. The reduced efficacy cannot be attributed to 
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differences in baseline ratings of urges and withdrawal as these did not appear to change 
from morning to evening in either study. Alternatively, the findings could reflect novelty 
effects, though it is possible that some participants had tried ECs previously, as only current 
EC users were excluded from the study (as opposed to ever-users). Furthermore, given that 
ratings of urge to smoke are extremely subjective, the EC may simply have been perceived 
by participants as more effective in the morning.   
Another possible explanation is that conditioned sensorimotor input per se, at least from 
the EC, remains reinforcing only for a short period time, thus helping to alleviate urge when 
used initially, above and beyond behavioural distraction. Once conditioned sensorimotor 
effects have dissipated, the EC may still offer some help, albeit limited, by providing a 
behavioural distraction or way of coping. This would have some implication for the notion 
of ‘behavioural’ withdrawal proposed by Baker et al (2006). This model posits that when 
smokers quit they will experience both pharmacological and behavioural withdrawal (i.e. 
the absence of the self-administration ritual, that is, smoking) and as a result, withdrawal 
symptoms would be exacerbated because individuals cannot revert to their usual means of 
coping. This would imply that SMR would be the most effective way of dealing with 
behavioural withdrawal and in turn, nicotine withdrawal symptoms. Indeed, it was 
suggested that pharmacological nicotine withdrawal symptoms should be eased even if the 
self-administration ritual is performed without the delivery of nicotine, and the findings 
from both Study 1 and 2 seem to provide some support for this, albeit it modest.  
However, the model also posits that behavioural withdrawal is what accounts for ex-
smokers experiencing (i) prolonged withdrawal symptoms (namely urges and negative 
affect) long after physical withdrawal has dissipated, and (ii) exacerbated reactions to 
environmental events or smoking-related cues. This therefore suggests that even after a 
prolonged period of abstinence, when an ex-smoker does experience an urge to smoke, 
SMR should help to ease this. However, the model does not consider for how long engaging 
in the self-administration ritual, or as in this case using a SMR product, can be effective for, 
and if we assume that SMR effects are short-lived, this may limit the practical utility of the 
effect.   
The model does assert that these prolonged symptoms can be overcome if either smoking-
related cues/triggers extinguish, and/or if the individual finds a new effective coping 
strategy. It may be then, as suggested above, a SMR product could still be of help after 
conditioned sensorimotor effects dissipate, because of the behavioural distraction/coping 
elements it provides. Coping strategies, distraction techniques and other cognitive-
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behavioural tools have been shown to help ease cue-induced cravings acutely (Ferguson 
and Shiffman, 2009), and as was seen in Study 1, the SB still generated some symptom 
alleviation.  
It could be argued that the EC does not fully replicate the self-administration ritual, and 
that only DNCs - which still involve the actual ritual of smoking - would be effective long-
term. The authors themselves make direct reference to the use of DNCs as a means of 
alleviating behavioural and physical withdrawal (Baker et al., 2006), and the findings of 
Study 2 would appear to lend some support for this (discussed further below).  
Regarding product preferences and user ratings, this part of the hypothesis was supported. 
Most participants preferred the EC over the SB, and rated the EC more highly on user 
acceptability items. In particular, the provision of cigarette-like sensorimotor input (i.e. 
smoke like vapour, the ability to inhale/exhale) and its overall similarity to conventional 
cigarettes, gave the EC an advantage over a product which did not provide this type of 
sensorimotor stimulation, adding weight to the notion that the sensorimotor input is 
perceived as helpful, or at least desirable. This is consistent with a recent qualitative study 
of EC users investigating the perceived efficacy of ECs in smoking cessation, which identified 
sensorimotor input - in particular the feeling of inhaling, the throat ‘hit’, and seeing the 
‘vapour cloud’ upon exhaling - as an important factor (Barbeau et al., 2013). Even if the EC 
does not give much more in the way of urge alleviation above and beyond simple 
behavioural distraction, the fact that it is similar to conventional smoking gives it added 
appeal. From a practical point of view it is unlikely that the SB would be adhered to if 
recommended to smokers as a coping/distraction strategy; the EC has more potential in 
this respect.  
 
7.2 Proximity of sensorimotor replacement to smoking 
 
It was hypothesised that the DNC would alleviate urge to smoke and withdrawal symptoms 
to a greater extent than the EC, would be rated higher in terms of user acceptability, and 
preferred over the EC. This was supported to some degree; compared to ECs, DNCs reduced 
baseline ratings of urge to smoke from the morning to the evening session to a greater 
extent, and MPSS ratings were lower over the course of the day. This would suggest that 
with more proximal SMR, conditioned sensorimotor factors may remain reinforcing for a 
longer period of time, helping to supress general or ‘background’ urges to smoke and 
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withdrawal when used regularly throughout the day. There was however, comparable urge 
relief during the controlled experiments, and very few differences between the two 
products in terms of product preferences and ratings.    
Consequently, proximity to real smoking may not necessarily be as important as previously 
hypothesised with regards to acute urge relief. Since both the EC and DNC provide key 
elements of smoking behaviour - namely the presence of smoke (or vapour in the case of 
the EC), inhalation/exhalation, airway sensations - this would imply that so long as these 
aspects are present, they are sufficient to alleviate symptoms acutely, without the need for 
more ‘realistic’ sensorimotor input. Exactly how long this would remain reinforcing for until 
more proximal input is needed is a key question. 
It should be considered that as DNCs do contain tobacco, some of these effects may be 
attributed to other tobacco smoke constituents which may themselves be reinforcing 
(Rose, 2006). It may be that some of these chemicals, such as MAO inhibitors, help to 
reduce general withdrawal and urges to smoke, along with some effects of conditioned 
sensorimotor input, but that sensorimotor input itself only provides some acute relief. This 
may help explain why both the EC and DNC were comparable during the controlled 
experimental sessions, but the DNC showed a benefit over the course of the whole day.      
The findings have some implications for treatment. DNCs may be a more effective product 
to use given that they may help supress ‘background’ urges and withdrawal, and potentially 
episodic symptoms as and when they arise; the EC on the other hand may only provide 
some acute relief in times of need, and potentially only during the initial treatment phase. If 
DNCs remain reinforcing for a longer period of time, they may also be of help as a relapse 
prevention tool. If behavioural withdrawal (described above) persists long after physical 
withdrawal subsides, and is eased by engaging in the self-administration ritual (Baker et al., 
2006), then DNCs may offer a way of alleviating these symptoms and preventing a lapse 
back to smoking.  
 
7.3 Moderators of sensorimotor replacement effects 
 
Behavioural dependence (measured with the GN-SBQ) was proposed by Caponnetto et al 
(2011a) as one possible moderator of sensorimotor effects in treatment. Based on their 
previous findings, it was therefore hypothesised that participants who were considered 
highly behaviourally dependent by this measure, and/or motivated by the sensorimotor 
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aspects of smoking - measured with the Sensorimotor subscale of the Motives for Smoking 
scale (SM-MFS;Russell et al., 1974) - would benefit more from SMR in treatment. This 
hypothesis was not supported. The addition of SMR with DNCs to current stop-smoking 
treatment, had a small benefit on short-term cessation outcomes (McRobbie et al., 2013) - 
providing some support for the rationale of addressing both primary and secondary 
reinforcers - but there was no evidence to suggest that behavioural dependence moderated 
these effects. The pattern of results was the same in both high and low GN-SBQ sub-groups. 
Data for the SM-MFS were more difficult to interpret (due to extremely unequal size of sub-
groups), but followed a similar pattern of results. In addition, there was no evidence of a 
relationship between the total scores on these baseline measures and cessation outcomes. 
These findings are in contrast to those reported by Caponnetto et al (2011a), but it should 
be noted that their findings were post-hoc. The present results appear to be in line with the 
general smoking-typology literature, which found little evidence that matching smoker 
typology to treatment would improve cessation outcomes (Shiffman, 1993). 
This is not to say that sensorimotor effects are not moderated by other variables, and 
indeed could still be moderated by behavioural dependence, but the GN-SBQ may simply 
be an inadequate measure of this construct. The lack of predictive relationship between the 
GN-SBQ and abstinence rates reported here and in another recent trial with ECs (Bullen et 
al., 2013), also calls into question its clinical utility. The marked variability in responses to 
the EC seen across the two experimental studies may imply that SMR is helpful for a 
particular sub-group not identified by the questionnaires used. Although there is no doubt 
that nicotine is the primary reinforcer in tobacco smoking, smokers may differ in their 
responsiveness to secondary reinforcers. Gender is one variable which has been identified 
as a potential moderator of responsiveness to conditioned reinforcement (Perkins, 1996). 
Research with SMR suggests that women may be more susceptible to the sensorimotor 
aspects of smoking, whereas for men, nicotine may be a more powerful reinforcer (Barrett, 
2010, Dawkins et al., 2013b, Dawkins et al., 2012). The literature is somewhat mixed 
though, with other studies reporting the opposite (Brauer et al., 2001).  
Another factor identified in previous work was level of physical dependence, whereby more 
dependent smokers may place more value on the sensorimotor aspects than those less 
dependent, presumably because the association between nicotine and sensorimotor 
aspects are stronger given more frequent and intensive pairings (Behm et al., 1993, Brauer 
et al., 2001). Participants across the two EC studies were similar in key demographics and 
characteristics such as age, gender, ethnicity, employment status, qualifications, CPD and 
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FTND scores as well as EC use over the day, and as such these factors perhaps may not 
moderate the findings here. It is unlikely that study procedures influenced these results as 
these were kept constant across both studies.  
The variability in responses could, of course, be specific to the EC only, though given 
previous research suggesting individual differences with DNCs (Brauer et al., 2001), it is 
likely that a variety of factors play a role in how smokers respond to SMR in general. For 
some individuals, engaging in a behaviour so similar to conventional smoking may have a 
negative effect; if proximal smoking-related cues such as lighters, cigarettes, seeing others 
smoke etc., can act as conditioned stimuli and trigger urges to smoke or smoking 
behaviour, the SMR product itself may have the same effect, particularly in the case of 
DNCs, and in individuals who are especially reactive to such cues. Furthermore, if the 
replacement is not deemed to be adequate or satisfactory, this may lead to feelings of 
frustration and exacerbate withdrawal. For others, SMR may be perceived positively and as 
a step towards quitting or way of bridging the gap; and although the replacement may not 
be as satisfactory as a real cigarette, it is considered better than nothing at all, particularly 
in high-risk situations where there is a danger of relapse to conventional smoking.  
 
7.4 Effects of sensorimotor replacement on urges to smoke: 
Implications for the central SMR hypothesis. 
 
The central mechanism of action proposed for SMR was the alleviation of acute urge to 
smoke via conditioned sensorimotor input. It is important to consider that although 
statistically significant reductions in urge were evident, the effects were modest, especially 
in Study 1, and could be reflective of a Type 1 statistical error. In Study 2, effects were more 
apparent, but without a control condition this is difficult to interpret. This calls into 
question whether or not sensorimotor factors have as much of an impact on reducing urges 
to smoke as previously hypothesised. A lack of an effect on urge to smoke however, does 
not necessarily relate to a lack of effect on cessation. Indeed, previous smoking cessation 
trials with DNCs have not consistently reported beneficial effects on craving and 
withdrawal, despite some benefits for cessation (Hatsukami et al., 2010, McRobbie et al., 
2013, Walker et al., 2012). This is in line with the general smoking-cessation literature; a 
recent review reported inconsistent findings regarding the relationship of craving (either 
measured pre-quit or post-quit) to smoking-cessation outcomes (Wray et al., 2013).  
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Thus, SMR products may exert their effects in ways other than directly alleviating urge to 
smoke. For example, SMR products may work well as a coping tool, providing engagement 
in a concrete behavioural task during high-risk relapse situations. This could help to 
alleviate the distress experienced during an urge/craving, something which has been put 
forward as a potential clinical target (Tiffany and Wray, 2012). In the case of DNCs 
specifically, as discussed previously, other tobacco smoke constituents may play a role 
(Rose, 2006). It is also theoretically plausible that over an extended period of time, SMR 
could help to extinguish the associations formed between smoking and other stimuli which 
provoke urges to smoke and/or smoking behaviour (Walker et al., 2009).  
Another possible mechanism not previously considered in the sensorimotor literature 
concerns the aversiveness of sensorimotor input. Despite participants reporting that they 
liked that the DNCs and ECs provided sensorimotor input, taste was frequently reported as 
the main disliked aspect of both products. Additionally, across both studies, ratings of 
pleasantness were modest and typically in the range of ‘slightly-somewhat’. This raises the 
possibility that the unpleasantness of the taste/flavour itself may help to deter away from 
thoughts of smoking, and potentially form or reinforce a negative perception of cigarettes. 
Since the flavour of ECs can be manipulated and users can ‘shop around’ for flavours they 
prefer, aversive processes may only be pertinent to DNCs. Previous research with DNCs has 
not examined the potential aversive properties of DNCs, but in our trial (McRobbie et al., 
2013), when participants were asked what they liked/disliked about the DNCs, 44 
participants listed taste as the main disliked aspect (as seen in Study 2 also), but two 
participants reported that although the DNCs were unpleasant, this actually helped deter 
them away from smoking conventional cigarettes. Such reports were not evident in Study 2 
though.  
The unpleasant taste/flavour of the products does not necessarily negate the SMR 
hypothesis; taste is only one aspect of SMR, and as other factors are still present (e.g. 
puffing, holding, inhaling/exhaling) they may still confer conditioned reinforcement. 
Instead, aversive properties for some individuals may provide an additional deterrent from 
smoking. Unpleasant taste/flavour could of course have negative consequences. If deemed 
too unpleasant, the product may not be adhered to at all, when it could confer some 
benefit. Despite negative comments regarding taste, across studies 1 and 2, most 
participants reported that they would at least consider using an EC or DNC in smoking 
cessation, or recommend to others for quitting. Improving the sensory input would likely 
enhance satisfaction and enjoyment and in turn adherence, potentially improving efficacy.  
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7.5 Cue-exposure effects 
 
The present findings also have some implications for cue-exposure research. A cue-
exposure procedure was used in the experimental studies to amplify urges to smoke and 
withdrawal in order to avoid potential floor effects, as well as to expose participants to a 
proximal smoking cue that they would typically encounter outside of the study setting. In 
this way, potential effects of the products on cue-induced urges, as opposed to just 
background withdrawal and urges to smoke, could also potentially be assessed, as per 
other interventions/medications (Ferguson and Shiffman, 2009). The impact of the cue-
exposure procedure across the two studies was inconsistent, and where there was an 
effect, change from baseline was quite modest. This resonates with recent literature 
questioning the relevance and utility of cue exposure research (Wray et al., 2013, Perkins, 
2012, Sayette and Tiffany, 2012, Perkins, 2009).    
Despite this, there were some interesting patterns of results that emerged. In Study 1, the 
cue-exposure increased urge to smoke during morning and evening sessions but only in the 
sample of participants who were able to comply with study procedures and abstain 
throughout both study sessions. Abstinence length may explain the finding that in the 
evening session, those who abstained showed an increase in urges following cue-exposure 
since previous cue-reactivity research has proposed this as a potential moderator.  
Most research with respect to this has in fact reported weaker reactions following longer 
deprivation as opposed to stronger reactivity (Bidwell et al., 2013, Payne et al., 1996, 
Heishman et al., 2010, Drobes and Tiffany, 1997, Sayette and Hufford, 1994, Tidey et al., 
2008). Some of these reports could be a reflection of ceiling effects or potential habituation 
to cues in repeated measures designs (though see below regarding habituation). One study 
did report increased cue-reactivity as abstinence length increased (Bedi et al., 2011). In this 
study however, participants were randomised to relatively long periods of abstinence (7, 
14, or 35 days) as opposed to overnight/12 hour’s abstinence, common in other designs. In 
addition, reactions to smoking cues were relatively stable over time when a within-subjects 
analysis was conducted in a fourth group, who remained abstinent for 35 days, and cue-
reactivity was measured at 7, 14 and 35 days (Bedi et al., 2011). Others have also reported 
no moderating effect of abstinence on cue-reactivity (Shiffman et al., 2013, Carter et al., 
2006, McDonough and Warren, 2001).  
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Even if abstinence length does play a role, it does not explain why only the abstainer 
sample was affected by the cue-exposure in the morning, as all participants were overnight-
abstinent at this point. The findings could be reflective of an acquiescence tendency in this 
sub-group of participants.   
In study 2, this pattern was not evident, and the cue-exposure appeared to have little effect 
overall (i.e. there were few main effects of time). But, there was some evidence to suggest 
that participants’ product expectancies moderated the extent of cue-reactivity in the 
morning. There was a marginal interaction between time and product for urge to smoke in 
the morning in the sample of abstainers. Urge increased after cue-exposure but only when 
participants were told they would be using the EC ; , when told they would be using the 
DNC, urge reduced slightly. This pattern was also reflected in ratings of irritability and 
restlessness. For example, in the whole sample, there was a marginal and significant 
interaction for ratings of irritability and restlessness, respectively; this wasn’t however 
evident in the abstainer sample, possibly due to the smaller sample size. These patterns 
were only evident in the morning when participants were naïve to the products. 
 It may be then that participants had the expectation that the DNC - which at least is still a 
tobacco cigarette - would be more helpful. Together with the knowledge that they would 
be able to smoke this cigarette after the cue-exposure, this may have helped to supress 
their urge and feelings of irritability/restlessness, compared to when they were told they 
would be using the EC, where their expectations of its helpfulness were maybe more 
ambiguous.  
Research regarding the role of perceived cigarette availability suggests that when 
participants believe they can smoke soon after cue-exposure, cravings actually increase 
compared to when they believe they are not able to smoke (Wertz and Sayette, 2001), and 
generally, craving is believed to increase when smokers have the opportunity or know that 
the opportunity to smoke is imminent (Jędras et al., 2014), though some inconsistencies 
were highlighted in this review. Jędras et al (2014), speculate that although imminent drug 
expectancy may well increase craving, cue-exposure, together with the knowledge that 
drug/drug self-administration procedure will not be available, could give rise to negative 
mood and/or frustration, potentially amplifying craving.  
This, of course, pertains to perceived (conventional) cigarette availability, as opposed to the 
expectancies of novel products. It may be that when participants have positive expectations 
that an imminent intervention will be helpful, this may moderate the impact of cue-
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exposure. In Study 1, there was also a significant interaction between time and product for 
restlessness ratings in the morning (in abstainers) where the cue-exposure had no impact 
when participants were told they would be using the EC, but increased restlessness when 
told SB.. Moreover, analyses also revealed significant main effects of product for urges to 
smoke, and trends for the other ratings, whereby baseline and post-cue ratings in the 
morning were overall lower prior to EC use vs. SB use. This again could reflect these 
expectations regarding product efficacy, and/or as noted, increased frustration/negative 
mood due to a lack of drug self-administration in the SB condition. 
Despite previous research suggesting that smoking-related cues generally increase craving 
in comparison to neutral cues (Carter and Tiffany, 1999), the inconsistent findings 
presented here raise questions for the cue-exposure paradigm. There are undoubtedly a 
number of methodological factors which may moderate reactions to smoking-related cues, 
including type of cues, such as proximal vs. distal cues (Shiffman et al., 2013, Conklin et al., 
2008), modality of cue-exposure (Wray et al., 2011, Niaura et al., 1998, Heishman et al., 
2010), and as discussed previously, abstinence length (Bidwell et al., 2013, Payne et al., 
1996, Heishman et al., 2010, Drobes and Tiffany, 1997, Sayette and Hufford, 1994, Tidey et 
al., 2008). The modest impact of the procedure in the present studies could potentially 
reflect the type of cue used. Although a commonly used in-vivo cue was chosen (lighting 
and holding a cigarette for 1 minute), in previous work, this has usually been conducted 
with the participants’ own brand of cigarette (Ferguson and Shiffman, 2009). This was not 
implemented in the current studies due to logistical reasons, but use of own brand 
cigarettes could help bolster the impact of the cue exposure. 
Individual differences will likely also play a role and there will no doubt be some individuals 
for whom cue-exposure (at least cue-exposure examined in the laboratory) will have no 
impact, and others who are highly reactive. In some studies, this has been acknowledged 
and outcomes have been examined in ‘reactor’ sub-groups, though definitions of ‘reactors’ 
have varied from simply change scores greater than zero (Weinberger et al., 2012), to an 
increase of at least one unit in average craving (Shiffman et al., 2003). Differences in cue-
reactivity could therefore relate to the possibility that some individuals are particularly 
responsive to secondary or conditioned reinforcers of smoking behaviour (discussed 
above). Some authors have proposed the notion of a ‘cue-reactive’ phenotype, which 
generalises across stimuli (Styn et al., 2013). For example, Styn et al reported a significant 
positive relationship between cue-induced cigarette cravings and cue-induced chocolate 
cravings in a sample of non-deprived (chocolate and cigarettes) smokers. Alternatively, as 
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was seen in one study (Shiffman et al., 2003), these differences could be attributed to other 
characteristics such as age, years smoked and baseline CO (all lower in ‘reactors’ vs. ‘non-
reactors’).    
 
7.6 Strengths and Limitations 
 
The current research extends upon the sensorimotor literature in several ways. Firstly, it 
adds to the limited data on the acute effects of nicotine-free ECs specifically as SMR 
products, and confirms that sensorimotor input from the EC can help reduce urge acutely 
to a certain extent, at least early on. As seen with other SMR products (e.g. flavoured non-
nicotine inhalators/aerosols) that provide limited input, conditioned sensorimotor effects 
per se may be short-lived.  
The research also provides the first comparison between different sensorimotor products. 
There was some speculation that the more consistent and robust effects seen with DNCs in 
the literature were due to the proximal sensorimotor input that this product provides, and 
the findings here provide some evidence for this, but only in relation to long-term effects. 
The research also contributes to the evidence base of DNCs in treatment, with the first trial 
to investigate the combination of DNCs not only with varenicline but with all types of NRT, 
within an intensive behavioural support context (McRobbie et al., 2013). There has been 
very little examination of potential moderators in treatment with SMR, and the final study 
here provides the first set of data (for this type of intervention), on the role (or lack of it as 
the case may be) of behavioural dependence and sensorimotor motives, on smoking-
cessation outcomes.  
There are some limitations with the current research that should be considered. Firstly, the 
use of controlled experimental sessions as in Study 1 and 2 can be highly artificial, hence 
findings may be difficult to generalise to ‘real world’ situations. Individuals are not in their 
typical environment, surrounded by the plethora of psycho-social factors which can 
influence smoking behaviour. One of the key strengths of the present studies however, was 
the use of products outside of the study setting to improve generalisability. The cue-
exposure procedure was also intended to provide a smoking cue that smokers may typically 
encounter in a ‘real-world’ context.   
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With regards to the cue-exposure procedure, participants could have habituated to the 
procedure over the course of the study, since it was repeated 4 times in total. Evidence 
suggests cue-reactivity effects can remain stable following repeated trials (Miranda et al., 
2008, Morissette et al., 2012, Bidwell et al., 2013, Conklin and Tiffany, 2001), though one 
study reported some decreases in reactions to both neutral and smoking cues (presented 
weekly with approximately one hour of abstinence beforehand), from session one to three, 
but no change at the fourth session, suggesting some novelty effects (LaRowe et al., 2007). 
In the present studies, the impact of the cue-exposure on urges within each condition at 
least, seemed to be fairly similar in the morning and evening. For example, in the abstainer 
sample in Study 1, across both products, urge increased by 0.50 and 0.56 units in the 
morning and evening respectively; and in Study 2, urge increased by 0.19 units across both 
products in the morning, and barely changed in the evening. These scores in the evening 
could have been confounded by abstinence over the day. To fully examine any habituation 
effects per se, an analysis of pre to post-cue exposure scores, with session number (1 to 4) 
as a repeated factor, would need to be conducted.  
It should be noted that although cue-exposure was used here in part to increase external 
validity, cue-exposure in the laboratory itself is still artificial and again may not reflect what 
occurs outside of the study setting. Cue-reactivity research could be applied clinically in 
several ways such as indexing addiction severity, identifying cues which may interfere with 
treatment, as a treatment itself (e.g. cue-exposure therapy), and in identifying those prone 
to relapse (Carter and Tiffany, 1999). But, its clinical utility has recently been questioned. 
Several reviews found that the relationship between cue-reactivity to relapse and other 
indicators of nicotine dependence (Perkins, 2009) and a variety of other treatment 
outcomes (e.g. abstinence, time to first lapse, likelihood of quitting; Wray et al., 2013, 
Perkins, 2012) was generally quite weak and inconsistent. Another common application of 
the cue-exposure paradigm concerns the efficacy of medications/interventions in 
alleviating cue-induced cravings (Ferguson and Shiffman, 2009). Given the inconsistency in 
cue-exposure effects and interactions with products (discussed above), it is difficult to draw 
any conclusions on whether or not SMR may impact on cue-induced urges specifically. If 
anything, the cue-exposure may have confounded the subsequent analyses where post-cue 
was used as ‘baseline’, though the modest impact of cue-exposure (where there was an 
effect) may mitigate these concerns.  
One limitation of the first study was that there was no control condition in which 
participants had no intervention at all. It is difficult then to ascertain how much behavioural 
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distraction itself added to any effects as opposed to just the procedural aspects of the 
study. There may have also been several confounding factors across both studies 1 and 2. 
Firstly, some participants were recruited from the Smokers’ Clinic and as such were actively 
seeking smoking-cessation treatment; others responded to advertisements and were not 
necessarily interested in quitting smoking. It is unlikely that motivation level impacted in 
any way on symptom ratings, since the experience of physical withdrawal would not be 
expected to vary with motivation; it may however impact on product preferences and user 
ratings.    
Although the study sessions were kept as consistent as possible throughout the two 
experimental studies, ensuring a consistent rest-period between study sessions (i.e. time 
between the first study day to the next) was problematic, and as such there was only a 
minimum rest-period implemented (of at least two days). The majority of participants 
completed the study within 7 days, but the inconsistency may have introduced some bias. 
In relation to this, some flexibility in the timings of morning and evening sessions was also 
allowed (up to 30 minutes either side), again introducing potential bias.      
The sample size calculated in Study 1 did not account for an attrition rate. This was 
however considered in Study 2, and overall attrition was fairly minimal. But in both studies, 
the sample size did not account for those participants who would not comply with study 
procedures and remain abstinent over the course of the day. Since the main outcomes of 
the study were urges and withdrawal symptoms, the effect of the products could only 
reliably be interpreted in those who abstained. This was not problematic for the primary 
outcomes since this specifically concerned acute relief of urges to smoke in the morning 
where everyone was abstinent overnight. For all other analyses of symptom ratings in 
abstainers, the analysed sample was reduced, especially in Study 1. With regard to 
abstinence verification itself, during the DNC condition in Study 2, abstinence was self-
report only due to the likelihood of increased CO from smoking DNCs.  
Another limitation of the first two studies concerns the measurement of product use over 
the course of the day. This was not a concern for the DNCs since quantifying DNC use was 
based on how many were smoked throughout the day. But for the EC and SB conditions, 
participants were instructed that taking at least 5 puffs of the EC and squeezing the SB at 
least 15 times constituted one ‘use’ of each product. Defining use in this way meant that for 
any participants who were using their products continuously over a prolonged period of 
time, this could be construed as just one use of the product, or if used for less than the 
defined amount (i.e. just a few puffs every now and again) would be considered as no use. 
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It is also likely that participants may not have been attentive at times to how many puffs 
they took or amount of times they squeezed the SB in order to quantify use as instructed. 
Most participants were able to quantify their product use and provide a record, but 
whether or not this was consistent with the instructions and thus consistent across 
participants is unknown.  
This approach was used because alternative methods may also have proved just as 
problematic or not particularly useful. For example, for the EC, the number of cartridges 
used could have provided an objective measure of use, but given that product use was 
measured only over several hours, all participants would have used between 1 and 2 
cartridges, providing no useful information. Recording each puff/squeeze would have been 
unrealistic and probably inaccurate if inevitably completed retrospectively. However, use of 
a manual counter for each puff/squeeze, as in a recent study (Nides et al., 2014), may have 
been appropriate for this and perhaps more ‘user friendly’.  
As discussed previously, one of the major limitations of the third study pertains to the 
measurement of ‘behavioural’ dependence with the GN-SBQ, which may not be adequately 
captured by this questionnaire. Sub-group analysis can also often be problematic in terms 
of statistical power to detect differences between groups, since sample sizes inevitably 
reduce. In Study 3, the trial was powered to detect a difference in urges to smoke (the 
primary outcome of the main trial), and it is likely that the analysis of abstinence rates 
among sub-groups was underpowered. This was particularly evident in the ‘high’ SM-MFS 
sub-group, where the sample size was substantially diminished. 
 
7.7 Future research 
 
The present findings raise several questions for future research. Recent developments in 
SMR have centred on the use of DNCs in treatment, and indeed the findings here would 
suggest that DNCs may have the most clinical utility. Until the arrival of ECs, no other SMR 
products had been developed that could have a decent chance of rivalling DNCs. Given the 
primacy of nicotine in tobacco addiction, it would be advisable for patients to use nicotine 
ECs over nicotine-free ECs, and research suggests that very few EC users who have 
successfully quit are using nicotine-free versions (Farsalinos et al., 2013). In terms of 
research priority then, a comparison of the effects of nicotine ECs and DNCs would have 
important theoretical and clinical implications, and help to extend the present findings.  
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Addressing both primary and secondary reinforcers should theoretically be most effective 
for treatment, and therefore should favour the nicotine EC, yet it is not known whether the 
almost complete sensory and behavioural replacement offered by DNCs, together with 
potential reinforcing effects of smoke constituents, would be enough to surpass nicotine EC 
effects. Assuming adequate nicotine delivery with the EC, if the DNC was superior, or even 
comparable, this would give a strong case in support of proximal SMR. There was some 
suggestion of this in comparison to the nicotine inhalator in a previous study (Barrett, 
2010), though this may not present a fair comparison, as nicotine delivery from the 
inhalator can be inadequate. In further support of the reinforcing efficacy of DNCs, some 
studies have reported comparable acute craving relief to even conventional nicotine 
cigarettes (Hasenfratz et al., 1993, Butschky et al., 1995, Rose et al., 1994, Baldinger et al., 
1995c, Baldinger et al., 1995b, Westman et al., 1996b, Gross et al., 1997, Pickworth et al., 
1999, Breland et al., 2002, Buchhalter et al., 2001, Dallery et al., 2003, Rose and Behm, 
2004, Eid et al., 2005, Buchhalter et al., 2005, Juliano et al., 2006, Donny et al., 2007, Brody 
et al., 2009, Cobb et al., 2010, Perkins et al., 2010, Barrett, 2010, Attwood et al., 2009, 
Domino et al., 2013). Clinically, a comparison of DNCs and nicotine ECs would also offer 
some insight as to which product may be preferable if SMR was implemented in treatment.   
A second priority concerns the mechanisms of action and potential mediators of SMR. 
There is some indication from the data that SMR may not necessarily be involved primarily 
in the alleviation of urges to smoke; that is, the measurement of urges and other symptoms 
perhaps does not adequately capture sensorimotor ‘treatment’ effects. Individuals may still 
find these products useful despite not reporting much urge alleviation per se. This is 
highlighted by the results of Study 1 in particular, whereby a vast majority of participants 
preferred the EC to the SB, and would consider using it as an aid in cessation, despite there 
being only modest symptom alleviation and not much difference between the two products 
in this respect.  
Thus, SMR may impact upon constructs yet to be examined other than urge alleviation, 
such as coping skills, and extinction of associations between smoking and other 
cues/triggers. A recent qualitative study with ECs also highlighted the impact of ECs on 
wider domains such as personal and social identity, and the perception of ECs (particularly 
third generation EC devices) as a ‘hobby’ (Barbeau et al., 2013). Establishing mechanisms 
would help guide the best way for SMR to be utilised in treatment. DNCs, for example, have 
so far been used prior to quitting as an extinction tool (Becker et al., 2008, Rezaishiraz et 
al., 2007, Rose et al., 2006); or post-quit in the early stages of abstinence (McRobbie et al., 
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2013, Walker et al., 2012, Hatsukami et al., 2010, Hatsukami et al., 2013b). One approach 
yet to be tested is the use of DNCs as a relapse prevention tool in recent quitters, used 
during ‘emergency’ situations when a lapse to smoking is likely. In Study 3, the way in which 
DNCs were used varied across participants for example, with some smoking DNCs regularly 
throughout the day (though less so vs. baseline cigarette consumption) and others only in 
high-risk situations. This was driven by individual preference, but one approach could be 
more useful than the other, and shed light on potential mediators.   
Other questions still remain regarding SMR. Firstly, for whom SMR may be of benefit for 
remains unknown. Secondly, the finding that the EC generated comparable symptom 
alleviation to the DNC during the experimental sessions raises a question as to whether or 
not there are key sensorimotor aspects that are more crucial for urge alleviation than 
others. Both products provide smoke/vapour and actions of puffing, inhaling/exhaling, and 
these may be more pertinent than, for example, other aspects such as the taste/flavour and 
possibly even strength of airway sensations. These latter sensorimotor aspects may be of 
more relevance for user acceptability and adherence, and the positive reinforcing effects of 
sensorimotor factors (i.e. enjoyment, satisfaction etc.), as opposed to negative 
reinforcement (urge to smoke/withdrawal alleviation).  
Previous research in the SMR literature resonates with this hypothesis. Rose and colleagues 
in their early work with citric acid, ascorbic acid, and black pepper extract 
inhalators/aerosols, maintained that strength of airway sensations (most notably the 
‘scratch’ or hit at the back of the throat) was particularly important with regards to 
reinforcing efficacy. In some studies, their hypothesis was supported in that there were 
associations reported between the perception of strength and satisfaction and liking (Levin 
et al., 1990), craving relief, help in refraining from smoking and even abstinence rates 
(Westman et al., 1995); in others though, the relationship between airway sensations and 
outcomes were inconclusive (Levin et al., 1993). One study examining the effect of sensory 
blockade on DNCs (Baldinger et al., 1995c), reported no impact of the blocking of olfactory 
cues on reductions in craving, yet ratings of taste and enjoyment were reduced. It is 
important to note however that strength ratings also did not differ as a result of sensory 
blockade, and it is still possible that there were no differences in craving reduction between 
blockade/no blockade, because the strength was similar.  
Theoretically, we would expect the throat scratch to be particularly reinforcing as it is the 
main sensory stimulus which is experienced just prior to nicotine delivery. Although the 
present studies did not examine the sensory impact of the products, the throat ‘hit’ or 
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scratch was mentioned by some participants in Study 2: 6 participants reported disliking the 
EC due to a ‘weak’ or lack of throat hit, but with the DNCs, 3 participants felt the hit was 
too harsh or strong, whereas 2 felt it was too weak. Given the variability in responses, it is 
likely that there are individual preferences regarding sensations, taste, etc. and that there is 
no ‘one size fits all’ SMR; but, so long as key elements of smoking behaviour are present 
this is sufficient to have some treatment effect. Future work could therefore try to establish 
the relative reinforcing efficacy of different aspects of sensorimotor input. 
 
7.8 Conclusions 
 
In conclusion, the findings of the present series of studies suggest that sensorimotor factors 
are perceived as important to smokers and the provision of a SMR product may help them 
to cope during abstinence, but this may not necessarily translate to urge alleviation. SMR 
likely has some scope in treatment but how best to utilise it, and for whom this may be 
beneficial for remains unclear. One approach yet to be tested is the use of SMR as a relapse 
prevention tool, or at least as a ‘last resort’ coping tool in the early treatment phase. This 
would most likely best be tested with DNCs, given that the findings here suggest more 
proximal input may exert more sustained effects, though a comparison of DNCs with 
nicotine ECs would be useful both from a theoretical and clinical perspective.    
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9 Appendix 
 
1 Study Advertisements 
 
Studies 1 and 2: 
  
 
 
 
 
 
 
 
 
 
  
Study 3: 
 
 
 
 
 
 
  
 
 
  
Barts and The London School of Medicine 
is testing new products to help smokers quit. 
If you would like to take part call: 
0207 882 5949  
At the end of the study, help will be 
available to assist you to stop smoking 
if you wish to do so. 
 
 
 
 
At the end of the study, help will be available to 
assist you to stop smoking if you wish to do so. 
Smokers Wanted 
 
Barts and The London School of Medicine is 
testing a new approach to help smokers quit. 
If you would like to take part call: 
0207 882 8230 
 
 
 
 
At the end of the study, help will be available to 
assist you to stop smoking if you wish to do so. 
Smokers Wanted 
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2 Clinical records form (Studies 1 and 2)2 
 
 
                                                          
2
 Note: forms were identical for both studies except where shown:  * indicates this item was 
removed in Study 1; **indicates item was amended for ‘stress ball’ condition in Study 1. 
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3 Baseline Questionnaire (used in all studies)3 
 
      
                                                                                              
                                                          
3 Note: FTND= Qs.8 and10-14; GN-SBQ= Qs. 18-28; SM-MFS= Qs. 29-33. 
 
 205 
 
  
 
  
 206 
 
 
  
 207 
 
 
  
 208 
 
 
 
 
  
 209 
 
4 Study 1 Participant Information Sheet 
 
 
 
 
INVITATION TO PARTICIPATE IN A 
RESEARCH PROJECT 
Sensorimotor Replacement of 
Cigarettes 
(SeROC STUDY) 
Barts and The London 
Queen Mary’s School of Medicine and Dentistry 
 
We would like to invite you to take part in a research study. The information which follows tells you 
about it.  It is important that you understand what is in this leaflet. It says what will happen if you 
take part and what the study entails. Try to make sure you know what will happen to you if you 
decide to take part. Whether or not you do take part is entirely your choice. Please ask any questions 
you want to about the research and we will try our best to answer them.  
The Study 
People wanting to quit smoking are normally treated with medications such as nicotine patches and 
gum or Champix, and support from NHS stop-smoking advisors. Although this approach is effective, 
it does not work with everyone. Many smokers miss the action and sensations of smoking (e.g. 
holding something in their hands or mouth, puffing, inhaling smoke).  Scientists refer to these as the 
‘behavioural’ and sensory aspects of smoking. We are investigating whether products that replace 
some of these aspects can help to ease urges to smoke and other withdrawal symptoms that most 
smokers experience when they stop smoking. In this study, we will be evaluating two such products: 
a nicotine-free electronic cigarette and a stress ball. 
Why should stress balls and electronic cigarettes help? 
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Stress balls are made from soft material and are pleasant to handle. They may distract you and give 
you something to do with your hands, which may be useful during the first few days of stopping 
smoking.  
Electronic cigarettes (ECs) are battery operated devices which mimic the act of smoking. ECs may be 
purchased with differing levels of nicotine, but in this study we will be using ECs containing no 
nicotine.  ECs also provide distraction and some sensations and actions similar to normal cigarettes 
(e.g. they produce a mist when you puff on them) which may be useful during the early quit attempt. 
What will happen if you take part? 
If you would like to take part and are eligible, you will be invited to attend two study sessions. The 
table below provides further details of what will happen on each day. You will also be offered 
treatment at the Royal London Hospital Smokers’ Clinic to help you stop smoking, once the study has 
been completed. 
 
Who can take part? 
You will be able to take part if you are  
 Aged 18 years or over 
 Smoke at least 10 cigarettes per day and smoke your first cigarette within the first hour of 
waking 
You will not be able to take part if you  
 Are pregnant or breast feeding   
 
Information 
Session 
 
At this first visit to the Smokers’ Clinic we will describe the study and go through this 
information sheet. You will then have the opportunity to ask any questions. We will then ask 
you to sign a consent form to show that you have agreed to take part. 
 
We will show you the ECs and Stress balls so you know what they look like and how to use 
them. 
 
Session 1 
 
 
 
You will visit the smokers’ clinic in the morning, after having not smoked the night before. We 
will measure the amount of carbon-monoxide (CO) in your breath to check this. You will then 
be randomly allocated (by chance) to either use the stress ball or EC.  
 
Before using the product, you will complete a short questionnaire to tell us about your mood 
and urges to smoke. We will then measure how you react to smoking related cues. For this 
you will be asked to hold a lit cigarette for a short period of time, without smoking it. You will 
then be instructed to use the product for a short period of time, and over the following hour you 
will be asked to answer some questions about your urges to smoke and mood. 
 
We will give you your product to use during the day when you leave the clinic, but you will be 
expected not to smoke any normal cigarettes for the rest of the day, or to use any 
nicotine replacement therapy. You will also be asked to record how often you are using your 
product during the day.    
 
You will be asked to stop using the product 1 hour before you return to the clinic in the 
evening. When you return we will measure the amount of CO in your breath and you will 
complete a questionnaire about your mood. We will measure your reaction to smoking related 
cues, (like in the morning), and you will then be asked to use your product for a short period of 
time, and answer some questions about your urges to smoke and mood over the following 
hour. You will then complete a short questionnaire about the product you used during the day.  
 
 
 
Session 2 
 
One week after session 1, the procedure above will be repeated with the other product (stress 
ball or EC).  
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 Have been diagnosed with an acute psychiatric illness 
 Are currently using Electronic Cigarettes or Nicotine Replacement Therapy (e.g. patches, 
gum etc.) 
 Are currently enrolled in another research project  
 
Risks/Side effects 
We do not expect there to be any risks from using ECs or stress balls. ECs do not contain tobacco, 
and therefore do not deliver the many harmful substances found in normal cigarettes. As a result 
they pose no increased risk compared to your normal cigarettes.   
 
Data Protection 
If you agree to take part you will be asked to fill out several questionnaires. Any information you give 
us will be kept confidential, and only study staff will have access to this data. The results of this study 
may be presented to other individuals working in the field of smoking cessation or may be printed in 
journals; however there will be no information included which could identify you. 
Your Rights 
Your participation in this study is entirely voluntary, and you are free to drop out of the study at any 
time. Your records will be kept strictly confidential and your ordinary medical care will not be put at 
risk if you decide not to take part or drop out. 
What happens if you are concerned or have any questions? 
You will be able to contact Dunja Przulj at the Smokers’ Clinic if you are worried about anything or 
have any questions. The number is 020 7882 8230 or email smokers-clinic@qmul.ac.uk.   
The principal investigator of this study is Dunja Przulj, Tobacco Dependence Research Unit, Wolfson 
Institute of Preventative Medicine, Barts and The London School of Medicine and Dentistry, 55 
Philpot Street, London, E1 2JH, Tel:  020 7882 8230. 
A summary of the results of this study will be available upon request from Dunja Przulj (see above 
for contact details). 
We believe that this study is safe and do not expect you to suffer any harm or injury because of your 
participation in it. However, Queen Mary and Westfield College, University of London has agreed that 
if your health does suffer as a result of your being in the study then you will be compensated. In such 
a situation, you will not have to prove that the harm or injury which affects you is anyone’s fault. If 
you are not happy with any proposed compensation, you may have to pursue your claim through 
legal action. 
If you have a complaint please contact Christine Bevan-Davies, Quality Development, Barts and the 
London NHS Trust, Healthcare Governance Directorate, Tel: 020 7480 4857, Email: christine.bevan 
davies@bartsandthelondon.nhs.uk 
 
We would like to thank you for your interest in this study, even if you decide not to take part. 
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5 Example Consent Form (Studies 1 and 2) 
 
Sensorimotor Replacement of Cigarettes 
(SeROC STUDY) 
 
Informed Consent Form 
 
Principal Investigator: Dunja Przulj 
 
Participant Name:          
 
Participant Number: 
 
 Please 
initial 
each 
line 
I confirm that I have read (or someone else has read to me) and I 
understand the Participant Information Sheet (insert version and date) 
for the above study. 
 
I have had the opportunity to consider the information, ask questions 
and have had these questions answered satisfactorily. 
 
I understand that my participation is voluntary (my choice) and that I 
may withdraw from the study at any time without giving reason, and 
that my medical care or legal rights will not be affected because of this. 
 
I understand that all information collected will be in accordance to the 
Data Protection Act of 1998. 
 
I agree to take part in the above study 
 
 
 
I understand that the research data collected during the study may be looked at by 
other individuals from the research team, sponsor, from regulatory authorities or 
from the NHS Trust, where it is relevant to my taking part in this research. I give 
permission for these individuals to have access to my data.  
 
 
____________________________ __________________ ________ 
Participant Name (please print) Signature of Participant Date 
 
 
____________________________ __________________ ________ 
Name of person explaining consent Signature of person  Date 
explaining consent 
 
Please complete two forms (one for the participant and one for the study file) 
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6  Summry of sensitivity analysis on primary outcome (Study 1) 
 
 Mean change score (SD)** Test statistic 
N= 30* EC  SB  Z p 
 1.20 (1.95) 0.7 (1.24) -1.77 0.076 
*N= 5 removed with morning CO levels >15ppm   
** change in urge to smoke from post-cue to 10mins post-product use. 
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7 Mean ratings and standard deviations for urge to smoke over 1 
hour (Study1) 
 
 Time point 
 Baseline PC 5 10 30 60 
 Mean (SD) 
Abstainers  (N=17) 
Morning 
EC 
 
5.94 
 
6.53 
 
4.71 
 
4.71 
 
5.41 
 
6.35 
 (2.73) (2.83) (3.10) (2.97) (2.77) (2.60) 
SB 6.88 7.29 6.18 6.47 6.35 7.18 
 (2.62) (2.60) (2.37) (2.68) (2.29) (2.60) 
Evening 
EC 
 
6.24 
 
6.76 
 
6.06 
 
6.06 
 
6.47 
 
6.82 
 (2.66) (2.80) (2.58) (2.75) (2.83) (2.88) 
SB 6.29 6.88 6.00 5.88 6.29 7.29 
 (2.69) (2.89) (2.87) (2.96) (3.10) (2.78) 
Whole sample (N= 35) 
Morning 
EC 
 
5.51 
 
5.66 
 
4.43 
 
4.46 
 
5.34 
 
6.34 
 (3.37) (2.95) (3.04) (2.91) (2.93) (2.77) 
SB 6.63 6.80 6.09 6.17 6.11 6.91 
 (2.90) (2.93) (3.20) (2.93) (3.21) (2.98) 
Evening 
EC 
 
5.69 
 
5.71 
 
4.89 
 
5.00 
 
5.57 
 
6.26 
 (3.12) (3.30) (3.21) (3.24) (3.31) (3.03) 
SB 6.37 6.63 6.11 5.94 6.09 6.83 
 (2.95) (3.25) (3.11) (3.20) (3.23) (3.20) 
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8 Mean ratings and standard deviations for irritability over 1 hour 
(Study 1) 
 
 Time point 
 Baseline PC 5 10 30 60 
 Mean (SD) 
Abstainers  (N=17) 
Morning 
EC 
 
4.59 
 
4.94 
 
3.71 
 
4.06 
 
4.06 
 
4.41 
 (2.79) (2.90) (2.89) (2.77) (2.41) (2.67) 
SB 5.47 5.53 4.82 4.94 5.06 5.41 
 (2.70) (3.00) (2.48) (2.68) (2.54) (2.65) 
Evening 
EC 
 
5.00 
 
5.53 
 
4.71 
 
4.59 
 
4.65 
 
4.88 
 (2.65) (2.65) (2.60) (2.65) (2.71) (2.67) 
SB 5.00 5.24 4.71 4.76 5.00 5.00 
 (2.94) (3.07) (2.85) (3.11) (3.14) (3.16) 
Whole sample (N= 35) 
Morning 
EC 
 
4.14 
 
4.31 
 
3.43 
 
3.51 
 
4.03 
 
4.40 
 (3.46) (3.26) (2.97) (2.90) (2.78) (2.66) 
SB 5.26 5.11 4.74 4.74 5.06 5.51 
 (3.13) (3.42) (2.99) (3.07) (3.03) (3.08) 
Evening 
EC 
 
4.23 
 
4.34 
 
3.74 
 
3.91 
 
3.97 
 
4.46 
 (2.79) (2.95) (2.79) (2.83) (2.61) (2.87) 
SB 4.69 4.83 4.69 4.57 4.57 4.63 
 (3.09) (3.36) (3.21) (3.31) (3.36) (3.56) 
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9 Mean ratings and standard deviations for restlessness over 1 
hour (Study 1) 
 
 Time point 
 Baseline PC 5 10 30 60 
 Mean (SD) 
Abstainers  (N=17) 
Morning 
EC 
 
4.94 
 
5.00 
 
3.76 
 
4.00 
 
4.18 
 
5.06 
 (2.95) (2.81) (2.66) (2.65) (2.48) (2.68) 
SB 5.47 6.00 5.53 5.53 5.82 5.94 
 (2.79) (2.72) (2.15) (2.18) (2.67) (2.46) 
Evening 
EC 
 
4.88 
 
5.06 
 
4.76 
 
4.71 
 
4.76 
 
5.12 
 (2.60) (2.90) (2.70) (2.71) (2.66) (2.47) 
SB 5.06 5.24 4.88 4.88 5.12 5.47 
 (2.70) (2.99) (3.08) (3.06) (2.93) (3.30) 
Whole sample (N= 35) 
Morning 
EC 
 
4.26 
 
4.57 
 
3.49 
 
3.57 
 
4.29 
 
5.11 
 (3.00) (2.98) (2.67) (2.59) (2.79) (2.56) 
SB 5.06 5.2 4.91 5.14 5.69 6.06 
 (2.91) (3.06) (2.89) (2.63) (2.77) (2.85) 
Evening 
EC 
 
4.46 
 
4.46 
 
4.03 
 
4.26 
 
4.54 
 
5.17 
 (2.76) (3.04) (3.03) (2.83) (2.80) (2.67) 
SB 4.91 5.17 5.03 4.91 4.97 5.46 
 (2.61) (2.82) (2.94) (2.92) (3.03) (3.32) 
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10 Mean ratings and standard deviations of difficulty concentrating 
over 1 hour (Study 1) 
 
 Time point 
 Baseline PC 5 10 30 60 
 Mean (SD) 
Abstainers  (N=17) 
Morning 
EC 
 
4.24 
 
4.65 
 
4.24 
 
4.35 
 
4.41 
 
4.65 
 (2.68) (2.83) (2.95) (2.74) (2.60) (2.87) 
SB 5.06 5.24 5.00 4.94 5.24 5.53 
 (2.82) (2.66) (2.74) (2.86) (3.07) (2.90) 
Evening 
EC 
 
4.94 
 
4.94 
 
5.00 
 
4.65 
 
4.82 
 
4.94 
 (2.73) (2.73) (2.81) (2.78) (2.83) (2.82) 
SB 5.24 5.41 5.18 4.88 4.94 5.24 
 (2.88) (2.94) (2.90) (2.98) (2.86) (3.05) 
Whole sample (N= 35) 
Morning 
EC 
 
3.63 
 
3.94 
 
3.40 
 
3.54 
 
3.91 
 
4.23 
 (2.95) (2.97) (3.03) (2.82) (3.00) (3.04) 
SB 4.40 4.54 4.34 4.37 4.69 4.66 
 (2.86) (3.00) (2.91) (2.94) (3.02) (2.86) 
Evening 
EC 
 
4.17 
 
4.14 
 
3.97 
 
3.91 
 
3.89 
 
4.26 
 (2.77) (2.96) (3.07) (2.99) (2.85) (3.02) 
SB 4.17 4.46 4.20 4.03 4.11 4.31 
 (2.99) (3.08) (3.01) (3.26) (3.18) (3.31) 
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11 Mean ratings and standard deviations of composite withdrawal 
over 1 hour (Study 1) 
 
 Time point 
 Baseline PC 5 10 30 60 
 Mean (SD) 
Abstainers  (N=17) 
Morning 
EC 
 
4.59 
 
4.86 
 
3.90 
 
4.14 
 
4.22 
 
4.71 
 (2.60) (2.65) (2.63) (2.54) (2.36) (2.57) 
SB 5.33 5.59 5.12 5.14 5.37 5.63 
 (2.51) (2.53) (2.12) (2.31) (2.62) (2.50) 
Evening 
EC 
 
4.94 
 
5.18 
 
4.82 
 
4.65 
 
4.75 
 
4.98 
 (2.44) (2.59) (2.58) (2.51) (2.54) (2.43) 
SB 5.10 5.29 4.92 4.84 5.02 5.24 
 (2.71) (2.90) (2.84) (2.94) (2.87) (3.02) 
Whole sample (N= 35) 
Morning 
EC 
 
4.01 
 
4.28 
 
3.44 
 
3.54 
 
4.08 
 
4.58 
 (2.90) (2.90) (2.69) (2.61) (2.73) (2.55) 
SB 4.90 4.95 4.67 4.75 5.14 5.41 
 (2.61) (2.87) (2.63) (2.62) (2.74) (2.53) 
Evening 
EC 
 
4.29 
 
4.31 
 
3.91 
 
4.03 
 
4.13 
 
4.63 
 (2.58) (2.83) (2.87) (2.73) (2.56) (2.64) 
SB 4.59 4.82 4.64 4.50 4.55 4.80 
 (2.69) (2.87) (2.80) (2.94) (2.97) (3.13) 
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12 Summary statistics: Simple contrasts for urge to smoke over 1 
hour during morning session (Study 1; whole sample) 
 
Contrast (Product*Time) F(1, 34) p 
EC vs. SB PC* vs. 5mins 1.91 0.176 
PC vs. 10mins 3.28 0.079 
PC vs. 30mins 0.89 0.352 
PC vs. 60mins 1.58 0.218 
N= 35, *PC= post-cue  
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13 Summary of mean scores and test statistics for individual MPSS 
items (Study 1) 
 
MPSS Item: Depression Irritability Restlessness Difficulty 
concentrating 
Hunger 
Abstainers  
(N= 17) 
M (SD)  
EC 2.12 (1.32) 2.53 (1.07) 2.53 (1.01) 2.59 (1.37) 2.82 (1.19) 
SB 1.65 (0.79) 2.82 (1.33) 2.76 (1.25) 2.59 (1.18) 2.71 (0.99) 
Test statistic  
 (p) 
z= -1.64 
(0.101) 
z= -1.16 
(0.238) 
z= -0.79 
(0.429) 
z= -0.09 
(0.927) 
t= 0.49 
(0.632) 
Whole Sample 
(N= 37)* 
  
EC  2.00 (1.20) 2.49 (1.17) 2.51 (0.99) 2.32 (1.13) 2.54 (1.07) 
SB 1.70 (0.88) 2.84 (1.39) 2.81 (1.18) 2.38 (1.09) 2.59 (1.14) 
Test statistic 
Sig. (p) 
z= -1.81 
(0.070) 
z= -2.08 
(0.038) 
z= -1.73 
(0.083) 
z= -0.43 
(0.664) 
z= -0.40 
(0.691) 
*Two participants who did not attend the evening session gave responses via telephone 
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14 Study 2 Participant Information Sheet 
 
 
 
 
INVITATION TO PARTICIPATE IN A 
RESEARCH PROJECT 
Sensorimotor Replacement of 
Cigarettes 
(SeROC STUDY) 
Barts and The London 
Queen Mary’s School of Medicine and Dentistry 
 
We would like to invite you to take part in a research study. The information which follows tells you 
about it.  It is important that you understand what is in this leaflet. It says what will happen if you 
take part and what the study entails. Try to make sure you know what will happen to you if you 
decide to take part. Whether or not you do take part is entirely your choice. Please ask any questions 
you want to about the research and we will try our best to answer them.  
The Study 
People wanting to quit smoking are normally treated with medications such as nicotine patches and 
gum or Champix, and support from NHS stop-smoking advisors. Although this approach is effective, 
it does not work with everyone. Many smokers miss the action and sensations of smoking (e.g. 
holding something in their hands or mouth, puffing, inhaling smoke).  Scientists refer to these as the 
‘behavioural’ and sensory aspects of smoking. We are investigating whether products that replace 
some of these aspects, can help to ease urges to smoke and other withdrawal symptoms that most 
smokers experience when they stop smoking. In this study, we will be evaluating two such products: 
a nicotine-free electronic cigarette and a de-nicotinised cigarette. 
Why should electronic cigarettes and de-nicotinised cigarettes help? 
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Electronic cigarettes (ECs) are battery operated devices which mimic the act of smoking. ECs may be 
purchased with differing levels of nicotine, but in this study we will be using ECs containing no 
nicotine.  ECs also provide distraction and some sensations and actions similar to normal cigarettes 
(e.g. they produce a mist when you puff on them) which may be useful during the first few days of 
stopping smoking. 
De-nicotinised cigarettes (Denics) contain tobacco but do not contain nicotine. Like ECs, they provide 
distraction and are similar in taste and other sensations to normal cigarettes, which may be useful 
during the early quit attempt. 
What will happen if you take part? 
If you would like to take part and are eligible, you will be invited to attend two study sessions. The 
table below provides further details of what will happen on each day. You will also be offered 
treatment at the Royal London Hospital Smokers’ Clinic to help you stop smoking, once the study has 
been completed. 
 
Who can take part? 
You will be able to take part if you are  
 Aged 18 years or over 
 Smoke at least 10 cigarettes per day and smoke your first cigarette within the first hour of 
waking 
You will not be able to take part if you  
 Are pregnant or breast feeding   
 have been diagnosed with an acute psychiatric illness 
 
Information 
Session 
 
At this first visit to the Smokers’ Clinic we will describe the study and go through this 
information sheet. You will then have the opportunity to ask any questions. We will then ask 
you to sign a consent form to show that you have agreed to take part. 
 
We will show you the ECs and Denics so you know what they look like and how to use them. 
 
Session 1 
 
 
 
You will visit the smokers’ clinic in the morning, after having not smoked the night before. We 
will measure the amount of carbon-monoxide (CO) in your breath to check this. You will be 
randomly allocated (by chance) to either use the Denic or EC.  
 
Before using the product, you will complete a short questionnaire to tell us about your mood 
and urges to smoke. We will then measure how you react to smoking related cues. For this 
you will be asked to hold a lit cigarette for a short period of time, without smoking it. You will 
then be instructed to use the product for a short period of time, and over the following hour you 
will be asked to answer some questions about your urges to smoke and mood. 
 
We will give you your product to use during the day when you leave the clinic, but you will be 
expected not to smoke any normal cigarettes for the rest of the day, or to use any 
nicotine replacement therapy. You will also be asked to record how often you are using your 
product during the day.    
 
You will be asked to stop using the product 1 hour before you return to the clinic in the 
evening. When you return we will measure the amount of CO in your breath and you will 
complete a questionnaire about your mood. We will measure your reaction to smoking related 
cues, (like in the morning), and you will then be asked to use your product for a short period of 
time, and answer some questions about your urges to smoke and mood over the following 
hour. You will then complete a short questionnaire about the product you used during the day.  
 
 
 
Session 2 
 
One week after session 1, the procedure above will be repeated with the other product (Denic 
or EC).  
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 are currently using Electronic or De-nicotinised Cigarettes or Nicotine Replacement 
Therapy (e.g. patches, gum etc.) 
 are currently enrolled in another research project  
 
 
Risks/Side effects 
We do not expect there to be any risks from using ECs or Denics for this short period of time. ECs do 
not contain tobacco, and therefore do not deliver the many harmful substances found in normal 
cigarettes. As a result they pose no increased risk compared to your normal cigarettes.   
Denics still contain tobacco, and therefore do deliver similar substances to that of normal cigarettes; 
however these cigarettes pose no greater harm compared to the cigarettes you normally smoke. 
Data Protection 
If you agree to take part you will be asked to fill out several questionnaires. Any information you give 
us will be kept confidential, and only study staff will have access to this data. The results of this study 
may be presented to other individuals working in the field of smoking cessation or may be printed in 
journals; however there will be no information included which could identify you. 
Your Rights 
Your participation in this study is entirely voluntary, and you are free to drop out of the study at any 
time. Your records will be kept strictly confidential and your ordinary medical care will not be put at 
risk if you decide not to take part or drop out. 
What happens if you are concerned or have any questions? 
You will be able to contact Dunja Przulj at the Smokers’ Clinic if you are worried about anything or 
have any questions. The number is 020 7882 8230 or email smokers-clinic@qmul.ac.uk.   
The principal investigator of this study is Dunja Przulj, Tobacco Dependence Research Unit, Wolfson 
Institute of Preventative Medicine, Barts and The London School of Medicine and Dentistry, 55 
Philpot Street, London, E1 2JH, Tel:  020 7882 8230. 
A summary of the results of this study will be available upon request from Dunja Przulj (see above 
for contact details). 
We believe that this study is safe and do not expect you to suffer any harm or injury because of your 
participation in it. However, Queen Mary and Westfield College, University of London has agreed that 
if your health does suffer as a result of your being in the study then you will be compensated. In such 
a situation, you will not have to prove that the harm or injury which affects you is anyone’s fault. If 
you are not happy with any proposed compensation, you may have to pursue your claim through 
legal action. 
For participants who wish to raise a complaint or would like to seek independent advice outside the 
study team, the number for the local patient advice and liaison service (PALS) will be provided 
(Telephone number: 0203 594 2040/2050 or email PALS@bartsandthelondon.nhs.uk) 
 
 
We would like to thank you for your interest in this study, even if you decide not to take part. 
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15 Summary of sensitivity analysis on primary outcome (Study 2) 
 
 Mean change score (SD)** Test statistic 
N= 39* EC  DNC Z p 
 3.05 (2.86) 3.18 (2.74) -0.67 0.506 
*N= 2 removed with morning CO levels >15ppm   
** change in urge to smoke from post-cue to 10mins post-product use. 
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16 Mean ratings and standard deviations of urge to smoke over 1 
hour (Study 2) 
 
 Time point 
 Baseline PC 5 10 30 60 
 Mean (SD) 
Abstainers  (N=28) 
Morning 
EC 
 
6.89 
 
7.54 
 
4.82 
 
4.29 
 
5.32 
 
5.96 
 (2.81) (2.77) (3.07) (3.20) (3.38) (3.46) 
DNC 7.14 6.89 3.96 3.79 4.25 5.57 
 (2.19) (2.78) (3.21) (3.00) (3.41) (3.26) 
Evening 
EC 
 
6.57 
 
6.29 
 
4.54 
 
4.39 
 
4.86 
 
5.93 
 (2.67) (3.00) (2.89) (2.86) (2.97) (3.20) 
DNC 4.75 5.00 3.21 3.39 3.89 5.14 
 (3.22) (3.50) (3.12) (3.19) (3.04) (3.03) 
Whole sample (N= 41) 
Morning 
EC 
 
6.80 
 
7.41 
 
4.98 
 
4.46 
 
5.24 
 
5.88 
 (2.87) (2.78) (2.94) (3.02) (3.24) (3.39) 
DNC 6.85 7.05 4.24 3.95 4.37 5.66 
 (2.52) (2.76) (3.18) (3.02) (3.18) (3.29) 
Evening 
EC 
 
6.41 
 
6.49 
 
4.71 
 
4.51 
 
4.93 
 
6.00 
 (2.76) (2.97) (2.94) (2.88) (2.92) (3.23) 
DNC 4.98 5.07 3.73 3.68 4.02 5.15 
 (3.33) (3.42) (3.42) (3.26) (3.24) (3.26) 
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17 Mean ratings and standard deviations of irritability over 1 hour 
(Study 2) 
 
 Time point 
 Baseline PC 5 10 30 60 
 Mean (SD) 
Abstainers  (N=28) 
Morning 
EC 
 
4.89 
 
5.57 
 
3.93 
 
3.68 
 
4.14 
 
4.71 
 (3.06) (3.12) (3.06) (3.19) (3.40) (3.54) 
DNC 5.07 4.96 3.64 3.00 3.46 4.04 
 (2.45) (2.84) (2.86) (2.61) (3.12) (3.33) 
Evening 
EC 
 
5.43 
 
5.29 
 
3.71 
 
3.82 
 
3.96 
 
4.39 
 (3.21) (3.45) (2.67) (3.06) (3.16) (3.28) 
DNC 3.43 3.54 2.79 2.61 3.04 3.50 
 (3.36) (3.36) (2.73) (2.63) (2.89) (2.98) 
Whole sample (N= 41) 
Morning 
EC 
 
4.61 
 
5.32 
 
3.80 
 
3.59 
 
3.95 
 
4.44 
 (3.08) (3.16) 92.97) (2.98) (3.20) (3.39) 
DNC 4.88 4.83 3.63 3.10 3.37 4.02 
 (2.70) (2.85) (2.95) (2.72) (2.89) (3.28) 
Evening 
EC 
 
5.02 
 
4.95 
 
3.68 
 
3.63 
 
3.73 
 
4.24 
 (3.09) (3.29) (2.59) (2.79) (2.82) (2.98) 
DNC 3.34 3.46 2.88 2.78 3.00 3.61 
 (3.24) (3.16) (2.71) (2.67) (2.85) (3.06) 
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18 Mean ratings and standard deviations of restlessness over 1 hour 
(Study 2) 
 
 Time point 
 Baseline PC 5 10 30 60 
 Mean (SD) 
Abstainers  (N=28) 
Morning 
EC 
 
5.07 
 
5.64 
 
3.54 
 
3.18 
 
4.07 
 
4.64 
 (2.96) (2.95) (2.85) (3.04) (3.24) (3.02) 
DNC 4.96 4.96 3.32 3.18 3.43 3.86 
 (2.59) (2.81) (2.70) (2.78) (3.23) (3.21) 
Evening 
EC 
 
4.89 
 
4.96 
 
3.89 
 
3.89 
 
4.21 
 
4.39 
 (3.26) (3.23) (2.99) (2.99) (3.20) (3.30) 
DNC 3.43 3.61 2.96 3.00 3.07 3.61 
 (3.28) (3.51) (3.19) (3.04) (3.16) (3.25) 
Whole sample (N= 41) 
Morning 
EC 
 
4.98 
 
5.59 
 
3.68 
 
3.39 
 
4.00 
 
4.61 
 (3.11) (2.95) (2.82) (2.93) (3.15) (3.15) 
DNC 4.98 4.95 3.44 3.12 3.41 3.93 
 (2.78) (2.77) (2.82) (2.65) (3.01) (3.00) 
Evening 
EC 
 
4.85 
 
4.95 
 
3.90 
 
3.83 
 
4.17 
 
4.39 
 (3.05) (3.10) (2.84) (2.85) (2.96) (3.11) 
DNC 3.44 3.63 2.93 3.07 3.15 3.78 
 (3.06) (3.35) (3.01) (2.90) (3.03) (3.26) 
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19 Mean ratings and standard deviations for difficulty concentrating 
over 1 hour (Study 2) 
 
 Time point 
 Baseline PC 5 10 30 60 
 Mean (SD) 
Abstainers  (N=28) 
Morning 
EC 
 
4.46 
 
5.04 
 
3.75 
 
3.57 
 
3.71 
 
4.04 
 (2.72) (3.09) (3.04) (3.19) (3.33) (3.43) 
DNC 4.18 4.29 3.32 3.04 3.04 3.36 
 (2.78) (2.79) (2.80) (2.65) (3.01) (3.11) 
Evening 
EC 
 
4.36 
 
4.36 
 
3.57 
 
3.61 
 
3.86 
 
4.18 
 (3.26) (3.39) (2.95) (2.92) (3.22) (3.26) 
DNC 2.93 3.14 2.86 2.68 2.71 3.11 
 (2.89) (3.26) (2.89) (2.86) (2.84) (2.66) 
Whole sample (N= 41) 
Morning 
EC 
 
4.54 
 
5.05 
 
3.80 
 
3.63 
 
3.71 
 
4.07 
 (2.81) (3.06) (2.93) (3.02) (3.16) (3.34) 
DNC 4.32 4.51 3.37 2.98 3.05 3.54 
 (2.91) (2.79) (2.84) (2.58) (2.74) (2.92) 
Evening 
EC 
 
4.32 
 
4.54 
 
3.63 
 
3.56 
 
3.80 
 
4.10 
 (3.17) (3.26) (2.79) (2.69) (2.90) (3.04) 
DNC 2.80 2.95 2.78 2.59 2.56 3.27 
 (2.74) (3.05) (2.75) (2.69) (2.72) (2.75) 
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20 Mean ratings and standard deviations of composite withdrawal 
over 1 hour (Study 2) 
 
 Time point 
 Baseline PC 5 10 30 60 
 Mean (SD) 
Abstainers  (N=28) 
Morning 
EC 
 
4.81 
 
5.42 
 
3.74 
 
3.48 
 
3.98 
 
4.46 
 (2.68) (2.91) (2.84) (3.01) (3.14) (3.11) 
DNC 4.74 4.74 3.43 3.07 3.31 3.75 
 (2.11) (2.63) (2.62) (2.54) (3.00) (3.07) 
Evening 
EC 
 
4.89 
 
4.87 
 
3.73 
 
3.77 
 
4.01 
 
4.32 
 (3.09) (3.21) (2.71) (2.90) (3.10) (3.16) 
DNC 3.26 3.43 2.87 2.76 2.94 3.40 
 (3.06) (3.30) (2.81) (2.74) (2.87) (2.83) 
Whole sample (N= 41) 
Morning 
EC 
 
4.71 
 
5.32 
 
3.76 
 
3.54 
 
3.89 
 
4.37 
 (2.77) (2.89) (2.78) (2.85) (3.01) (3.09) 
DNC 4.72 4.76 3.48 3.07 3.28 3.83 
 (2.42) (2.64) (2.74) (2.52) (2.76) (2.92) 
Evening 
EC 
 
4.73 
 
4.81 
 
3.74 
 
3.67 
 
3.90 
 
4.24 
 (2.94) (3.04) (2.59) (2.68) (2.79) (2.87) 
DNC 3.20 3.35 2.86 2.81 2.90 3.55 
 (3.02) (3.02) (2.63) (2.57) (2.72) (2.86) 
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21 Summary of mean scores and test statistics for individual MPSS 
items (Study 2) 
 
MPSS Item: Depression Irritability Restlessness Difficulty 
concentrating 
Hunger 
Abstainers  
(N= 28) 
M (SD)  
EC 1.71 (0.98) 2.54 (0.92) 2.64 (0.95) 2.57 (1.1.7) 2.89 (1.07) 
DNC 1.39 (0.88) 2.21 (0.74) 2.21 (1.00) 1.86 (0.85) 2.39 (1.07) 
Test statistic  
 (p) 
z= -2.22 
(0.026) 
z= -1.50  
(0.133) 
z= -1.93 
(0.053) 
z= -3.03 
(0.002) 
z= -1.72 
(0.084) 
Whole Sample 
(N= 41) 
  
EC  1.71 (0.93) 2.59 (0.89) 2.66 (0.99) 2.56 (1.12) 2.93 (1.06) 
DNC 1.39 (0.80) 2.27 (0.81) 2.22 (0.96) 1.95 (0.84) 2.49 (1.12) 
Test statistic 
Sig. (p) 
z= -2.40 
(0.016) 
z= -1.79  
(0.073) 
z= -2.43 
(0.015) 
z= -3.30 
(0.001) 
z= -2.02 
(0.043) 
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22 Study 3 Participant Information Sheet 
 
 
 
 
INVITATION TO PARTICIPATE IN A 
RESEARCH PROJECT 
 
 
Complementing current NHS Stop Smoking Service 
treatments for smokers with behavioural replacement: The 
role of de-nicotinised cigarettes 
 
Barts and The London 
Queen Mary’s School of Medicine and Dentistry 
 
We would like to invite you to take part in a research study which we think may be important. 
The information which follows tells you about it.  It is important that you understand what is in 
this leaflet. It says what will happen if you take part and what the study entails. Try to make 
sure you know what will happen to you if you decide to take part. Whether or not you do take 
part is entirely your choice. Please ask any questions you want to about the research and we 
will try our best to answer them.  
 
The Study 
People wanting to quit smoking are normally treated with medications such as nicotine 
replacement therapy or Champix and support from stop-smoking advisors. Although this 
approach is effective, it does not work with everyone. Many smokers miss the ‘behavioural’ 
and sensory aspects of smoking such as the taste, smell, handling the cigarettes etc. In this 
study, we are evaluating an idea that cigarettes which do not contain nicotine but which have 
a similar taste to normal cigarettes can provide these behavioural and sensory aspects over 
the first two weeks of quitting and help more people to stop smoking for good. We aim to 
recruit a total of 200 people who want to quit smoking (100 using varenicline and 100 using 
nicotine replacement therapy). 
 
If you agree to take part in the study, you will be randomly allocated (by chance) to one of 
two groups. Both groups will receive the usual treatment with medication and support, but in 
addition to this, one group will receive de-nicotinised cigarettes for the first two weeks after 
they stop smoking their normal cigarettes.  
 
What is in the de-nicotinised cigarettes? 
The tobacco used in these cigarettes is from a transgenic (genetically modified) tobacco 
variety where an enzyme involved in making nicotine has been suppressed. However the 
leaves from these tobacco plants still contain a small amount of nicotine (about 5% of the 
normal nicotine content), but this is so small that it has little effect on the smoker. Normal 
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cigarettes are dangerous, and the de-nicotinised cigarettes are not much safer, but they are 
not meant to replace normal cigarettes with a safer alternative. Their use for two weeks is to 
see if they alleviate the discomfort and urges to smoke many smokers experience when 
quitting and whether they have a potential to improve the efficacy of the existing treatments.  
 
 
What will happen if you take part? 
If you are eligible and would like to take part, you will receive the normal treatment that we 
provide at our clinic, with three additional sessions. The table below shows what will happen 
in each session. 
Outline of the study and treatment sessions 
 
Session 
1 
Baseline 
visit 
 
2 weeks 
before quit 
day 
At this first visit to the Smokers’ Clinic we will describe the study and go through this 
information sheet. You will then have the opportunity to ask any questions. We will 
then ask you to sign a consent form to show that you have agreed to take part. You 
will then complete a short questionnaire to tell us about your smoking and mood. We 
will also measure the amount of carbon monoxide (CO) in your breath and your 
reaction to smoking-related pictures.  
 
You will be helped to select stop-smoking medication best suited to your needs (e.g. 
NRT, Champix). 
Session 
2 
Preparation 
visit  
 
1 week 
before quit 
day 
At this second visit to the Smokers’ Clinic we will ask you to complete a short 
questionnaire. We will also record the number of cigarettes that you are smoking per 
day and measure the amount of CO in your breath.  
You will be given a prescription for your stop-smoking medication.  
 
We will also help you prepare for your Quit Day the next week. 
Session 
3 
Quit Day You will visit the Smokers’ Clinic and we will ask you to complete some short 
questionnaires to measure any withdrawal symptoms. We will also record the 
number of cigarettes that you are smoking per day and we will measure the amount 
of CO in your breath. You will be given a prescription for your stop-smoking 
medication.  
 
  
We will provide you with some counselling to help you get through the first week. 
You will be randomised at this session to either use de-nicotinised cigarettes along 
with usual care or to continue with usual care only. If you are in the de-nicotinised 
cigarettes group, you will be given a week’s supply of these cigarettes. You will be 
asked to try one and to rate it on a short questionnaire at this session. 
Phone call – 24 hours 
after quitting 
We will call you to assess your withdrawal symptoms and if you are using the de-
nicotinised cigarettes we will ask you to rate your experience with them. 
Session 
4 
1 week after 
quit day 
You will visit the Smokers’ Clinic and we will ask if you have smoked or not, 
measure the amount of CO in your breath and ask whether you are experiencing 
withdrawal symptoms. Medication will be given to you if required at this session. We 
will also assess your reaction to smoking-related pictures.  
 
If you are in the de-nicotinised cigarettes group, you will be provided with another 
week’s supply. 
Session 
5 
2 weeks 
after quit 
day 
You will visit the Smokers’ Clinic and we will ask if you have smoked or not, 
measure the amount of CO in your breath and ask whether you are experiencing 
withdrawal symptoms. Medication will be given to you if required at this session.  
 
 
Participants who have been using the de-nicotinised cigarettes will also complete a 
questionnaire regarding their thoughts on using these cigarettes. Any unused 
cigarettes will be returned, and participants will be asked to stop using them.  
Sessions 
6-9 
3-6 weeks 
after quit 
day 
At each of these sessions you will visit the Smokers’ Clinic and we will ask if you 
have smoked or not, measure the amount of CO in your breath and ask whether you 
are experiencing withdrawal symptoms. Medication will be given to you at each 
session. Medication will be given to you if required at this session. 
 
During session 7 only, we will also assess your reaction to smoking-related 
pictures. 
Support and advice will be provided at all sessions. 
 
After session 9 we will not formally contact you again until you have finished the 
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As standard NHS treatment usually ends at session 7, you will be reimbursed for your time 
and travel for the additional treatment sessions. You will be given £20 at the end of session 
9, and a further £10 at the final visit (session 10). 
 
Who can take part? 
You will be able to take part if you are aged 18 years or over and are seeking treatment to 
stop smoking. 
You will not be able to take part if you are pregnant or breast feeding or have been 
diagnosed with an acute psychiatric illness.  
 
Risks/Side effects 
We do not anticipate that there will be any risks from using de-nicotinised cigarettes. As with 
any cigarettes you will still be exposed to tobacco smoke; however there are no increased 
health risks with de-nicotinised cigarettes compared to your normal cigarettes.  
 
Data Protection 
If you agree to take part you will be asked to fill out several questionnaires. Any information 
you do give us will be kept confidential, and only study staff will have access to this data. No 
medical information about you will be requested from your doctor, however your GP will be 
informed about your participation in this study, with your consent. The results of this study 
may be presented to other individuals working in the field of smoking cessation or may be 
printed in journals; however there will be no information included which could identify you. 
 
Your Rights 
Your participation in this study is entirely voluntary, and you are free to drop out of the study 
at any time. Your records will be kept strictly confidential and your ordinary medical care will 
not be put at risk if you decide not to take part or drop out. 
 
What happens if you are concerned or have any questions? 
You will be able to contact Dunja Przulj or Hayden McRobbie at the Smokers Clinic if you are 
worried about anything or have any questions. The number is 020 7882 8230 or email 
smokers-clinic@qmul.ac.uk.  Outside office hours you can call this number 07866846818. 
 
The principal investigator of this study is Hayden McRobbie, Tobacco Dependence 
Research Unit, Wolfson Institute of Preventative Medicine, Barts and The London School of 
Medicine and Dentistry, 55 Philpot Street, London, E1 2JH, Tel:  020 7882 8230. 
 
A summary of the results of this study will be available upon request from Dunja Przulj or Hayden 
McRobbie (see above for contact details). 
 
We believe that this study is safe and do not expect you to suffer any harm or injury because of 
your participation in it. However, Queen Mary and Westfield College, University of London has 
agreed that if your health does suffer as a result of your being in the study then you will be 
compensated. In such a situation, you will not have to prove that the harm or injury which affects 
you is anyone’s fault. If you are not happy with any proposed compensation, you may have to 
pursue your claim through legal action. 
course of treatment (8 weeks later). Of course you should feel able to contact us 
during this time if you have any questions or concerns. 
 
Sessions 
10 
12 weeks 
after quit 
date 
We will ask you to attend one final visit to see how you are after finishing the 
medication and how you are managing with not smoking. We will ask if you have 
smoked or not, measure the amount of CO in your breath and ask whether you are 
experiencing withdrawal symptoms. Advice will be given on how to stay stopped or 
try to quit again if you have not been able to stop. 
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If you have a complaint please contact Christine Bevan-Davies, Quality Development, Barts 
and the London NHS Trust, Healthcare Governance Directorate, Tel: 020 7480 4857, Email: 
christine.bevan davies@bartsandthelondon.nhs.uk 
 
 
We would like to thank you for your interest in this study, even if you decide not to 
take part. 
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23 Study 3 Consent Form 
 
 
Complementing current NHS Stop Smoking Service 
treatments for smokers with behavioural 
replacement: The role of de-nicotinised cigarettes 
 
Informed Consent Form 
 
Principal Investigator: Dr Hayden McRobbie 
 
Participant Name:          
 
Participant Number: 
 
 Please 
initial 
each 
line 
I confirm that I have read (or someone else has read to me) and I 
understand the Participant Information Sheet (insert version and date), 
for the above study. 
 
I have had the opportunity to consider the information, ask questions 
and have had these questions answered satisfactorily. 
 
I understand that my participation is voluntary (my choice) and that I 
may withdraw from the study at any time without giving reason, and that 
my medical care or legal rights will not be affected because of this. 
 
I agree to my GP being informed about my participation in this study 
 
 
I understand that all information collected will be in accordance to the 
Data Protection Act of 1998. 
 
I agree to take part in the above study 
 
 
 
I understand that the research data collected during the study may be looked at by other 
individuals from the research team, sponsor, from regulatory authorities or from the NHS 
Trust, where it is relevant to my taking part in this research. I give permission for these 
individuals to have access to my data.  
 
____________________________ __________________ ________ 
Participant Name (please print) Signature of Participant Date 
 
 
____________________________ __________________ ________ 
Name of person explaining consent Signature of person  Date 
                                                             explaining consent 
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24 Summary of test statistics for between groups baseline 
comparisons (Study 3; DNC+ST vs. ST) 
 
Baseline variable Test statistic Sig (p). 
 Chi-square (  )  
Gender 0 1.00 
Ethnicity 12.49 0.567 
Employment status 11.23 0.129 
Education 0.19 0.667 
GN-SBQ (high/low) 0.04 0.839 
SM-MFS (high/low) 0.66 0.416 
 One-way ANOVA (F[df])  
Age F(1, 199) = 0.85 0.358 
CPD F(1, 199) = 0.05 0.823 
FTND F(1, 193) = 0.48 0.491 
GN-SBQ total F(1, 194) = 1.27 0.261 
SM-MFS total F(1, 198) = 1.25 0.265 
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